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1. Summary  
 
Summary  
 
Echinococcus multilocularis is the causative agent of alveolar echinococcosis (AE), a life-
threatening disease with limited options of chemotherapeutic treatment. Anti-AE 
chemotherapy is currently based on a single class of drugs, the benzimidazoles. Although 
acting parasitocidic in vitro, benzimidazoles are merely parasitostatic during in vivo treatment 
of AE and cause severe site effects. In the case of operable lesions, the resection of parasite 
tissue needs to be supported by a prolonged chemotherapy. Thus, the current treatment 
options for AE are inadequate and require alternatives.  
In the present work, the flatworm signaling pathways were analyzed to establish potential 
targets for novel therapeutic approaches. I focused on factors that are involved in 
development and proliferation of E. multilocularis using molecular, biochemical and cell 
biological methods. Among the analysed factors were three MAP kinases of the parasite, 
EmMPK1, an Erk-1/2 orthologue, EmMPK2, a p38 orthologue and EmMPK3, an Erk7/8 
orthologue. Further, I identified and characterized EmMKK2, a MEK1/2 orthologue of the 
parasite, which, together with the known kinases EmRaf and EmMPK1, forms an Erk1/2-like 
MAPK module. 
Moreover, I was able to demonstrate several influences of host growth factors such as EGF 
(epidermal growth factor) and insulin on worm signaling mechanisms and larval growth, 
including the phosphorylation of Elp, an ezrin-radixin-moesin like protein, EmMPK1, 
EmMPK3 and increased mitotic activity of Echinococcus cells. In addition, several 
substances were examined for their efficacy against the parasite including (i) general 
tyrosine kinase inhibitors (PP2, leflunamide), (ii) compounds designed to inhibit the activity of 
receptor tyrosine kinases, (iii) anti-neoplastic agents (miltefosine, perifosine), (iv) 
serine/threonine kinase inhibitors that have been designed to block the Erk1/2 MAPK 
cascade and (v) inhibitors of p38 MAPKs. 
In these studies, EmMPK2 proved to be a promising drug target for the following reasons. 
Amino acid sequence analysis disclosed several differences to human p38 MAPKs, which is 
likely to be the reason for the observed enhanced basal activity of recombinant EmMPK2 
towards myelin basic protein in comparison to human recombinant p38 MAPK-α. In addition, 
the prominent auto-phosphorylation activity of the recombinant EmMPK2 protein together 
with the absence of an interaction with the Echinococcus MKKs suggest a different 
mechanism of regulation compared to the human enzyme. EmMPK2 activity could be 
effectively inhibited in vitro and in cultivated metacestode vesicles by treatment with 
SB202190 and ML3403, two ATP-competitive pyridinyl imidazole inhibitors of p38 MAPKs, in 
a concentration-dependent manner. Moreover, both compounds, in particular ML3403, 
caused parasite vesicle inactivation at concentrations which did not affect cultured 
mammalian cells. Likewise, during the cultivation of Echinococcus primary cells, the 
presence of ML3403 prevented the generation of new vesicles.  
Targeting members of the EGF signaling pathway, particulary of the Erk1/2-like MAPK 
cascade, with Raf and MEK inhibitors prevented the phosphorylation of EmMPK1 in 
metacestodes cultivated in vitro. However, although parasite growth was prevented under 
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these conditions, the structural integrity of the metacestode vesicles maintained during long-
term cultivation in the presence of the MAPK cascade inhibitors. Similar results were 
obtained when studying the effects of other drugs mentioned above.  
Taken together, several targets could be identified that reacted with high sensitivity to the 
presence of inhibitory substances, but did not cause the parasite’s death with one exception, 
the pyridinyl imidazoles. Based on the presented data, I suggest pyridinyl imidazoles as a 
novel class of anti-Echinococcus drugs and imply EmMPK2 as survival signal mediating 
factor, the inhibition of which could be used for the treatment of AE. 
 
 
Zusammenfassung 
 
Echinococcus multilocularis verursacht die Alveoläre Echinokokkose (AE), eine 
lebendsbedrohliche Krankheit mit limitierten chemotherapeutischen Möglichkeiten. Die 
jetzige Anti-AE Chemotherapie basiert auf einer einzigen Wirkstoffklasse, den 
Benzimidazolen. Obwohl Benzimidazole in vitro parasitozid wirken, wirken sie in vivo bei AE-
Behandlung lediglich parasitostatisch und rufen schwere Nebenwirkungen hervor. In Fällen 
operabler Läsionen erfordert die Resektion des Parasitengewebes über einen längeren 
Zeitraum eine chemotherapeutische Unterstützung. Damit sind die jetzigen 
Behandlungsmöglichkeiten inadäquat und benötigen Alternativen. 
In der vorliegenden Arbeit wurden die Signalwege von Plattwürmern analysiert, um 
potentielle Targets für neue therapeutische Ansätze zu identifizieren. Dabei konzentrierte ich 
mich unter Anwendung von molekularbiologischer, biochemischer und zellbiologischer 
Methoden auf Faktoren, die an Entwicklung und Proliferation von E. multilocularis beteiligt 
sind. Darunter waren die drei MAP kinases des Parasiten EmMPK1, ein Erk1/2-Ortholog, 
EmMPK2, ein p38-Ortholog und EmMPK3, ein Erk7/8-Ortholog. Des Weiteren identifizierte 
und charakterisierte ich EmMKK2, ein MEK1/2-Ortholog des Parasiten, welches zusammen 
mit den bekannten Kinasen EmRaf und EmMPK1 ein Erk1/2-ähnliches MAPK Modul bildet. 
Ich konnte zudem verschiedene Einflüsse von Wirtswachstumsfaktoren wie EGF (epidermal 
growth factor) und Insulin auf die Signalmechanismen des Parasiten und das 
Larvenwachstum zeigen, darunter die Phosphorylierung von Elp, ein Ezrin-Radixin-Moesin 
ähnliches Protein, die Aktivierung von EmMPK1 und EmMPK3 und eine gesteigerte 
mitotische Aktivität der Echinokokkenzellen. Zusätzlich wurden verschiedene Substanzen auf 
ihre letale Wirkung auf den Parasiten untersucht, darunter befanden sich (1.) generelle 
Inhibitoren von Tyrosinkinasen (PP2, Leflunamid), (2.) gegen die Aktivität von Rezeptor-
Tyrosin-Kinasen gerichtete Präparate, (3.) ursprünglich anti-neoplastische Wirkstoffe wie 
Miltefosin und Perifosin, (4.) Inhibitoren von Serin/ Threonin-Kinasen, die die Erk1/2 MAPK 
Kaskade blockieren und (5.) Inhibitoren der p38 MAPK.  
In diesen Untersuchungen hat sich EmMPK2 aus den folgenden Gründen als 
vielversprechendes Target erwiesen. Aminosäuresequenz-Analysen offenbarten einige 
Unterschiede zu menschlichen p38 MAP Kinasen, welche sehr wahrscheinlich die 
beobachtete gesteigerte basale Aktivität des rekombinanten EmMPK2 verursachen, 
verglichen mit der Aktivität humaner p38 MAPK-α. Zusätzlich suggerieren die prominente 
Autophosphorylierungsaktivität von rekombinantem EmMPK2 und das Ausbleiben einer 
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Interaktion mit den Echinococcus MKKs einen unterschiedlichen Regulierungsmechanismus 
im Vergleich zu den humanen Proteinen. Die Aktivität von EmMPK2 konnte sowohl in vitro 
als auch in kultivierten Metazestodenvesikeln durch die Behandlung mit SB202190 und 
ML3403, zwei ATP kompetitiven Pyridinylimidazolinhibitoren der p38 MAPK, in 
Konzentrations-abhängiger Weise inhibiert werden. Zudem verursachten beide Substanzen, 
insbesondere ML3403 die Inaktivierung von Parasitenvesikeln bei Konzentrationen, die 
kultivierte Säugerzellen nicht beeinträchtigten. Ebenso verhinderte die Anwesenheit von 
ML3403 die Generation von neuen Vesikeln während der Kultivierung von Echinococcus 
Primärzellen.  
Das Targeting von Mitgliedern des EGF-Signalwegs, insbesondere der Erk1/2-ähnlichen 
MAPK Kaskade mit Raf- und MEK- Inhibitoren verhinderte die Phosphorylierung von 
EmMPK1 in in vitro kultivierten Metazestoden. Obwohl das Parasitenwachstum unter diesen 
Konditionen verhindert wurde, blieb die strukturelle Integrität der Metazestodenvesikeln 
während der Langzeitkultivierung in Anwesenheit der MAPK Kaskade-Inhibitoren erhalten. 
Ähnliche Effekte wurden beobachtet nach Behandlung mit den anderen zuvor aufgeführten 
Inhibitoren.  
Zusammenfassend lässt sich festhalten, dass verschiedene Targets identifiziert werden 
konnten, die hoch sensibel auf die Anwesenheit der inhibitorischen Substanzen reagierten, 
aber nicht zum Absterben des Parasiten führten, mit Ausnahme der Pyridinylimidazolen. Die 
vorliegenden Daten zeigen, dass EmMPK2 ein Überlebendsignal vermittelnden Faktor 
darstellt und dessen Inhibierung zur Behandlung der AE benutzt werden könnte. Dabei 
erwiesen sich p38 MAPK Inhibitoren der Pyridinylimidazolklasse als potentielle neue 
Substanzklasse gegen Echinokokken.  
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2. Introduction 
 
Echinococcus multilocularis as causative agent of alveolar echinococcosis (AE) 
 
2.1 Phylogeny and distribution of the genus Echinococcus 
 
Platyhelminths of the genus Echinococcus belong to the family of Taeniidae that are grouped 
into the class of Cestoda (Fig. 2.1). Closely related human parasites are the pig tapeworm 
Tania solium and the beef tapeworm Taenia saginata. General features of the phylum 
Platyhelminthes which they share with all protostomes are bilateral symmetry, the formation 
of three germ layers as well as the development of the mouth near the gut entrance during 
the gastrulation. The protostomes can be divided into two major branches: Ecdysozoa and 
Lophotrophozoa. The group of Ecdysozoa covers all moulting animals including the fruit fly 
Drosophila melanogaster and the nematode Caenorhabditis elegans. Lophotrophozoa 
encompass flatworms, annelids as well as molluscs and are characterized particulary by 
spiral cleavage and a prominent digestion system. The term “helminths” is historically used 
for all endoparasitic living nematodes and platyhelminths and is not based on phylogenetic 
findings [1].  
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Fig. 2.1: Phylogenetic tree of the animal kingdom. Species highlighted in blue are parasitic living, 
examples for free living worms are in green [1]. 
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A B C
 
Fig. 2.2: Distribution of Echinococcus species in Europe. Endemic area of E. multilocularis (A), E. 
granulosus s.s. (B) and E. granulosus G7 (pig strain). Romig et al, 2006 [2] . 
 
 
 
The genus Echinococcus is responsible for a variety of clinical pictures and comprises at 
least eight species. These are E. oligarthus, E. vogeli, E. shiquicus, the small fox tapeworm 
E.multilocularis, various strains of the dog tapeworm E. granulosus and the newly 
repositioned E. felidis from African lions [3]. The E. granulosus strains and the small fox 
tapeworm E. multilocularis represent the species with the greatest impact on human and 
animal health and economic issues. In humans, they cause life-threatening diseases; E. 
granulosus causes cystic echinococcosis (CE) and E. multilocularis alveolar echinococcosis 
(AE). Their management has become increasingly important in Europe in the last two 
decades [4]. In the following section, particular emphasis will therefore be put on E. 
multilocularis and E. granulosus 
In recent years, the taxonomic classification of the E. granulosus strains (G1-G10) has been 
modified and some strains were considered as standalone species based on the genetic 
stability in sympatric areas and the priority for specific hosts. According to that, E. granulosus 
G1 is named E. granulosus sensu stricto and separated from G5 E. ortleppi and G4 E. 
equinus. The cervid strain G10 and the pig strain G7 including the variant G9 were integrated 
together with the non-European strain G6 in one monophyletic group [2]. Among them, E. 
granulosus sensu strico occurs world-wide as concomitant of sheep farming and is 
distributed in Europe the Mediterranean area, Wales and Bulgaria [5].  
In contrast to E. granulosus, strain diversity has not yet been found for the fox tapeworm E. 
multilocularis. Since the 1990’s, E. multilocularis is endemically distributed in arctic and 
temperate zones of the Northern Hemisphere. Its occurrence has extended in Europe from 
the south-central to central Europe including Denmark, Flanders, central France, northern 
Italy to the Balkan states (Fig.1.2) [2]. However, the area might be larger than described due 
to insufficient data [5-7]. Besides the expansion of the endemic area, an increase of definitive 
density host has been promoted by rabies vaccination of foxes, which leads to higher 
survival rates and as a consequence, to an increased infection rate of E. multilocularis 
intermediate hosts (detailed in section 2.3.1) [2, 7].  
Two other species, namely E. oligarthus and E. vogeli, are responsible for polycystic 
echinococcosis (PE) in South and Central America and breed mostly in sylvatic life cycles.  
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E. vogeli prefers bush dogs (Speothos venaticus) as final host and agoutis (Dasyprocta spp.) 
and pacas (Cuniculus paca) as intermediate hosts, whereas E. oligarthus’ definitive hosts are 
various species of wild felids. Infections of humans are rare and occur after contact with 
contaminated domestic animals [8]. Echinococcus shiquicus from the Tibetan highlands was 
recently described and executes preferably fox-lagomorphe cycles [9, 10]. For this species, 
no case of human infection has been observed yet [10].  
 
 
 
2.2 Life cycle of E. multilocularis  
 
As a parasitic cestode, E. multilocularis has a di-heteroxenous life cycle (Fig.1.3). Preferably 
wild foxes (Vulpes ssp.) and raccoon dogs (Nyctereutes procyonoides), but also other 
carnivores like domestic dogs and cats serve as definitive hosts [5, 8]. A wide spectrum of 
mammals can serve as intermediate hosts, but in the case of a sylvatic cycle, mostly small 
rodents (especially Microtus arvalis and Arvicola terrestris) are affected [2, 7]. 
In the definitive host, E. multilocularis settles between the villi of the small intestine. The adult 
worm is characterized by a size between one and four millimetres and a maximum of five 
segments, so-called proglottides. Approximately four weeks after its settlement in the small 
intestine, up to 200 eggs are produced daily in the last proglottide by protandry. Infective 
eggs contain the multicellular, first larval stage, the oncosphere, and are surrounded by a 
massive egg shell, primarily made up of carbohydrate compounds. They are released into 
the environment by shedding the gravid proglottide or the loose eggs together with the 
faeces. The eggs are considerably resistant against external influences and can protect the 
oncosphere for months [8]. Upon oral uptake by the intermediate host and subsequent 
hatching, the oncosphere penetrates the gut epithelium from where it reaches the target 
organ passively via blood and lymph system. Within the target organ, which is predominantly 
the liver, the oncosphere differentiates into the second larval stage, designated metacestode. 
The metacestode growths via exogenous budding into the surrounding host tissue. 
Therefore, the asexual high-rate proliferation of metacestode tissue is often compared with a 
sponge-like tumour growth. The metacestode stage of E. granulosus, the causative agent of 
cystic echinococcosis (CE), in the other hand, differs through the formation of a main cyst 
and endogenous budding [8].  
A single metacestode vesicle is built of two layers surrounding the hydatid fluid. The outer, 
acellular laminated layer (LL) contains high-polymer carbohydrates which are responsible for 
immune evasion effects [11]. It is formed two to four weeks after the encystment process 
from components secreted by the vesicle cells comprising the inner germinal layer (GL). 
Besides germinal cells, the GL is composed of several different cell types including muscle 
cells, glycogen storage cells and undifferentiated cells. The germinal cells actually represent 
are the only mitotically active cells of the parasite and differentiate into brood capsules within 
which protoscoleces are formed as third larval stage [12, 13]. The protoscolex consists of the 
head structure of the adult stage with suckers and hooks and remains initially in a resting 
form. Due to the space demanding growth of the parasite, the host’s organs cannot longer 
fulfil their functions and the small rodent becomes an easy prey for the final host. During the 
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digestion processes of the bagged intermediate host by the definitive host, the protoscolex is 
activated by low pH in the stomach and the influence of bile salts, leading to evagination. 
Now, the protoscolex is able to persist in the gut and to mature into the adult stage, thus 
completing the life cycle. It is important to mention that the specific factors influencing the 
metamorphosis of the larval stages, the host specifity as well as the organ tropism remain to 
be elucidated.  
 
 
 
 
 
 
 
Fig. 2.3: Life cycle of E. multilocularis. Foxes and, increasingly, racoon dogs are considered as 
main spreader of infectious eggs containing the oncospheres in Germany. Upon uptake by small 
rodents or accidentally humans as intermediate hosts, the oncosphere develops into the second larval 
stage, the so called metacestode. The establishment of the metacestode tissue takes place 
predominantly in the liver where growth proceeds without contact inhibition into the host tissue. Then, 
the third larval stage develops within the brood capsules that are built by differentiated germinal layer 
cells. The so-called protoscolex larva contains the head structure of the adult worm and remains 
initially invaginated. After digestion of the intermediate host by the final host, the larva is activated by 
the passage through the digestion system and turns inside out. Reaching the gut, the evaginated 
protoscolex develops into a mature adult producing eggs and the life cycle commences again [14].  
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2.3 Alveolar echinococcosis  
 
2.3.1 Alveolar echinococcosis and transmission risk  
 
The passage of E. multilocularis between definitive and intermediate host becomes 
interrupted when the infectious stage of the worm is accidentally taken up by humans instead 
of herbivores. The successful development of the metacestode with the accompanying lesion 
in the host tissue is referred to alveolar echinococcosis (AE). Persons with a high-risk for 
transmission are humans with close contact to animals and contaminated material, e.g., 
hunters, farmers, gardeners and mushroom collectors, and in particular dog owners [15].  
The transmission ways are difficult to validate because of the large time span between time 
point of infection and diagnosis of AE. In central Europe, the prevalence of AE is estimated to 
be between 2 up to 40 cases per 100,000 habitants in endemic areas, whereas in eastern 
France 152 per 100,000 cases were observed [2].  
The transmission rate has increased in recent years and AE has gained significance as one 
of the worst non-tropic parasitosis particulary in Europe, Japan and China [2, 16]. 
Environmental factors like soil humidity influence the survival period of excreted eggs and 
create specific vegetation and thus probably the suitable habitat for hosts [2, 5]. Further, the 
population of infected definitive host has expanded (section 2.1). Amongst others, the role of 
raccoon dogs in AE transmission increases due to increasing immigration rates from eastern 
Asia and enhance the suitable host pool [2]. A direct correlation between the increase of 
infected definitive hosts and the increase of infected intermediate hosts was, until recently, 
not reported. A very recent publication by Peter Deplazes and co-workers found strong 
support that this is the case for AE in Switzerland [17]. Moreover, in the last years the risk of 
transmission to humans is likely to be increased due to the shift from sylvatic life cycles to 
domestic life cycles involving dogs, as it has been observed for regions in China and Alaska 
and a change to urban life cycle of red foxes in European areas [5-7, 18]. These changes 
lead to a higher density of infectious material and therefore, to higher transmission risks for 
humans.  
 
2.3.2 Alveolar echinococcosis and its manifestation  
 
In humans, the metacestode targets in most cases primarily the liver and can proliferate from 
single germinal cells to massive tissues, which is referred to as AE [13]. For untreated 
patients, the lethality rate of AE is 96% [15]. AE can persist for up to twenty years [14]. In the 
late infection, the metacestode can spread into the abdomen and other organs like spleen, 
brain, and bones. The early infection appears clinically asymptomatic without significantly 
affecting the host's quality of life and organ damage. This suggests immune modulatory 
properties of the parasite. Later on, the organs are impeded in their function through the 
infiltrative growth of E. multilocularis. This phase is accompanied by an exacerbated 
inflammatory response [19]. Abdominal pain, jaundice, hepatomegaly, sometimes fever and 
anaemia, weight loss, and pleural pain belong to the early symptoms and end in dysfunction 
of the affected organs resulting in the death of the host [8]. Interestingly, only approximately 
10% of E. multilocularis expositions develop active AE [14]. Spontaneous calcification of the 
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lesions and cellular effector mechanism of the host defense suggested to cause early 
inactivation of the parasite in the remaining 90%. The granulomatous surrounding of the 
metacestode is mostly formed by macrophages, myofibroblasts and a high number of CD4+ 
T cells [20]. During the course of AE, the cytokine profile switches from a TH1 pattern in the 
early stages to a TH2 profile in the late stages. Hence, the established lesion is characterized 
by high levels of IL-4, IL-5, IL-6, IL-10 and INF-γ compared to the predominant high levels of 
IL-12, TNF-α, INF -γ early in infection [12, 19-22].  
Chances of cure strongly depend on the time of diagnosis and adequate treatment. If AE is 
diagnosed within the first 10 years after infection, the survival rate ranges about 30%, within 
15 years at 0% [8]. Imaging techniques for diagnose of AE are based on ultrasonography, 
computed tomography (CT) and magnetic resonance tomography (MRT). Especially with CT 
most of the lesions and calcifications can be detected [8, 23].  However, immunodiagnostic 
tests using a wide range of available antigens proved to be more effective than the imaging 
techniques for primary diagnosis [24-28]. The antigen Em2 isolated from the metacestode 
larval stage, for example, has been successfully used for detection of human and monkey 
AE via ELISA. Using a mixture of Em2 and Elp (also termed Em10; see section 2.4.1), the 
sensitivity of serodiagnosis was even further increased [23].  
 
2.3.3 Treatment options and chemotherapy 
 
Treatment options for AE are limited. Radical surgery of the parasite tissue has been 
recommended but has often proven difficult due to the metacestode’s infiltrative growth. Liver 
transplantation has been used as an alternative therapeutic approach; however, the required 
immunosuppression may result in rapid growth of the remaining parasite material [14]. The 
surgery option should ideally be supported by life-long medication, but at least for a two-year 
minimum. Chemotherapeutic treatment is based on benzimidazole compounds such as 
mebendazole and albendazole [29, 30]. The efficiency of chemotherapy is difficult to 
evaluate due to the lack of methods to assess whether the parasite was killed. The success 
of treatment can be measured indirectly only via patients survival rates, reduced parasite 
proliferation or a lack of recurring lesions [31]. This requires continued surveillance of the 
clinical status with imaging tests over a long period. In Switzerland, this procedure cost an 
estimate of  €350,000  per case [18]. Although benzimidazole derivates  are effective in 
parasite killing in vitro, e.g. due to alterations on laminated and germinal layer, they are 
merely parasitostatic in vivo [32, 33]. The cellular targets of benzimidazoles are β-tubulins, 
which are essential components of the cytoskeleton [34]. However, due to the high level of 
similarity between host and parasite β-tubulins (approximately 94% on amino acid sequence 
level), benzimidazoles also have a high level of affinity to host tubulin, resulting in severe 
side effects and liver toxicity upon prolonged treatment (Fig. 2.4) [33, 35]. In the case of long-
term treatment, proteinuria, hair loss, neurological deficit, gastrointestinal disorders, 
decreased numbers of leukocytes and thrombocytes, headache, fever, urticaria, and bone 
marrow toxicity were additionally stated as side effects [20]. For the antimycotic compound 
amphotericin-B, comparable effects on parasite growth could be shown in vitro, but for in vivo 
treatment, this drug is of limited use due to significant side effects [36, 37]. Nitazoxanide, a 
broad-range drug against intestinal bacterial and parasitical diseases, has recently been 
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shown to exhibit parasitocidic activity on E. multilocularis metacestode in vitro and in infected 
mice, in particular in combination with albendazol [33, 38]. Additionally, there are efforts to 
combine praziquantel and albendazole to obtain a synergistic effect for parasitocidic activity 
in the CE treatment. Joined application resulted in an increased number of patients with 
parasitic tissue compared to single medication [20]. Nevertheless, an alternative 
chemotherapy does not exist for patients who do not tolerate or do not respond to 
benzimidazole at the current time point.  
 
 
 
 
 
Fig. 2.4: Chemotherapy for AE- Benzimidazole derivates target β-tubulins. Depicted is an amino 
acid sequence alignment of human and Echinococcus tubulins demonstrating high homology of the 
cellular benzimidazole targets [35]. Marked is amino acid residue 200, the major determinant of affinity 
of a given β-tubulin to benzimidazoles, which is typically Phe in certain invertebrate β-tubulins. 
 
 
 
2.4 Signaling in developmental and proliferation processes  
 
In mammals, the MAP kinase (MAPK) cascades are crucially involved in signal transduction 
mechanisms that control proliferation, development, and apoptosis. Four classical MAPK 
cascades have been described at least in humans. The MAPK modules are distinguished 
from each other by the activating stimulus and the particular nature of the activated MAPK, 
but share a consecutive three-step phosphorylation of intracellular kinases as the mutual 
signal transduction process (see Fig. 2.5): An upstream Ser/Thr kinase, the MAPK kinase 
kinase (MKKK), modifies its substrate kinase, the MAPK kinase (MKK), leading to its 
activation. The dual-specific Thr/Tyr MKK then activates a corresponding MAPK, another 
Ser/Thr kinase. The MAPK‘s phosphorylation occurs on the threonine and the tyrosine 
residues located in the highly conserved T-X-Y triplet within the activation loop [39].  
A well-characterized mammalian MAPK cascade module is the Erk (extracellular signal-
regulated kinase) 1/2- pathway, which regulates the cellular response to extracellular growth 
factors. The receptor tyrosine kinases (RTK) of insulin, EGF (epidermal growth factor), and 
FGF (fibroblast growth factor) signaling act as upstream sensors of this pathway (see 
Fig.2.5). The JNK/SAPK (c-Jun N-terminal kinase/ stress activated protein kinase) -pathway 
as well as the p38 MAPK pathway, on the other hand, are mainly involved in the stress 
response. Osmotic and oxidative alteration, ultraviolet radiation, heat shock, as well as 
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mechanical stress belong to the respective stimuli. In addition, transforming growth factor 
(TGF) -β and other inflammatory signals (TNF (tumour necrosis factor) -α, IL-1) are potential 
inducers of the p38 MAPK module. The fourth MAPK module leads to the activation of Erk5 
(BigMAPK), also activated in response to stress and growth factor stimuli but not in response 
to inflammatory cytokines [39].  
Together with the assembled core components, various regulator proteins affect the fine-
tuning of the cascades. The specific cellular response is further dependent on the kinetics, 
the sublocalization of the kinases within the cells and the availability of substrates and 
scaffold proteins [40]. The identification of at least twenty MKKKs, seven MKKs and eleven 
MAPK in human cells indicates that MKKs are able to activate more than one MAPK and are 
activated by several MKKKs [41]. Nevertheless, the interactions of MKKs with their 
downstream kinases are specific since they recognize a tertiary structure of a specific MAPK 
instead of the linear sequence in which the T-X-Y motif is localized [41]. 
In the following passages, I will elaborate on several points of the aforementioned signal 
machinery, incipiently with RTK signaling and MAPK modules that are relevant for the 
present work. Then, I will continue with atypical MAPKs found in humans and some further 
aspects of signaling pathways. 
 
 
 
 
 
 
Fig. 2.5: RTK signaling and MAPK cascade activation. Upon binding of ligand such as EGF, the 
intrinsic kinase activity of the receptor tyrosine kinase (RTK) is activated leading to auto-
phosphorylation of the kinase at critical tyrosine residues. That creates the docking sites for 
downstream effector like Shc, Src, Grb2 and Sos, which form a multiprotein complex at the 
intracellular domain of RTK. Activated Sos catalyzes the exchange of GDP to GTP of the membrane-
associated Ras leading to its activation. In turn, GTP-Ras activates the upstream kinase of the MAPK 
cascade, namely MKKK, which phosphorylates MKK. Once activated, MKK activates the MAPK that 
on the one hand interacts in the cytosol with cytoskeleton-associated proteins and further kinases or it 
migrates into the nucleus enhancing specific gene transcription [42, 43].  
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2.4.1 Peptide growth factors and their receptors 
 
In humans, four members comprise the epidermal growth factor receptor (EGFR) family 
(EGFR (ErbB1), ErbB2, ErbB3 and ErbB4) which sense at least thirteen ligands of the EGF 
family [43, 44].  
The intracellular domain of the EGF RTKs is highly conserved and composed of a 
juxtamembrane domain involved in the binding of Src protein kinases (see below), followed 
by the tyrosine kinase domain and a weakly conserved C-terminal part. An exception of 
conservation is given for the kinase domain of ErbB3. Its intracellular domain lacks functional 
tyrosine residues. As consequence, ErbB3 acts only as regulatory receptor. The extracellular 
domain of the EGFRs displays less homology and so the RTKs show different affinities for 
the various ligands. The extracellular part contains an EGF-like domain, an immunoglobulin 
like-domain, heparine-binding and glycosylation sites. For example, EGFR preferably senses 
EGF, TGF (tumour growth factor) -α and amphiregulin stimuli. ErbB3 as heterodimer, 
however, displays preference towards neuregulin-1 and 2 [42, 43]. 
The binding of a ligand to a receptor induces, in addition to its activation, the migration from a 
caveolae component of the cell membrane into clathrin-cloated pits where the associated 
receptors are internalized. The varying composition of receptor heterodimerization allows the 
stimulation of several different downstream signaling pathways [43].  
The globular EGF peptide of 6.4 KDa represents the archetype of EGF-like proteins and was 
originally isolated from mouse submaxillary glands in 1962 [45]. EGF is a component of most 
human body fluids (plasma concentration 1 ng/ml) and is produced in a variety of tissues 
including kidney, brain, stomach, salvary glands. Its production is promoted by testosterone 
and suppressed by estrogen [46]. The EGF peptides from different phylogenetic species of 
vertebrates are well conserved and display over 70% identity. The biological activity of EGF 
depends on three intermolecular disulfide-bonds. Interference with these disulfide bonds has 
been shown to comprise proliferation and differentiation stimulation of various cell types. The 
closely related TGF-α is procuded by various transformed cells and shows a similar spectrum 
of biological activity like EGF [47].  
The peptide growth factors, which contain a single transmembrane domain (TM) exist as 
proform at the cellular surface. After cleavage of the extracellular domain representing the 
actual ligand by a disintegrin and metalloproteases, the ligand is capable to activate RTK in 
auto- or paracrine manner [43].  
The activation of RTK is regulated by a spatiotemporal expression and the post-translational 
modification of the ligands and occurs frequently via a trans-activation process. 
In principle, the growth factor stimulates the intrinsic tyrosine kinase activity of its 
corresponding receptor by the formation of 2:2 ligand-receptor-complex (depicted in Fig. 2.5). 
In this so called trans-activation mechanism, the receptors autophosphorylate specific Tyr 
residues, which increases their kinase activity. Once activated, adaptor proteins like Shc bind 
to the receptor and become tyrosine-phosphorylated by the receptor’s kinase activity. 
Alternatively, other tyrosine kinases, for instance Src, are recruited to the activated receptors 
to mediate phosphorylation of downstream effector molecules. The phosphorylation of Shc, 
then, allows the association of the Grb2 adaptor protein and guanidine nucleotide exchange 
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factor (GEF) son of sevenless (Sos). The binding of Sos to the receptor complex results in 
the GDP to GTP exchange of Ras whereupon the Erk1/2 MAPK pathway is activated [47]. 
 
Fibroblast growth factor (FGF) signaling established among metazoans is involved in 
developmental processes as well. In humans, the FGF receptor family consists of four 
members FGFR1-4 in various splicing variants, which bind at least 22 growth factors of the 
FGF family [48]. The activation of members of the FGFR family occurs very similar to the 
mechanisms for EGFR activation. However, for the stable receptor-ligand-complex formation, 
heparin or heparin sulphate proteoglycans are required to increase binding affinity [48, 49].  
 
Besides EGFs and FGFs, insulin and insulin-like growth factors (IGF) have been shown to 
stimulate the Erk1/2 MAPK cascade upon interaction with insulin receptors (IR). The ligand 
family consists, at least in humans, of nine IGFs, among them insulin, IGF-I and IGF-II and 
have been well characterized since the identification of insulin in 1921 by Banting and Best 
[50, 51]. Unlike insulin, which is produced by pancreatic β-cells to regulate sugar and fatty 
acid metabolism, IGF-I and-II are produced in various tissues and cell types. In addition to 
the classical receptors of the insulin/IGF receptor family (IR, IGF-IRI and IGF-IIR), an insulin-
receptor related receptor (IRR) was recently described, for which a corresponding ligand is, 
however, unknown as yet. IGF-I and IGF-II have nearly equal affinities to the ubiquitously 
expressed IGF receptors and can also activate IR [50]. 
 
2.4.2 The Erk1/2 MAPK module 
 
The Erk1/2 MAPK module is activated by the small GTPase Ras in the GTP bound form 
upon ligand binding to RTK. Ras GTP mediates the localization of Raf MKKK (or other 
MKKKs) to the cytoplasmic membrane where Raf becomes activated by membrane-bound 
tyrosine kinases. Raf in turn activates MEK1 and MEK2, which then phosphorylate the Erk1 
and Erk2 MAPKs. The activation of MEK1 requires the phosphorylation of Ser218 and Ser222 
by Raf [52]. Erk1’s double phosphorylation on the T-E-Y triplet leads to its dimerization and 
translocation into the nucleus, where it activates several transcription factors including Elk-1, 
c-Myc, STATs. Besides its involvement in gene regulation, Erk1 modifies cytoplasmic protein 
substrates on Ser/Thr residues within proline-directed motifs. Among the activated proteins 
are effectors involved in translation and cytoskeletal rearrangements, e.g. ribosomal S6 
kinase and microtubule-associated proteins. Further, members of the MAPK module are 
phosphorylated by Erk1/2 suggesting a negative feedback mechanism.  
In general, the activation of MEK1 and MEK2 by specific MKKKs depends on the 
environmental stimuli [39]. The MKKs of the Erk1/2 pathway in humans are MEK1 and 
MEK2, which share 80% amino acid sequence identity [53]. They display low homology (21% 
identity) in the MEK-specific sequence, which contains the recognition site for upstream 
kinase Raf [54]. In addition, they differ in their N-terminal region where both possess the Erk 
docking site but only MEK1 the nuclear exclusion sequence (NES). Since the NES 
determines the cytoplasmatic localization of MEK1, it was supposed that MEK1 in its inactive 
state sequesters Erk1/2. Upon activation, MEK1 phosphorylates Erk1 and Erk2 and then 
dissociates. In turn, activated Erk1 and Erk2 translocate into the nucleus [39, 54, 55].  
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One way to achieve specifity of Erk and MEK might be the tissue specific expression 
patterns. Mouse MEK1 and MEK2 are differently expressed in the various tissues and it has 
been shown that mek1 but not mek2 null mice are embryonic lethal, indicating its important 
role during embryogenesis [54, 56]. 
Another way to determine the specific components of the MAPK module is accomplished by 
the varying set of scaffold proteins. In the case of the growth factor stimulated Erk1/2 
pathway, KSR (kinase suppressor of Raf; isoforms KSR1 and 2) plays an important role 
through the formation of a high molecular weight complex with Raf, MEK1/2, ERK1/2, 14-3-3 
and several chaperones. In the absence of growth factor stimuli, KSR forms a 
cytoplasmatically located complex with MEK1/2, PP2A (protein phosphatase 2A), 14-3-3 and 
the Ras sensitive E3 ubiquitin ligase impedes mitogenic signal propagation (IMP). Upon 
stimulation, Ras activation leads to the degradation of IMP and its release from the complex. 
Simultaneously, KSR and Raf become dephosphorylated on residues involved in the 14-3-
3/PP2A binding resulting in the translocation of the cleaved KSR- MEK1/2 complex to the 
plasma membrane. There, KSR-MEK1/2 assemble with Erk1/2 and Raf whereby the turn-in-
turn phosphorylation subsequently proceeds [57]. 
The 14-3-3 proteins are evolutionary conserved and abundantly expressed in all cell types 
and are interaction partners of various components of the signaling pathways. Members of 
the 14-3-3 family very often regulate developmental processes by binding and alteration of 
the intracellular compartment of the target proteins thereby leading to their inactivation. 
Initially, 14-3-3 has been identified as the phospho-serine specific adaptor of Raf in the 
process described above. Further, 14-3-3 proteins interact amongst others with the cell-cycle 
regulating phosphatase Cdc25, members of the fork head transcription factor family and Bad, 
which prevents the cell entering apoptosis [58]. 
 
2.4.3 The p38 MAPK module 
 
The Hog1 protein of budding yeast presents the archetype of p38 MAPKs, which is activated 
in response to physical stress [59]. The mammalian p38 MAPK family is composed of at 
least four isoforms, p38 MAPK α,-β,-γ and –δ, which display around 60% identical amino acid 
residues [60]. p38 α and β are ubiquitously expressed, whereas isoform γ is mainly found in 
the skeletal muscle tissue and isoform δ in various tissues such as endocrinic glands [61]. 
The mainly stress-activated p38 MAPK becomes phosphorylated on the dual-
phosphorylation motif T-G-Y by MKK3, MKK4, and MKK6, which shows different preferences 
for the relevant isoforms. MKK6 preferentially activates p38 MAPK β, whereas p38 MAPK α 
is to the same degree the substrate of MKK3, 4 and 6 [62]. Substrates of p38 MAPK are 
MAPKAPK (MAPK activated protein kinases)-2 and-3, and the transcription factors ATF-2, 
AP-1, Max and Chop. Here, p38-β revealed a 20fold higher preference toward ATF-2 than 
the other isoforms tested in in vitro and in vivo experiments [63]. The varying preferences of 
the p38 isoforms for substrates and activator kinases suggest for each an individual task in 
the signaling transduction, which is not completely understood yet. The MKKKs MEKK1-4, 
MLK 1-3 and TAK1 were described as upstream activator kinases, which are additionally 
involved in JNK MAPK pathway [39]. As mentioned above, stress-inducing agents and 
inflammatory cytokines are the predominant activation stimuli, however, p38 MAPK is weakly 
  2. INTRODUCTION 
  - 15 - 
sensitive towards growth factors in a Rac dependent manner. In other circumstances, the 
reduction of growth factor leads to p38 MAPK pathway activation inducing apoptosis [64]. 
Further, upon several stress stimuli, its activation results in Ser/Thr phosphorylation of the 
EGFR that is removed from the surface via endocytosis without its degradation. These 
functions of the p38 MAPK prevent cell survival under stress condition in two ways, the 
induction of apoptosis and through the removal of mitogenic receptors from the surface [64].  
 
2.4.4 The atypical MAPKs    
 
Apart from Erk1/2 MAPK, the characteristic of serum sensitivity is attributed to further 
MAPKs:  Erk3 and Erk8. Together with Erk4 and Erk7, they belong to the atypical MAPKs 
due to alternative activation mechanisms that differ from the classical three-tier model. 
Upstream activator kinases for all three of them have not been indentified yet [65]. Due to the 
relevance for the present work, the characteristics of Erk7 and Erk8 presented only. The 
Erk7 and Erk8 MAPKs are related MAPKs, which display an overall homology of 69% (on 
amino acid sequence level). They bear the canonical T-E-Y triplet of Erk-like MAPKs and 
possess a C-terminal extension, which has been shown to be important for their activity [66, 
67]. Indeed, both Erk proteins contain two SH3 binding domains within their tails, which 
represent docking sites for Src non-receptor tyrosine kinases. This suggests the involvement 
of both Erk7 and Erk8 MAPK in Src-dependent signalling [65, 68]. In vitro studies have 
demonstrated that Erk7 and Erk8 are distinguishable in their activation and in their activity 
profile towards their substrates [66, 67]. However, despite structural and biochemical 
differences, it is uncertain if they represent paralogues since genome analyses rather 
suggested a classification as orthologues [66, 67, 69]. In spite of the remaining controversial 
discussion and distinct features, Erk7 and Erk8 are considered as distinct MAPKs in the 
present work. 
 
2.4.5 Alternative pathways 
 
Besides the MAPK cascade activation, additional pathways are activated in response to 
growth factor stimuli by RTK. Those are the lipid kinase phosphatidylinositol 3 kinase (PI3K), 
the STAT and the phospholipase Cγ (PLCγ) pathway.   
PLCγ is recruited to the cell membrane and becomes tyrosine phosphorylated by the 
activated RTK. Upon activation, PLCγ produces diacyglycerol (DAG) and inositol-(1,4,5)-P3 
(IP3) by the hydrolysis of phosphatidylinositol-4,5-phosphate (PIP2), which is followed by the 
Ca2+ release from the ER. Free Ca2+ ions and DAG act together in the activation of protein 
kinase C (PKC) which subsequently activates further effectors [64]. 
In the PI3K pathway, the p85 regulatory subunit of PI3K binds to the activated RTK leading 
to the activation of the p110 catalytic subunit of PI3K. Alternatively, PI3K is activated by Ras. 
Activated PI3K causes conformational alteration of IP3, thereby unmasking binding sites for 
proteins containing phospholipid binding domains. As a consequence, PDK1 and PKB/Akt 
dock to the cytoplasmic membrane where Akt is phosphorylated by a heteromeric complex. 
Finally, activated Akt phosphorylation induces the apoptosis pathway.  
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The cytosolic STAT transcription factors are capable to dimerize upon direct activation by 
RTK. Subsequently, they are imported into the nucleus where they induce the expression of 
proliferation genes [64] .  
 
 
 
2.5 Host-parasite interplay during alveolar echinococcosis  
 
2.5.1 Early molecular and biochemical approaches  
 
In 1855, Rudolf Virchow described the clinical course of AE for the first time and 
Echinococcus sp. as causative agent of the disease [70]. Nevertheless, until the 1990s the 
biology of E. multilocularis was poorly characterized on the molecular level. By this time, 
investigations addressed mainly diagnostic probabilities and pathology. Screening of cDNA 
expression libraries with patient sera, some antigens such as Em2, EM10, EM13, Em16 and 
EM18 were identified and proved suitable for diagnosis [24, 25, 71, 72]. Amongst the 
antigens, EM10 was further analysed by functional studies [25, 73]. During this process, 
Em10 was identified as member of the ezrin-radixin-moesin (ERM) cytoskeleton associated 
protein family of E. multilocularis that interacts with PDZ-1 and was thereupon designated 
Elp (ezrin-radixin-moesin like protein) [74]. In general, the ERM proteins are involved in the 
cytoskeletal arrangement and in the signal transduction of Rho and PKB dependent 
developmental processes [75]. In 1999, the characterization of the elp gene locus was the 
first molecular study to shed light on organisation and expression of echinococcal genes [76].  
A further significant work in the molecular characterization was the discovery of trans-spliced 
mRNA in cestodes by Brehm et al [77]. The conventional splicing process is defined as 
fusion of exons from a pre-mature mRNA, resulting in the excision of introns from the same 
RNA strand (cis splicing). In the case of trans-splicing, the exons from different transcripts 
are fused (Fig. 2.6). Usually, a mini-exon of a small nucleolar pre-mRNA, the so-called 
spliced leader (SL), is fused to the 5’ end exon of a mRNA. In 1986, the process was initially 
described for Trypanosoma brucei by showing that all transcripts in this organism contained 
the same 5’ end [78]. Later on, the mechanism was found in the nematode C. elegans where 
60% of all transcripts were trans-spliced and four different SL exist [79, 80]. Among 
cestodes, trans-splicing was described firstly for E. granulosus and E. multilocularis, later for 
T. solium [77, 81]. The Echinococcus SL (36 nt) derives from a small non-poly- adenylated 
snRNA (104 nt) and carries a tri-methyl-guanosine cap. Although in trypanosomes and 
nematodes trans-splicing is clearly involved in resolving poly-cistronic transcripts into mono-
cistronic units for translation, there are additional, as yet unknown mechanisms of gene 
regulation which require this specific mode of transcript processing. Likewise, since poly-
cistronic transcripts have not yet been described in flatworms, the precise functions of 
flatworm SLs are presently unclear although for a few mRNAs it has been shown that the SL 
provides the start ATG for translation initiation [77, 81]. 
Since the mechanism does not occur in humans, SL-containing transcripts are essentially  of 
parasite origin and can be employed for molecular techniques like differential display or SL 
cDNA libraries [81, 82]. 
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Fig. 2.6: Mechanism of trans-splicing. A mini-exon of a small nucleolar pre-mRNA (snRNA), the so-
called spliced leader (SL), is fused to the 5’ end exon of an mRNA. 
 
 
 
2.5.2 In vitro cultivation of E. multilocularis 
 
For the investigation of developmental processes in host-parasite interplay, it is important to 
reduce the complexity of the in vivo situation. The first in vitro cultivation of E. multilocularis 
metacestode larval stage was done in the presence of host tissue blocks or, later on, in the 
presence of defined hepatocyte cell lines [83, 84]. Secreted factors of feeder cells allow the 
metacestode to grow over months so that proliferation and differentiation could be observed 
in vitro. After starting the co-culture, the development of small vesicles of 1 to 2 mm in 
diameter takes up to two weeks while the development of brood capsules takes 
approximately two months. Refinement of the cultivation method was undertaken by 
excluding feeder cells. Here, metacestode vesicles were kept axenically under reducing 
conditions and a nitrogen atmosphere allowing studies on host-parasite interaction without 
indirect effects of host cells [85]. The differentiation to protoscoleces took place only in 
medium pre-conditioned with rat hepatocytes demonstrating the influence of secreted host 
factors of less than 15kDa on the parasite development [86]. Moreover, a culture system for 
E. multilocularis primary cell was recently established [13]. The primary cells were isolated 
from axenically cultivated vesicles and were incubated in the presence of feeder cells 
physically separated or alternatively with pre-conditioned medium under reducing conditions. 
Within a period of approximately five weeks, the primary cells generated new metacestode 
vesicles causing lesions as usual by subsequent injection into the peritoneum of mice [13, 
86]. This method allows prospectively the genetic manipulation of E. multilocularis primary 
cells and in long-range, the regeneration of transgenic parasites. Taken together, the 
established cultivation systems of E. multilocularis allow the analysis of the host-parasite 
interplay and larval parasite development under laboratory conditions. 
 
2.5.3 Genomic sequencing project  
 
Important question in infectious diseases led to whole genome sequence projects by the 
Wellcome Trust Sanger Institute (Hinxton, Cambridge, UK). In cooperation with the groups of 
Klaus Brehm (Würzburg) and Cecilia Fernandez (Montevideo), the Sanger centre therefore 
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engaged in 2003 in a whole genome sequencing project for E. multilocularis, supported by 
extensive EST sequencing on both E. multilocularis and E. granulosus larval stages. Since 
this year, the genomic sequence as fourfold coverage is available under 
http://www.sanger.ac.uk/projects/Echinococcus/. Additional sequence information exists in 
the form of EST data from its relative, the dog tapeworm E. granulosus 
(http://www.nematodes.org/ NeglectedGenomes/Lopho/LophDB.php) [82]. The access to 
genomic sequence data will considerably facilitate the work with E. multilocularis with respect 
to factors involved in the development of the parasite. 
 
2.5.4 Evolutionary conserved signaling in E. multilocularis  
 
Developmental processes in a metazoan organism require the exchange of information 
between cells. Hereby, a given cell does not only need knowledge about its location and 
function in the organism, but also needs the mechanisms to communicate with others to 
adjust to environmental conditions. The systems for cell-cell communication were established 
early in the evolution process of metazoans and can be found already in sponges, the most 
basal animals (see Fig.2.1) [87, 88]. Ions, cell metabolites, as well as hormones represent 
signals for cellular communication, among which the latter are suitable for the communication 
over long distances. Hormones are messengers produced in endocrine cells and exit their 
effect away from the production site by docking on their specific receptors. Amongst 
hormones, lipophilic steroids are capable to pass the cell membrane and to interact with their 
specific receptors and co-regulators in the cytoplasm or nucleus. In contrast, peptide 
hormones bind extracellularely to specific membrane-anchored receptors transducing the 
signal to inner components of the signal pathway. The mechanism of several evolutionarily 
conserved signaling pathways which are involved in development and growth are introduced 
in section 2.4 
In recent years, several members of the respective E. multilocularis signaling pathways have 
been identified (Fig. 2.6). EmNHR1, EmNHR2, EmNHR3, EmSkip and EmGt198 have been 
characterized as factors of nuclear hormone signaling [89-91]. Belonging to peptide hormone 
pathways, the parasite’s homologues of surface RTK of EGF, FGF as well as insulin 
pathways and four surface receptor serine/threonine kinases of the TGF-β family were 
identified [92-96]. For the transduction of external stimuli downstream of these surface 
receptors, the parasite’s homologues of small GTP binding proteins, factors showing 
homology to MAPK cascade members as well as several Smad molecules have been shown 
to play an important role [97-100]. Since the signaling pathways essential for development 
and growth are conserved within the animal kingdom, the question arose to what extent they 
participate in the host-parasite interplay. Several influences of host cytokines on growth and 
differentiation of in vitro cultivated metacestode have been shown so far. Host EGF, for 
example, only slightly stimulates the growth of metacestode vesicles compared to the 
significant effect of host insulin. In contrast, host BMP-2 is able to direct differentiation 
process towards brood capsule formation rather than proliferation [85, 86, 93]. These 
findings suggest that host cytokines are not only essential for the parasite growth, but also 
might be involved in differentiation as well as in the establishment of larvae in the 
corresponding host. The investigation of these signaling pathways may lead to insights 
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concerning the question why protoscoleces develop during the infection of the small rodent 
and less during the infection of humans. 
To conclude, it is essential to examine the signaling pathways for the understanding of the 
host-parasite interplay since the survival of the worm depends not only on the protection 
against the host’s immune defence, but also on the host derived growth factors.  
 
 
 
 
 
Fig. 2.7: Evolutionary conserved signaling in E. multilocularis. See section 2.5.4. 
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2.6 Aim of the project 
 
The uptake of the E. multilocularis oncosphere larvae by humans causes the serious AE. 
The treatment of AE confine of surgery, if it could be applied, and of chemotherapy in any 
case. That means that in operable cases the application of pharmaceuticals should be 
continued for a minimum of two years and the relapse observed for ten years after surgery. 
For inoperable cases, a life-long chemotherapy is recommended. The chemotherapeutical 
option solely consists of the benzimidazole class, in particular albendazole and 
mebendazole. Severe side effects were reported as a result. Problematically, there are no 
alternatives for patients with an incompatibility for benzimidazoles.  
Certainly, there are some efforts to enhance the efficacy of benzimidazole through 
simultaneous application of drugs approved against parasitic diseases such as praziquantel. 
Praziquantel was successfully used as drug of choice for schistosomiasis. However, 
evidences for development praziquantel resistance have emerged in the last decade [101]. In 
addition, studies on animals have shown that cases of resistance were mounted against 
benzimidazole by alteration of the target structure [20, 101].  
The wealth of action with the available options for AE treatment is limited and the medication 
with benzimidazole derivates bears the aforementioned disadvantages, which implicates the 
pursuit of an innovative option. Reliable candidate target structures are parasite unique 
factors that are vital for its development. However, the current knowledge about such 
structures is insufficient since the research on helminths represents a neglected area, which 
is due to the fact that the impact of helminthic infections is insignificant in investing nations 
and the diseases affect primarily the developing world. The identification of such factors 
requires a large investment of cost and time, yet inhibitory agents are still not available at this 
point in time. The second group of suitable target candidates consists of parasite factors, 
which exist as counterpart in the host, but display a low level of homology combined with a 
significantly higher affinity towards the drug compound in comparison to host factors. Based 
on the differences between host and parasite signal transduction pathways a swift success 
through the access to enormous structural and functional data for human homologue can be 
expected. Moreover, inhibitory substances are available in a broad spectrum. Since several 
factors involved in the developmental and proliferation processes are conspicuous in tumour 
formation, amongst EGF receptor and members of MAPK cascade, activity inhibitory drugs 
for those, including even the data for the consequences for cell growth and 
pharmacokinetics, might be used with less additional cost and time. Miltefosine, for example, 
has been originally developed as anti-neoplastic agent, which exerts its effects as inhibitor of 
the PKB/Akt pathway, which is now employed with success for the treatment of leishmaniasis  
[102, 103].  
Despite the fact that the signaling pathways are conserved among the animal kingdom, the 
most members of the E. multilocularis signal transduction display a lower level of homology 
to the respective host factor than the current target structure of the benzimidazole 
compounds. Therefore, the aim of this project was the characterization of signaling pathways 
involved in development and proliferation of the cestode. The identification of unique 
properties of the parasite signal transduction molecules, which distinguishes them from their 
human counterparts, will allow the development of novel anthelminthic therapies. 
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3. Results 
 
3.1 EmMPK2 – the p38 MAPK orthologue of E. multilocularis as a possible target for the 
treatment of AE 
 
3.1.1 Identification and characterization of emmpk2 
 
After initial description of the Erk-like MAPK EmMPK1 by Spiliotis et al. (2006), a cDNA 
encoding a second Echinococcus MAPK has been identified in the course of a MD thesis by 
Rocio Caballero-Gamiz (unpublished). The respective protein was designated EmMPK2 (E. 
multilocularis MAPK 2), encoded by the gene emmpk2. 
The trans-spliced cDNA was identified via degenerative PCR approach using 
oligonucleotides designed to bind the coding regions of the oligopeptides WSVGCIF and 
WYRAPEIM, which are conserved within kinase domains of Ser/Thr kinases. The full-length 
cDNA of emmpk2 was subsequently determined. It comprised 1371 bp (without polyA tail) 
including a 36 bp spliced leader sequence at the 5’ end. A single ORF of 1104 bp was 
present which encoded a protein of 368 amino acids (a deduced molecular weight of 42.5 
kDa; calculated by Compute pI/Mw; ExPasy [104]). EmMPK2 displays significant homology 
on amino acid sequence level to various p38 MAPK orthologues, e.g. human MAPK14, D. 
melanogaster MPK2, C. elegans PMK1 as well as yeast HOG1 (Fig. 3.1). Amino acid 
sequence identity values range from 38% to approximately 50% for yeast HOG1 and human 
p38 MAPKs, respectively. In the case of human p38 MAPKs, the highest homology could be 
found for isoform p38-α (HsMAPK14; 53% identity), followed by p38-β (51%), p38-γ (46%) 
and p38-δ (45%). 
As indicated in Fig. 3.1, the Echinococcus protein contains all residues which are invariant in 
all known eukaryotic protein kinases [105]. In addition, a typical MAPK serine/ threonine 
kinase domain was predicted to be located between Tyr25 and Phe309 by computer based 
SMART analysis [105, 106]. A hallmark of MAP kinases is the presence of a highly 
conserved T-X-Y motif close to the activation loop of the kinase domain in which both the Thr 
and the Tyr residues are phosphorlyated by upstream MKKs. The typical consensus for this 
motif is T-G-Y in p38 MAPKs while Erk- and JNK/SAPK-like MAPKs harbor T-E-Y and T-P-Y 
motifs, respectively. EmMPK2 contained the T-G-Y motif which is typical for p38 MAPKs 
(Fig.3.2). Furthermore, the activation loop of EmMPK2 comprised 6 residues (Fig. 3.2) which 
is characteristic of p38 MAPKs while Erk- and JNK/SAPK-MAPKs typically contain activation 
loops of 12 or 8 residues, respectively [98]. 
Taken together, these structural features identified EmMPK2 as a member of the p38 
subfamily of MAPKs. Interestingly, EmMPK2 showed several differences to known p38 
MAPKs, which included amino acid exchanges at positions previously shown for yeast HOG1 
and human p38 MAPK-α to be involved in the regulation of enzymatic activity [61, 107-109]. 
Furthermore, one of the conserved Asp residues in the so-called ‘common docking site’ is 
replaced by Asn in the case of EmMPK2. This site regulates the interaction of MAPKs with 
upstream MKKs and with phosphatases (Fig. 3.1)[110].  
Analysis of the chromosomal emmpk2 locus revealed that the ORF is contained within 10 
exons, separated by 9 introns (Fig. 3.1), which all displayed canonical GT- and AG-motifs at 
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the splice-donor and -acceptor sites, respectively. Of these 9 introns, 7 shared conserved 
exon-intron boundaries with the human genes encoding p38 MAPKs while only 2 and 4 
conserved boundaries were shared with introns of the human genes encoding Erk-like 
MAPKs and JNK/SAPKs, respectively. Besides the high degree of identity, this also indicates 
a close evolutionary relationship between emmpk2 and mammalian p38 MAPK genes.  
Using the cDNA sequence as query for genome data analysis, its chromosomal organization 
could be verified (Tab. 3.1). The emmpk2 chromosomal locus localized to a contig of 21.211 
bp and displayed a nucleotide sequence and exon-intron organization identical to that, which 
has been determined by PCR approach. As expected, the genomic locus contained a 
consensus splice acceptor site at the position where the SL was found in the cDNA (data not 
shown). Extensive BLAST analyses using the sequences of EmMPK2 and human p38 MAPK 
isoforms as queries did not reveal the presence of p38 MAPK encoding genes other than 
emmpk2 in the E. multilocularis genome. However, a gene with high similarity to emmpk2 
was identified which encodes an unusual MAPK (EmSSY) and is presented in section 3.3. 
Taken together, these data verified our analyses of the emmpk2 cDNA and genomic locus 
and indicated that EmMPK2 is the only typical p38-like MAPK of the parasite. 
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Fig. 3.1: Amino acid sequence comparison between EmMPK2 and other p38 MAPKs. Shown are 
sequences of EmMPK2, human p38 MAPK-α (HsMAPK14; Q16539), D. melanogaster p38 MAPK 
(DmMK14A; O62618), C. elegans stress activated protein kinase PMK-1 (CePMK1; Q17446) and 
yeast HOG-1 (ScHOG1; P32485). The threshold for identical amino acid residues, which are 
highlighted in white on black background, is set to 60%. Similar residues are shaded in blue. Asterisks 
above the alignment mark residues which are highly conserved in eukaryotic protein kinases [106]. 
‘V’s indicate intron positions on the encoding gene. Brackets above the lines highlight ATP-binding 
pocket, catalytic and activation loop as well as common docking (CD) site. ‘P’ marks Thr and Tyr 
residues of the conserved T-G-Y motif within the activation loop. Replacements of conserved residues 
within the CD site, which are assumed to be important for the interaction with regulator proteins are 
marked by ‘U’s [110]. ‘M’s above the alignment indicate mutation of residues which lead to 
constitutively activated forms of yeast HOG1 and HsMAPK14 [61, 107-109]. ‘S’ marked residues 
involved in stabilization of the L16 loop [109]. Black points indicate residues of human p38 MAPK-α, 
which are involved in the binding of pyridinyl-imidazole inhibitors [61].  
 
 
 
 
 
Fig. 3.2: Comparison of MAPK activation loops. Alignment of amino acid sequences of EmMPK2 
and MAPKs from the p38, Erk and JNK/SAPK family of different phylogenetic origins.The activation 
loops are flanked by the highly conserved subdomains VII and VIII and contain the hallmark of MAPK, 
the dual-phosphorylation motif T-X-Y[105].  
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Tab. 3.1: Gene structure of emmpk2. The gene emmpk2 is localized of contig no.7471 of the first 
assembly. Eight exon/ intron boundaries could be found at corresponding positions in hsp38 MAPK-α, 
two exon/ intron boundaries in hserk1 and four in hsjnk1. All exon/ intron boundaries display canonical 
GT…AG motifs.  
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3.1.2 Expression analysis of emmpk2 in Echinococcus larval stages 
 
The expression of emmpk2 was analysed in larval stages metacestode and protoscolex 
before and after activation through pepsin/ low pH via semi-quantitative RT-PCR using RNA 
isolated from the corresponding stages as a template. The activation of protoscolex by the 
treatment with low pH and bile salts mimicks the transition of the larvae to the digestive 
system of the definitive host and leads to the evagination of the protoskolex. In a first step, 
the isolated RNAs were normalized for the expression of the housekeeping gene elp 
encoding the Echinococcus Ezrin-Radixin-Moesin (ERM) like protein Elp [73, 76]. As 
depicted in Fig.3.3 A, emmpk2 is equally expressed in metacestode and in both 
protoscoleces preparations. In addition, the expression of emmpk2 was compared between 
metacestode vesicles cultivated in the axenic system and vesicles cultivated in the presence 
of feeder cells. For this, the isolated RNA was reverse transcribed and the expression levels 
of the standard gene elp and emmpk2 were addressed via multiplex PCR developed in this 
work. As presented in Fig. 3.3 B, emmpk2 displays a constitutive expression level under both 
cultivation conditions. 
 
 
  
Fig. 3.3: Analysis of emmpk2 
expression in different larval 
stages of E. multilocularis. 
(A) Total RNA was isolated from in 
vitro cultivated metacestode vesicles 
(MV) as well as from protoscoleces 
after cultivation in Mongolian jirds 
before (invaginated (P)) and after the 
in vitro activation (Pact)) by low pH 
and bile salts.  Different dilutions of 
cDNA were used in the semi-
quantitative RT-PCR approach to 
analyze specifically the expression 
levels for emmpk2 and the 
housekeeping gene elp. (B) 
Multiplex RT PCR analysis to 
compare the expression of emmpk2 
in metacestode vesicles of the co-
culture (MVco) and the axenic culture 
(MVax). 
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3.1.3 Expression and activity analyses of EmMPK2 in Echinococcus larval stages 
 
3.1.3.1 Recombinantly expressed EmMPK2 - specific detection of the activated protein via 
antibodies raised against human p38 MAPK 
 
For the detection of EmMPK2 in Echinococcus larval stages and for downstream analyses, 
suitable antibodies were needed. In the case of human p38 MAPK, an antibody specific for 
the phosphorylated form is commercially available, which recognizes the dual-
phosphorylation motif pT-G-pY. To examine if this antibody also detects phosphorylated 
EmMPK2, EmMPK2 was recombinantly expressed in E. coli and purified under denaturing 
and native conditions using the pBAD expression system. Western blotting revealed that the 
phospho-specific antibody detected only the natively purified recombinant EmMPK2 
appearing as band with an expected size of approximately 50kDa (Fig. 3.4 A). Since the 
suitability of this antibody had thus been proven, I used it to detect EmMPK2. 
In lysates of echinococcal larvae, the antibody recognized a protein of approximately 47.5 
kDa, which is in agreement with the deducted molecular weight of EmMPK2 (Fig.3.4 A). 
Nevertheless, the findings that this antibody detected several proteins in the crude lysate of 
metacestode vesicles raised the possibility that cross-reactivity with other MAPK might occur. 
Hence, supplementary approaches were carried out to clarify the specificity of the employed 
anti-phospho p38 MAPK antibody. For this, crude lysates of protoscoleces as well as 
recombinant EmMPK1 were subjected to Western blotting (Fig.3.4 B, C).  
EmMPK1 has a deducted MW of 42 kDa (appearing as 46 kDa band) and might represent, 
due to its similarity with EmMPK2, one MAPK with which the phopsho-p38 MAPK antibody 
might cross-react. Therefore, EmMPK1 was recombinantly expressed, fused to either GST 
(pGEX-3X vector) or to a hexahistidine tag and the V5-epitope (pBAD vector), and 
investigated using the anti-ERK and the anti-phospho-ERK antibodies (Fig.3.4 B). The result 
showed that EmMPK1 was correctly identified as fusion proteins in the expected sizes by the 
anti-ERK antibody. In contrast, EmMPK1 was not recognized by the phospho-specific ERK 
antibody confirming the previously presented data that EmMPK1 is not phosphorylated in its 
T-E-Y motif after recombinant expression [73, 76, 98]. However, the phospho-specific p38 
antibody did not only detected recombinant EmMPK2 but also recombinant EmMPK1 of both 
expression systems, particulary in the pBAD system. Taken together, these findings suggest 
that the phospho-specific p38 antibody non-specifically also interacts with EmMPK1 and 
either recognizes the T-X-Y motif in its non-phosphorylated form or an epitope outside the T-
X-Y motif. Nevertheless, despite non-specific interactions of the p38 antibody with EmMPK1 
and several other proteins, the specific detection of EmMPK2 still was feasible as 
demonstrated by the following approach. I applied available p38 MAPK inhibitors to the in 
vitro cultivated metacestode vesicles and analyzed protein phosphorylation by Western 
blotting. Adding as less as 100 µM ML3403 inhibitor abolished the detection of the 47.5 kDa 
protein in the lysates (Fig.3.4 C). Since EmMPK2 displays a pronounced 
autophosphorylation activity upon recombinant expression in E. coli (see above), these data 
indicate that the 47.5 kDa band indeed represents EmMPK2. This is also supported by the 
specificity of the ML3403 inhibitor towards EmMPK2, not EmMPK1 as outlined below. 
Additionally, regarding the calculated sizes of both MAP kinases with the corresponding 
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bands in Western blot experiments, the higher running band could represents EmMPK2. 
(Fig. 3.4 C).  
Taken together, the human anti-phospho-p38 antibody clearly detected the 47.5 kDa band 
attributed to the parasite p38 MAPK orthologue EmMPK2.  
 
 
 
 
Fig. 3.4: Heterologue expression of EmMPK2 and its identification in E. multilocularis larvae 
with the cross-reacting human anti-active p38 antibody. Western blot analyses after sample 
separation via 12 % SDS-PAGE. (A) Detection of recombinant EmMPK2 after native and denatured 
protein purification (see also chapter 3.1.5) and analysis of EmMPK2 in in vitro cultured metacestode 
vesicles (MV) using the anti-phospho-p38 antibody. (B) Cross-reactivity of the anti-phospho p38 
antibody analysed by comparison of recombinantly expressed MAP kinases of the parasite using the 
anti-Erk, the phospho-specific anti-phospho-Erk (recognizing the phoshorylated T-E-Y motif) and the 
phospho-specific anti-active p38 antibodies (produced against the phosphorylated T-G-Y motif). 
EmMPK1, the Erk orthologue was expressed in the bacterial expression vectors pBAD and pGEX-3x, 
EmMPK2 in the pBAD vector. (C) Analysis of lysates from protoscoleces before (P) and after 
activation (Pact) by low pH and bile salts and MV, which were cultivated without or with ML3403 (a p38 
MAPK inhibitor) and the inhibitor solvent DMSO, respectively using the anti-phospho p38 antibody 
(see chapter 3.1.6).  
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3.1.3.2 Activity of EmMPK2  
 
The expression of EmMPK2 was investigated in the different larval stages of E. multilocularis 
by Western blot analysis with the human anti-phospho-p38 antibody recognizing the dual-
phosphorylated motif T-G-Y. Elp was used as loading control [73, 76]. As shown in Fig. 3.5, 
the western blot experiment confirmed the result of the RT-PCR that EmMPK2 is expressed 
and phosphorylated in the metacestode. It is also expressed and phosphorylated in 
activated, and to less degree in non-activated protoscoleces.  
 
 
 
Fig. 3.5: Expression of EmMPK2 in E. multilocularis 
larval stages. Lysates of in vitro cultivated metacestode 
vesicles (MV), invaginated protoscoleces (P) and 
activated protoscoleces (Pact) were separated on 12% 
SD-PAGE and after transfer onto nitrocellulose 
membrane analysed by Western blotting using the 
phospho-specific anti-phospho-p38 antibody. Elp was 
observed as loading control [73, 76]. 
 
 
3.1.4 EmMPK2 activation in in vitro cultivated metacestode vesicles 
  
Initial experiments to investigate the influence of exogenous stimuli on EmMPK2 activation 
revealed that the protein was always phosphorylated when the metacestode vesicles had 
been mechanically damaged prior to the application of sample buffer. Since p38-like MAPKs 
are known to be induced by stress conditions, these results could have been due to a similar 
function of EmMPK2 in Echinococcus. Therefore, in an alternative approach, intact 
metacestode vesicles were frozen in liquid nitrogen directly after isolation from culture and 
were then investigated through western blot analysis (Fig. 3.6 A). Indeed, after applying this 
procedure, phospho-EmMPK2 was no longer detectable, indicating that the protein is 
specifically activated upon physical disruption of metacestode vesicles and supporting the 
idea that EmMPK2 might serve as a stress-kinase in the parasite. 
To verify the result that EmMPK2 is activated in response to mechanical disruption, 
metacestode vesicles were damaged by different methods. First, the vesicles were disrupted 
by resuspending with a pipette and the samples were prepared in the two ways, i.e. 
mechanical disruption before addition of sample buffer (A) or after the addition of sample 
buffer (B). Second, the vesicles were cut with a scalpel and third, the damage was performed 
by pricking the vesicles with a needle. Notably, EmMPK2 phosphorylation was detectable 
upon disruption only and independent of the order of working steps (Fig. 3.6 B). So the result 
indicated that the phosphorylation of EmMPK2 is induced by strong mechanically destruction 
of the vesicles. It needs to be mentioned that the phosphorylation induced by mechanical 
stress might be caused indirectly by osmotic changes due to the loss of hydatid fluid.  
Based on this result, the subsequent investigation, which addressed the identification of 
activation or stress conditions for E. multilocularis, were performed on metacestode larvae 
pricked to remove the hydatide fluid.  
Besides the mechanical stress, several oxidative stress situations, in which human p38 is 
activated, were tested on metacestode vesicles cultivated in vitro. DMSO, hydrogen peroxide 
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and paraquat were selected as oxidative stress inducers. However, neither of these stress 
conditions led to phosphorylation of EmMPK2. 
In case of mammalian cells, it has been shown that p38 MAPK can be activated by TGF-β, 
BMP and insulin. Stimulatory effects of these factors on E. multilocularis could already be 
demonstrated [86, 93]. Thus, the potential influence of these host growth factors on 
EmMPK2 was addressed by incubation of metacestode vesicles in the presence of either 
host insulin, TGF-β, BMP or EGF. In addition, the presence of serum as well as the presence 
of feeder cells were tested as activation stimuli. However, in all experimental setups neither 
host factors nor serum had an effect on the EmMPK2 T-G-Y phosphorylation (data not 
shown). A possible explanation for failure to detect altered phosphorylation states of 
EmMPK2 could be normalization of samples for their total protein content via Western 
blotting for Elp. This could mean that changes in EmMPK2’s amount in these otherwise 
normalized samples were overlooked. Several antibodies covering total amount of human 
p38 MAPK did not recognize EmMPK2 and therefore, Elp was observed only for protein 
content.  Nevertheless, this seemed to be very unlike explanation since a multitude of 
experiments was carried out. In neither case, an indication for altered amount of EmMPK2 
was observed.  
Taken together, the failure to stimulate phosphorylation of EmMPK2 suggests that the 
EmMPK2 signaling did not show resemblance to the activation of human p38 MAPK. 
Besides strong physical damaging of integer vesicles, no stimulus or stress situation could 
be identified leading to increased phosphorylation, i.e. activation of the p38 MAPK orthologue 
of E. multilocularis (Fig. 3.7).  
 
 
 
 
 
 
 
Fig. 3.6: Phosphorylation of EmMPK2 upon physical stress. Indicated are Western blot analyses 
of metacestode vesicle lysates, which were separated on 12% PAA detecting the phosphorylation on 
the activation motif T-G-Y of EmMPK2 by the anti-phospho-p38 antibody. Elp served as loading 
control. Vesicles were prepared for lysates in different ways: (A) Mechanical disruption before addition 
of sample buffer (A) or liquid nitrogen treatment before the addition of sample buffer (BN2).  
(B) Addition of sample buffer before (A) or after (BSM) damaging of vesicles. Damaging was performed 
by disruption with a pipette (dis), cutting with a scalpel (cut) and pricking with a needle (lance). 
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Fig. 3.7: Summary of environmental conditions tested on in vitro cultivated metacestode 
vesicles monitoring EmMPK2 phosphorylation. 
 
 
 
3.1.5 EmMPK2 – an enzymatically active MAP kinase  
 
3.1.5.1 TGY- phosphorylation of EmMPK2 after recombinant expression – differences to 
human p38 MAPK 
 
Although sequence homology clearly identified EmMPK2 as a member of the MAPKs, no 
experimental data were available proving that it also exerts kinase activity. Toward this end, 
EmMPK2 was expressed as fusion protein with V5-epitope and 6xHis-tag in E.coli (see also 
3.1.3). The purification was done either under denaturing or native conditions. Protein 
expression was performed via Western Blot analyses with anti-V5 antibody and detected 
EmMPK2 as fusion protein with the expected size of approximately 50 kDa as shown in Fig. 
3.8 A. Further, I investigated whether EmMPK2 is enzymatically active after recombinant 
expression and subsequent purification. To this end, the anti-phospho-p38 antibody 
recognizing the dual-phosphorylated TGY motif of active p38 MAPK was used. The result 
showed that heterologously expressed EmMPK2 was both phosphorylated and active, only 
when purified under native conditions (Fig. 3.8 A). This was compared with the activity of 
host p38 MAPK-α expressed in the same way as EmMPK2. Using the anti-V5 antibody, the 
p38 MAPK-α fusion protein was detected with the expected size of approximately 48 kDa. 
When the activity of human p38 MAPK-α was analysed using the phospho-specific anti-p38 
antibody, only a weak band was detected, meaning a lower activation level of the human 
kinase compared to EmMPK2. As negative control, lacZ was expressed.  
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3.1.5.2 In vitro activity of EmMPK2 and its inhibition  
 
EmMPK2 kinase activity was tested through in vitro phosphorylation of the common kinase 
substrate myelin basic protein (MBP) in the presence of radioactively labelled γ-ATP.  As 
shown in Fig. 3.9 A, EmMPK2 phosphorylated MBP. In contrast, human p38 did not exert 
detectable enzymatic activity. 
Furthermore, the enzymatic activity of EmMPK2 could be blocked by incubation with 
commercial available ATP competitive p38 inhibitors SB202190  and ML3403 (Fig. 3.9 B) 
[111, 112]. In this assay, the kinase activity was reduced with increasing inhibitor 
concentration and ML3403 was more effective than SB202190.   
Interestingly, in the assays using recombinant EmMPK2, an additionally 50 kDa band 
appeared. Since the recombinant Echinococcus protein has 50 kDa, this strongly suggested 
an auto-phosphorylation-reaction (Fig. 3.9 C). This auto-phosphorylation was also inhibited 
by the p38 inhibitors in the same manner as observed for MBP. In case of human p38 
MAPK, no auto-phosphorylation was detected (Fig. 3.9 D).  
 
 
 
 
 
 
 
Fig. 3.8: EmMPK2 as active enzyme after recombinant expression and purification under native 
condition. Indicated are Western blot analyses after previous separation of recombinant proteins via 
12% SDS-PAGE. (A) After heterologue expression of EmMPK2 as fusion protein in the bacterial 
expression vector pBAD and subsequent purification under native and denatured conditions the 
phosphorylation pattern of EmMPK2 was investigated using the anti-phospho-p38 antibody. 
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Additionally, the enzymatic activity of EmMPK2 from both preparations was observed by incorporation 
of radioactive labelled phosphate into the common kinase substrate myelin basic protein (MBP). The 
samples were separated on 15 % SDS-PAGE and the signal detected by exposing the blotted 
membrane on x-ray films. (B) Phosphorylation of EmMPK2 after recombinant expression and 
subsequent native preparation was compared to human MAP kinase p38 isoform α by unchanged 
experimental settings. LacZ was used as negative control. For Western blot detection, an anti-V5 
antibody was used.  
 
  
 
 
 
Fig. 3.9: In vitro kinase assay of EmMPK2 and its inhibition by human p38 inhibitor 
compounds.  Enzymatic activity of echinococcal EmMPK2 and human p38- α was analysed detecting 
the incorporation of radioactive labelled γ- ³²P from ATP into myelin basic protein (MBP). As negative 
control LacZ in the pBAD expression vector was used. After expression in E.coli, the fusion proteins 
were affinity purified under native conditions and set in equal amounts in the kinase assay. The 
reactions were stopped by adding stop mix. The samples were separated on 15% SDS-PAGE and 
subsequently transferred on nitrocellulose membrane. X-ray films were exposed for 4 days. (A) 
Detection of radioactively phoshorylated  isoforms of MBP by LacZ, EmMPK2 and Hsp38α. (B) 
Inhibition of the substrate phosphorylation by incubation of EmMPK2 in the presence of two 
commercial available ATP competitive p38 inhibitors SB202190 and ML3403 in the indicated dilution. 
EmMPK2 was incubated with inhibitor dissolvent DMSO as control. (C) Detection of radioactive 
labelled kinases (D) Inhibition of autophosphorylation of EmMPK2 by SB202190 and ML3403.  
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3.1.6 Treatment of in vitro cultivated metacestode vesicles with pyridinyl imidazoles 
 
3.1.6.1 Increased alkaline phosphatase activity as consequence of drug influence 
 
The p38 inhibitor compound ML3403 was tested concerning influences on the growth of in 
vitro cultivated metacestode vesicles. In a first set of experiments, metacestode vesicles from 
hepatocytes co-culture were used and incubated in groups of five in 12well plates with 
normal culture medium containing 10% FCS. Incubation was performed for four days in the 
presence of the p38 inhibitor in the indicated dilution steps. Vesicles incubated in the 
presence of dissolvent DMSO served as controls.  
As marker for vesicle viability, alkaline phosphatase (AP) activity in the culture supernatant 
was measured, using p-nitrophenyl phosphate as substrate according to the previously 
published protocol [113]. Figure 3.10 displays the absorbance of 405 nm over the time 
course representing free alkaline phosphatase activity. All values are normalized against rat 
hepatocytes incubating in culture. In the presence of ML3403, a significant increase of AP 
activity was measured at a concentration of 1 mM and a slight increase at 0.1 mM in 
comparison to DMSO treated vesicles. 
After four days, sixty percent of the vesicles treated with 1 mM exhibited damage in the 
laminated and germinal layer and lost structural integrity as observed by light microscopy. 
 
 
 
 
 
Fig. 3.10: Alkaline Phosphatase activity in 
the culture supernatant of E. multilocularis 
as indication of metacestode vesicle 
damage. p38 inhibitor ML3403 was tested in a 
time course experiment with in vitro cultured 
metacestode vesicles. Metacestode vesicles 
were incubated over 4 d in the presence of the 
compound in dilution steps of 5 µM up to 1mM 
and in the presence of dissolvent DMSO. At 
the indicated time points, the alkaline 
phosphatase activity was determined using p-
nitrophenyl phosphate as substrate by 
measurement of absorbance at 405 nm. 
 
 
 
 
3.1.6.2 Pyridinyl imidazoles specifically target EmMPK2 
 
To investigate whether the pyridinyl imidazole compounds specifically targeted EmMPK2, the 
phosphorylation of EmMPK2 in drug treated metacestode vesicles was measured using the 
phospho-specific p38-antibody since, as outlined above, the phosphorylation of EmMPK2 
mainly depends on autophosphorylation activity (Fig. 3.11). Additionally, the phosphorylation 
on the T-E-Y motif of EmMPK1, the Erk orthologue of E. multilocularis was assessed using 
the phospho- specific Erk-antibody [98]. The Elp protein and total EmMPK1 acted as 
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standards for protein content. As indicated in Fig.3.11, the dissolvent DMSO affected neither 
the activity of EmMPK2 nor the phosphorylation of EmMPK1; in contrast, the p38 inhibitor 
blocked specifically the phosphorylation on the T-G-Y motif of EmMPK2.  
 
 
 
 
Fig. 3.11: The p38 inhibitor ML3403 targets 
EmMPK2, the p38 orthologue of the parasite. 
One millilitre of axenically cultivated metacestode 
vesicles (MV) were incubated for 3.5 h with 10 µM 
ML3403 or with the inhibitor dissolvent DMSO alone 
Samples were separated on 12% PAA and 
analysed via Western blotting. EmMPK1 was 
detected by the anti-ERK antibody and the anti-
phospho-ERK antibody, EmMPK2 by the anti-
phospho-p38 antibody. Elp was used as loading 
control using the anti-Em10 antibody. 
 
 
 
3.1.6.3 Inactivation of metacestode vesicles by pyridinyl imidazole compounds 
 
The results from the in vitro MAPK assay revealed that the pyridinyl imidazole compounds 
ML3403 and SB202190 inhibit the enzymatic activity of EmMPK2. Hence, the influence of 
both cell-permeable drugs was investigated on in vitro cultivated metacestode larvae. 
Metacestode vesicles which either derived from long-term axenic cultivation or from co-
cultivation with feeder cells were incubated in groups of five in normal culture medium. After 
one day of incubation, vesicle integrity was assessed microscopically. ML3403 and 
SB202190 were then added in defined concentrations and the physical appearance of the 
vesicles was assessed daily. Structurally intact vesicles were defined as viable whereas 
vesicles that have lost turgor were defined as inactivated (for examples, see fig. 3.13).  
As shown in Fig. 3.12, SB202190 and ML3404 significantly diminished vesicle survival in a 
concentration dependent manner. Approximately 50% of vesicles were killed by 5 µM of 
SB202190 at day 4 (A, B), whereas for the same effect a lower concentration of 0.5 µM 
ML3403 was sufficient (C, D). The survival on the last day of the experiment was analysed 
separately in the bar graphs E and F. The influence of 5 µM of the two compounds was 
highly significant in comparison to the DMSO treated control. Furthermore, there was a 
significant difference in the ability of both drugs to inactivate metacestode vesicles, as 
evaluated by ANOVA and Tukey’s multiple comparison test. The inhibitory concentrations 
(IC50) of ML3403 and SB202190 were graphically determined by linear regression (Fig.3.12, 
G and H). For ML3403, IC50 values of 55 nM for vesicles originating from co-culture and 42 
nM for vesicles from the axenic culture were obtained. Higher concentrations of 3.8 and 3.5 
µM, respectively, were calculated for SB202190 (Fig.3.12, I). Hence, although both drugs 
display different capacities to inactivate E. multilocularis, it was irrelevant whether the 
metacestode vesicles had previously been incubated in the presence of feeder cells or under 
axenic conditions. 
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Fig. 3.12: Killing of in vitro cultivated metacestode vesicles upon treatment with the p38 
inhibitors SB202190 and ML3403. Co-cultivated (A, C, E, G, I) and axenically cultivated (B, D, F, H, 
I) metacestode vesicles were transferred into culture medium including high serum concentration. One 
day later, the integrity of vesicles was assessed via LM and the time course experiment was started by 
adding inhibitor dissolvent DMSO or SB202190 (A, B) and ML3403 (C, D) in the indicated 
concentrations. The viability of the vesicles was monitored each day by light microscopy. At the end, 
the survival of metacestode vesicles was quantified and analysed separately in figure E and F. IC50 
values, indicating the concentration where 50% of the vesicles were killed, were determined via linear 
regression (G, H). Both r squared values indicate an extremely high significance of fitting. Accordingly, 
IC50 of 3.8 µM and 3.5 µM, were calculated for SB202190; IC50 of 55 nM and 42 nM for ML3403 (I).  
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3.1.7 Treatment of Echinococcus primary cells with pyridinyl imidazoles 
 
Very recently, it has been reported that primary cell cultures from digested metacestode 
vesicles contain totipotent germinal cells (the cestode equivalent to planarian 'neoblasts') 
which are able to regenerate new vesicles when incubated in vitro [13]. Due to the fact that in 
vitro cultivated metacestode vesicles were inactivated by treatment with the compounds 
ML3403 and SB212090, the question arose whether a regeneration of new vesicles is 
possible after treatment. Axenically cultivated metacestode vesicles were incubated in 
DMEM containing 10% FCS, antibiotics and DMSO with or without ML3403 or SB202190. 
After 4 days, the time after which 90% or 50% of vesicles were destroyed by 5 µM ML3403 
or 5 µM SB202190, respectively, Echinococcus primary cells were isolated and incubated in 
well- plates to assess the regeneration process for 4 weeks (Fig. 3.13). Primary cells from 
the DMSO treated control group formed cell aggregates with central cavities, indicating 
active regeneration. In contrast, primary cells from ML3403 treated vesicles remained single 
cells throughout the incubation. The result for vesicle regeneration originating from the 
SB202190 treated group was similar to ML3403 with the exception that several small 
aggregates were formed which did, however, not develop central cavities. 
In a further experiment, primary cells were isolated from intact and untreated metacestode 
vesicles and then incubated in medium containing the inhibitory compounds. The time course 
of vesicles regeneration in the presence of DMSO without or with SB202190 or ML3403 is 
shown in fig. 3.14. After 7d, the formation of aggregates was similar in all groups. However, 
the morphology of drug treated cells was more granular as those of the control cells, an 
indication for decreased vitality. One week later, the number of DMSO treated primary cells 
had increased and the aggregates appeared cloudy indicating cavity formation. SB202190 
treated cells formed slightly more aggregates than ML3403 treated cells but both cultures 
showed less and more amorphous cell clusters than the control. 
In addition, the medium of the drug treated cells remained red in contrast to cells, which were 
incubated in the presence of DMSO, where the colour of culture medium containing pH 
indicator turned yellow after one week. This indicated the excretion of acid metabolism final 
products from the viable DMSO treated cells.  
At day 28, all cell clusters of primary cells incubated in the presence of ML3403 were 
dissolved and the colour continued to be red. SB202190 treated primary cells showed small 
aggregates and spread diffuse in most instances on the well bottom. In the cavities of DMSO 
treated primary cells, on the other hand, small vesicles emerged.  
After one week of cultivation, emmpk2 expression was investigated using RT-PCR. As 
shown in Fig. 3.14 A, the emmpk2 mRNA was clearly detectable in DMSO- and in ML3403-
treated cultures. Furthermore, the 42 kDa protein band which reacted with the anti-phospho-
p38 antibody was present in primary cultures (Fig. 3.14 B). Upon treatment with 5 µM 
ML3403 for one week, phospho-EmMPK2 was no longer detectable (Fig. 3.14 B). 
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Fig. 3.13: Generation of 
metacestode vesicles out of 
Echinococcus primary cells in the 
presence of ML3403. Axenically 
cultivated vesicles were incubated in 
the presence of DMSO with or without 
5 µM p38 inhibitor ML3403 for 4 days, 
after which 90% of the vesicles were 
killed. Subsequent to isolation, primary 
cells from treated vesicles were 
seeded in 24 well plates. The 
formation of cell aggregates, central 
cavities and intact vesicles was only 
observed for primary cells that derived 
from DMSO-controls. No regeneration 
was observed for inhibitor-treated 
cultures. 
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Fig. 3.14: Treatment of Echinococcus multilocularis primary cells with ML3403 and SB202190. 
Primary cells were isolated from axenically cultivated metacestode vesicles. Subsequent incubation 
occurred with pre-conditioned medium in 24well plates in the presence of inhibitor dissolvent DMSO 
with or without 5 µM ML3403 and SB202190. After one week incubation, emmpk2 and elp expression 
was analysed via RT PCR (A) in DMSO (lane 1) and ML3403 (lane 2) treated cells. At the same time 
point, EmMPK2 phosphorylation (B) was monitored in primary cells incubated in the presence of 
DMSO (3) and ML3403 (4). Recombinant LacZ (lane 1) and EmMPK2 (lane 2).served as controls 
(C).The pictures were taken after 7, 14 and 28 days of incubation time (CC = central cavity). 
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3.1.8 Treatment of in vitro cultivated protoscoleces with pyridinyl imidazoles 
 
Addressing the survival capability of E. multilocularis larval stages in the presence of p38 
MAPK inhibitors, protoscoleces of isolate J31 were cultivated in vitro under the influence of 
ML3403. The protoscoleces, derived from in vivo cultivated E. multilocularis, were treated 
with bile salts and pH2 after isolation to obtain evaginated larvae (thus also removing 
contaminating host cells). Aliquots of 100 µl protoscoleces suspension in 1x PBS were 
incubated in 24 well plates with 1 ml DMEM containing high serum concentration and 
antibiotics per well. Control groups were larvae without and with DMSO. ML3403 was added 
to a final concentration of 10 µM. At the beginning of the experiment, all protoscoleces 
appeared evaginated and were motile. Untreated and DMSO treated protoscoleces 
maintained this phenotype to the end of experiment; inhibitor-treated protoscoleces, on the 
other hand, displayed variable morphologies from lightly bloated to globular appearance (Fig. 
3.15, A-E). In some cases a transparent blister could be observed on tail or head (Fig. 3.15, 
A, B). After two weeks, the majority of control larvae appeared globular. Rostellum and 
suckers were well-defined and the border of the body was clearly visible during three weeks 
of incubation. Protoscoleces, which were incubated in the presence of 10 µM ML3403, 
condensed over time and presented an oval corpus, lacking a defined neck region. In 
addition, they were more granular and unable to move after two weeks. Bodylines did not 
appear well- defined and the tegument as well as single cells were detached.  
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Fig. 3.15: Treatment of in vitro cultivated protoscoleces with ML3404. Jirds infected with E. 
multilocularis isolate J31 were sacrificed for protoscoleces recovery according to the standard 
procedure. Incubation with bile salts and low pH was performed successively for protoscolex activation 
and the elimination of host cells. For in vitro cultivation, 100 µl of the obtained protoscolex suspension 
were transferred to 24 well plates with 1 ml DMEM including 10% FCS and antibiotics per well. 24 h 
later, ML3403 was added to a final concentration of 10 µM, DMSO as control. During cultivation of 
three weeks, untreated protoscoleces appeared in variable morphology just like protoscoleces in the 
presence of DMSO (A-E). Most of protoscoleces presented the strobilar form with or without bubbles 
on head or tail (A, B) with high agility in the beginning and changed the morphology finally to the 
globular form (C, D, E). The body form with tegument and structures like rostellum and suckers were 
clearly defined throughout incubation. Drug treated protoscoleces appeared as indicated in F-J. 
Initially agile protoscoleces with well-defined structures showed a rounded off and contracted form 
with leaking-like blisters (coming off of the tegument) and were unable to move after two weeks. A 
neck structure was not identifiable anymore. The appearance was darker and more granular as in the 
DMSO control group.  
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3.1.9 Effects of pyridinyl imidazoles on mammalian cells 
  
The influence of SB202190 and ML3403 on the viability of several host cell lines was 
investigated using inhibitor concentrations which effectively inactivated in vitro cultivated 
metacestode vesicles. For this, rat Reuber hepatoma cells (RH-), human brain-derived 
endothelial cells (HBMEC) and human embryonic kidney cells (HEK293) were incubated with 
concentration from 0.5 to 50 µM of both drugs or DMSO. After 4 days, live-dead-staining of 
the mammalian cells was performed (Fig. 3.16). No significant effects on the viability were 
observed for either of these cell lines up to concentrations of 5 µM. The only deleterious 
effect was detectable for ML3404 of 50 µM on RH- cells. The result showed that both 
compounds SB202190 and ML3403 in concentrations of 0.5 to 50 µM, which inactivated over 
50% of the metacestode vesicles after 4 days, did not decrease the viability of the 
mammalian cells cultivated under comparable conditions.  
 
 
 
 
 
 
 
Fig. 3.16: Treatment of host cells with 
SB202190 and ML3403. According to the 
established crystal violet live-dead staining 
protocol [114], the viability of the mammalian cell 
lines HEK293 (A), HBMEC (B) and RH- (C) was 
observed after treatment for 4 days with the 
dissolvent DMSO or both p38 inhibitors 
SB202190 and ML3403 in concentration, which 
inactivated E. multilocularis metacestode 
vesicles. Error bars indicate SD over the mean. 
Using ANOVA and Tukey’s multiple comparison 
test for statistical analyses, the values for inhibitor 
treated cells are not significantly (ns) different 
from values of DMSO treated control.  
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3.2 Treatment of the cestodes E. granulosus and T. crassiceps with pyridinyl imidazoles 
 
In vitro cultivated metacestode larvae of E. multilocularis were killed by the compounds 
ML3403 and SB202190, which were originally designed to inactivate human p38 MAP 
kinases. In view of these results, the question arose whether the inhibitors show similar 
effects on other cestodes. In this regard, the p38 MAPK orthologues of Taenia crassiceps 
and Echinococcus granulosus were investigated as possible targets. 
 
3.2.1 Partial characterization of the p38 MAPK homologue of E. granulosus  
 
E. granulosus parasite material for inhibitor treatment is not readily available so that merely 
in silico analyses were performed to identify the EmMPK2 ortholog of E. granulosus. For this, 
the LophoDB database (http://www.nematodes.org/NeglectedGenomes/ Lopho/LophDB.php) 
which contains numerous E. granulosus EST sequences obtained by Fernandez et al. 
(2002), was mined using the EmMPK2 activation loop sequence as a query. 
A protein with significant homologies to EmMPK2 was encoded by EST EGC02047 and the 
respective protein was designated EgMPK2. The deposited EST sequence corresponded 
closely to the emmpk2 cDNA sequence determined above with the exception that, probably 
due to alternative splicing, exon VIII was directly fused to exon X, thus completely removing 
the sequence information of exon IX (coding for amino acids 281 to 341). Due to this splicing 
event, a stop-codon is introduced directly after the exon VIII sequences, leading to a 
truncated protein which only encompasses amino acids 1 to 281. Whether this splicing mode 
is typical for egmpk2 or whether, by chance, an mRNA containing a splicing error was 
sequenced, remains to be established. However, within the available parts of the cDNA, the 
deduced EgMPK2 amino acid sequence only differed in three positions from EmMPK2 (Fig. 
3. 17), making it highly likely that both genes code for proteins that are to over 99% identical. 
Hence, if sensitivity to pyridinyl imidazoles solely bases on the structure of the p38 MAPK 
ortholog, it is highly likely that E. granulosus is also sensitive to this compound group.  
 
 
3.2.2 The p38 MAPK homologue of T. crassiceps  
 
3.2.2.1Treatment of in vitro cultivated T. crassiceps larvae with p38 MAPK inhibitors 
 
Since parasite material of T. crassiceps was available, metacestode larvae were treated in 
vitro with ML3403 and SB202190 in order to address the question whether Taenia 
crassiceps are sensitive to pyridinyl imidazoles. The experiments were performed under 
similar experimental settings as used for E. multilocularis. T. crassiceps cultivated in mice 
were isolated from the peritoneal cavity and transferred into the in vitro culture system. 
Initially, the cultivation conditions for T. crassiceps were optimized. Medium with or without 
10 % FCS and antibiotics was tested and the larvae were incubated alone and in co-culture 
with rat hepatocytes. As indicated in Fig. 3.18, T. crassiceps showed better growth and 
maintenance in medium with high serum conditions and in the presence of host cells. The 
treatment of T. crassiceps larvae subsequently took place in medium with serum and 
antibiotics, but in the absence of feeder cells to avoid indirect effects. Interestingly, during 4 
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weeks treatment with pyridinyl imidazoles at concentrations which effectively inactivated E. 
multilocularis larvae, no significant effects on T. crassiceps were observed. 
 
3.2.2.3 Identifying the p38 MAPK homologue from T. crassiceps 
 
To investigate whether the failure to inactivate T. crassiceps larvae by pyridinyl imidazoles 
was due to differences in the structure of its p38 MAPK orthologue when compared to 
EmMPK2, biochemical and molecular studies were carried out. 
In the first step, total RNA was isolated from in vitro cultivated metacestode larvae to produce 
first strand cDNA using Omniscript RT PCR kit. By a second PCR approach using the cDNA 
as template and oligonucleotids p38-kp-dw (5’ GCT AAG CGC ACT TAC CGT GAG) and 
p38-lo-up (5’ CGC CGA TCC GGA TCC AG) designed to amplify a partial sequence of 
emmpk2, an product of expected 693 bp length was obtained, cloned into the cloning vector 
pDrive (Qiagen) and sequenced. The DNA fragment coded for 231 AA of a protein with 
highest homologies to p38 MAPK family members. The deduced protein shows about 60% 
identical residues to human p38 MAPK-α and is depicted in 3.18. The protein was 
designated TcMPK2. The partial sequence of TcMPK2 exhibits 97% identity to EmMPK2 and 
contains the catalytic and the activation loop of Ser/Thr kinases as identified by SMART 
analyses. To complete the sequence, RACE experiments were performed but could not be 
finished in time. 
The amino acid residues of the identified partial TcMPK2 sequence on positions known to be 
functionally important and involved in the interaction with pyridinyl imidazoles, did not differ 
from EmMPK2 [110]. The expression of the TcMPK2 on protein level was investigated via 
Western blot using the human anti-phospho-p38 antibody detecting the pT-G-pY motif within 
the conserved activation loop of p38 MAPK. As shown in fig. 3.19, a single signal of 
approximately 70 kDa was detected indicating that the p38 orthologue might be larger than 
EmMPK2. Without detailed sequence analysis of the TsMPK2 encoding cDNA, adequate 
conclusions about the molecular nature of the detected 70 kDa protein cannot be drawn. 
Since the antibody has been specifically designed to bind to phosphorylated T-P-Y motifs, it 
is, however, possible that TsMPK2 contains N- or C-terminal extensions which could affect 
the interaction with small molecule inhibitors. Future investigations are clearly necessary to 
address these points. 
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Fig. 3.17: Amino acid sequence alignment of EmMPK2 with the homologue from E. granulosus 
(EgMPK2). The respective amino acid sequence of E. granulosus representing a partial sequence and 
is derived from the EST sequence with accession number EGC02047 from LophoDB database. Over 
the depicted area, the proteins share 98% identical residues. 
 
 
 
 
 
 
 
Fig. 3.18: Long-term in vitro cultivation of 
Taenia crassiceps larvae. Metacestode 
vesicles of T. crassiceps were cultured for 
four weeks in the presence (A, B) or absence 
(A, C) of rat hepatocytes in DMEM with 
10%FCS and 1% penicillin/ streptomycin.  
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Fig. 3.19: Amino acid sequence alignment of p38 MAPK family members from the species 
Taenia crassiceps (TcMPK2; partial sequence), E. multilocularis (EmMPK2) and H. sapiens 
(HsMAPK14; Q16539). Identical amino acid residues are shaded in black, similar residues in blue.  
 
 
 
 
 
 
Fig. 3.20: Analysis of TcMPK2 expression. 
Lysate of in vitro cultivated T. crassiceps larvae 
were analysed for expression of a p38 MAPK like 
protein by immunoblotting using the anti-
phospho-p38 antibody after sample separation on 
12% acryl amid and transfer on nitrocellulose. 
Recombinantly expressed EmMPK2 served as 
positive control. 
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3.3 EmSSY- an unusual MAPK / a new type of MAPK? 
 
Analyses of the Echinococcus genome sequences revealed that emmpk2 encodes the only 
p38 like MAPK of the parasite with a typical T-G-Y motif as outlined in section 3.1.1. 
However, upstream of the emmpk2 gene, a sequence was identified which displayed 
remarkable homology to emmpk2. In gene specific RT-PCR and RACE experiments, two 
different transcripts for this gene were identified (Fig.3.22). The respective sequences 
encoded proteins of 468 AA and 356 AA, respectively. The amino acid sequences were 
aligned with EmMPK2 and revealed 63% identical and 78% similar residues between the 
newly identified proteins and EmMPK2 (Fig. 3.21). By SMART analyses, a Ser/ Thr kinase 
domain amongst an ATP-binding pocket, a catalytic as well as an activation loop and a 
common docking site were identified (Fig.3.21) [106]. Hence, the unknown proteins were 
clearly identified as MAPKs. Interestingly, the activation loops did not feature any of the 
common dual-phosphorylation motifs, which would allow the classification of MAPK family 
members (see section 3.1.1). These proteins contained neither the T-E-Y (Erk-like), nor the 
T-P-Y (JNK/SAPK-like) nor the T-G-Y (p38-like) triplet. Instead, it revealed an unusual S-S-Y 
motif at the corresponding position within the otherwise conserved activation loop. Based on 
this unusual motif, the proteins were named E. multilocularis SSY MAPK, abbreviated 
EmSSY. Since there were two transcripts of the corresponding gene emssy, the resulting 
proteins were designated EmSSY-a and EmSSY-b (Fig. 3.21). 
For computer based emssy gene analysis, the contig database was used again. It became 
obvious that emssy is composed of nine exons (I-IX; 43- 229 bp), which were interrupted by 
eight introns (1-8; 51-1801 bp) (Tab. 3.2). Seven of eight exon/ intron boundaries could be 
found at corresponding positions in emmpk2 (see section 3.1.1). All exon/ intron boundaries 
display the canonical GT and AG motifs. The start codon for the longer emssy-a transcript is 
the first ATG highlighted in bold type in exon I. The length of this emssy-a transcript is due to 
an intron retension event at intron 1, leading to a 336 bp longer ORF. The ORF of the second 
transcriptional variant emssy-b started at the second ATG triplet within exon I and continued 
in exon II (Fig. 3.22, Tab. 3.2). 
The expression of the splice variants was demonstrated by qualitative RT-PCR experiments 
with transcript specific oligonucleotides and cDNAs of the relevant larval stages as 
templates. The result was that emssy-a and emssy-b were transcribed in metacestode as 
well as resting and activated protoscolex (Fig. 3.23). 
So far, these data did not allow the classification of EmSSY as a functional MAPK. Further 
investigation to characterize the function of EmSSY was not undertaken. An interesting topic 
would be to examine the enzymatic activity, which should be present according to the 
structural features, and the identification of interaction partners. Interestingly, extensive 
literature and database searches, revealed that proteins with considerable overall homology 
to p38 MAPKs but carrying a SSY motif have so far not been reported for any other 
organism.  A protein with the highest similarity to S-S-Y triplet was identified from C. elegans. 
This protein contains a S-D-Y triplet and is classified as JNK MAPK (Kgb-2; O44182) for 
which the evidence exists only at transcriptional level and functional analyses are lacking.  
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Fig. 3.21: Amino acid sequence alignment of the two identified variants of EmSSY and 
EmMPK2. The translation start for EmSSY-a begins 171 bp upstream of the start codon for EmSSY-b  
that yielded in 468 AA and 356 AA proteins. The intron positions at the corresponding emssy gene 
sequence are marked by ‘V’s above the lines (compare Fig.3.22). Identical amino acid residues are 
shaded in black, similar residues in blue. Highlighted are the ATP-binding site, the catalytic loop, the 
activation loop with the dual-phosphorylation motif (extra marked by encircled ‘P’s) and the common 
docking (CD) site where regulatory proteins like MKK’s and phosphatases bind.   
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Fig. 3.22: The two transcriptional variants of emssy. Shown are the 5’ ends of the both emssy 
transcripts which were identified by 5’ RACE experiments. When the transcripts contained the 
extension at the 5’ end, the reading frame was open to the interruption by intron 2 at the 
corresponding Cys149 and encodes 468 AA (EmSSY-a). In the 5’ region, ORF of emssy-b was 
interrupted by the additional intron 1 at the corresponding Ser2 (see also Fig. 3. 21 and Tab. 3.2). 
 
Tab. 3.2: Genomic characterization of emssy. The gene emssy is localized upstream of the 
emmpk2 gene and is composed of nine exons (I-IX; 43- 229 bp) and eight introns (1-8; 51-1801 bp). 
Seven of eight exon/ intron boundaries could be found at corresponding positions in emmpk2 (see 
section 3.1.1). All exon/ intron boundaries display canonical GT…AG motifs. Two different transcripts 
for emssy were identified. The start codon for emssy-a is the first ATG highlighted in bold type in exon 
I. In this transcript, intron 1 was not spliced out leading to a 336 bp longer ORF. The ORF of the 
second transcriptional variant emssy-b started at the second ATG triplet within exon I and continued in 
exon II.  
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Fig. 3.23: Expression of emssy in the larvae 
metacestode (MV), protoscoleces before (P) 
and after activation (Pact) by low pH and bile 
salts. RT-PCR analysis was conducted with 
cDNAs of the indicated larval stages as templates 
and emssy gene specific oligonucleotides. The 
amplicons of expected 1407 bp represented the 
complete ORF of emssy-a. 
 
 
3.4 Effects of miltefosine and perifosine on in vitro cultivated parasite material  
 
3.4.1 In vitro treatment of E. multilocularis metacestode vesicles 
 
Miltefosine and perifosine, originally developed as antineoplastic drugs, are anti-protozoal 
compounds which target the PIP3K/ AKT pathway as well as SAPK/JNK and Erk MAPK 
pathways [102, 103, 115, 116]. In particular, miltefosine was shown to be effective against 
Leishmania and Trypanosoma [117, 118]. The influence of both cytostatic drugs on 
Echinococcus growth was investigated. Co-cultured metacestode vesicles were separated 
from host cells and settled in groups of five into medium containing 10% FCS and antibiotics 
in 24 well multiplates. Treatment with miltefosine (D-18506, Zentaris) and perifosine (D-
21266, Zentaris) took place over two weeks in concentrations from 25 nM to 250 µM in 
10fold dilution steps. Light microscopical observation and the determination of AP activity in 
the supernatant were done daily to assess the integrity of vesicles.  As illustrated in Fig. 3.24, 
the untreated control vesicles and vesicles incubated in the presence of less than 250 µM of 
either drug were not affected and remained intact till end of the experiment. High dosages of 
D-18606 and D-21266 led to damaging effects on laminated layer after 5 days, but neither of 
the supernatants showed a detrimental increase in AP activity.  
 
 
 
 
 
Fig. 3.24: Treatment of in vitro cultivated metacestode vesicles with miltefosine and perifosine. 
Metacestode vesicles were cultured in groups of five in 24 well plates in the presence or absence of 
drug compounds miltefosine (D-18506, Zentaris) or perifosine (D-21266, Zentaris) dissolved in sterile 
water in various concentrations for 14 d. Vesicle viability was controlled daily via LM.  A destruction of 
metacestode vesicles was visible only by treatment with high dosages for both drugs. In addition, AP 
activity in the supernatant of treated vesicles was measured as marker for destruction, but no increase 
of AP activity was detectable over the whole time course. 
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3.4.2 In vitro treatment of E. multilocularis primary cells 
 
Simultaneously to the incubation of the metacestode vesicles, E. multilocularis primary cells 
were treated with miltefosine (D-18506) and perifosine (D-21266). Metacestode vesicles 
grown for four weeks in the axenic culture system after breeding for four weeks in the 
presence of hepatocytes were utilized for the isolation of primary cells. After isolation, the 
cells were seeded with pre-conditioned A4 medium and the supplements β-MEtOH, BAT and 
L-cysteine in 24 well multiplates. D-18506 and D-21266 were dissolved in sterile water and 
added to a final concentration of 50 µM, untreated primary cells were used as control. Shown 
in Fig. 3.25 is the course of vesicle formation after 7, 14, and 28 days. After one week, 
primary cells aggregated to clumps in which cavities formed in the following week. Further 
two weeks later, small vesicles appeared. These progression steps of cyst formation could 
not be observed for primary cells incubated in the presence of the drug compounds. Treated 
primary cells remained spreaded on the well bottom and appeared granular as indication for 
low vitality after seven days. The effects of both drugs were similar. Western blot analyses of 
treated primary cell lysates did not show influences on EmMPK1 and EmMPK2 
phosphorylation (data not shown). 
 
   
 
 
Fig. 3.25: Treatment of Echinococcus multilocularis primary cells with the compounds 
miltefosine (D-18506, Zentaris) and perifosine (D-21266, Zentaris). Primary cells were isolated 
from axenically cultivated metacestode vesicles and subsequently incubated with pre-conditioned 
medium in 24well plates in the presence of D-18506 or D-21266. The pictures were taken after 7, 14 
and 28 days of incubation.  
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3.5 EmMKK2 - a factor of the E. multilocularis MAP kinase cascade  
  
Although the initially identified E.multilocularis MKK (EmMKK1) has been shown to interact 
with EmRAF in yeast two hybrid binding studies, it did not interact with EmMPK1 [86]. This 
suggested that EmMKK1 does not represent the upstream kinase of EmMPK1 in the E. 
multilocularis MAPK cascade. Hence, one aim of this work was the identification of a so far 
unidentified Echinococcus MKK which could form the link between EmRaf and EmMPK1.  
 
3.5.1 Classification of EmMKK2 as MAPK kinase on the basis of structural features 
 
A cDNA fragment of 300 bp was amplified via degenerative PCR using oligonucleotides 
against regions encoding highly conserved residues of MKKs (IVGFYGAF and CDFGVSG). 
Sequence analysis revealed the amplicon as part of a full-length transcript with homology to 
MKK1/2 kinases. The transcript was completed via 5’RACE and 3’RACE experiments and 
the corresponding gene designated emmkk2 for E. multilocularis map kinase kinase 2. The 
contained ORF of emmkk2 cDNA comprises 1614 bp (excluding the polyA tail) and codes for 
a 250 AA protein (57.2 kDa) (Fig. 3.26). For the emmkk2 transcript a spliced leader 
sequence on the 5’end could not been identified. In addition, all characterized transcripts 
showed the same ORF sequence indicating the absence of splice variants. 
The translated ORF displayed all conserved residues for eukaryotic protein kinases at the 
corresponding positions. Further, in silico analyses using the SMART tool  identified a 
catalytic Ser/ Thr protein kinase domain as well as the hydrophobic ATP-binding clamp with 
the consensus motif GxGxxGxV (x for any amino acid residue) [106]. The catalytic loop with 
the motif HRDVKxxN with Asp as proton-acceptor and the conserved Glu and Lys involved in 
the ATP-binding is identical in all displayed MKKs. The ‘DFG’ triplet marks the beginning of 
the activation loop which ends with the ‘APE’ triplet. The residues in-between are highly 
conserved among MKK protein family members and are important for substrate recognition. 
Notably, on structural level, EmMKK1 shows higher homologies to mammalian MKK3/6 
whereas EmMKK2 is more similar to mammalian MKK1/2 [58]. At the C-terminus, EmMKK1 
and EmMKK2 share the Hxah consenus motif of serine protein kinases, where ‘a’ represents 
an aromatic and ‘h’ a hydrophobic amino acid residue [105]. EmMKK2, however, displayed 
the highest homology to the MAPK kinases 1/2 with 50% identity and 67% similarity, 
respectively. Ser residues for phosphorylation and MKK activation by upstream MKKKs such 
as Raf were also present (Ser218 and Ser222; Fig. 3.26) and displayed a sequence context 
with considerable homology to mammalian MKKs [119]. Computer analyses using the freely 
available ELM tool (http://elm.eu.org/) identified the N-terminal oligopeptide ‘HTSTSS’ as 
putative binding domain for 14-3-3 proteins in EmMKK2, such a domain was present in 
EmMKK1 [120]. The same software tool identified the motif ‘RRSSIRF’ as docking motif for 
MAPKs. The classic consensus sequence for a Kinase interaction motif (KIM) is (R/K)xxxhxh  
and is usually located close to the N-terminus [58]. Two putative KIMs were present in 
EmMKK1 next to the N-Terminus. EmMKK2, on the other hand, carried the predicted MAPK 
interaction motif close to the C- terminus. 
Since comprehensive information on the E. multilocularis genome sequence is available, 
genomic analyses for the chromosomal emmkk2 locus were performed in silico. The 
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genomic locus of emmkk2 was present on contig 803 and 804 of the first assembly and 
comprised six exons (47-526 bp). The ORF was interrupted by five introns (145-2342 bp) 
(Fig. 3.26 and Tab. 3.3). Conserved exon/ intron boundaries in the genomic loci of emmkk2 
and the human homologues were not observed with two exceptions. On position Gly246 
(Gly146, respectively) and position Pro346 (Ser246) of the coding sequences of emmkk2 and 
hsmkk1, introns are present. Furthermore, the exon/ intron boundaries of the Echinococcus 
genes emmkk1 and emkk2 do not match. In general, these findings reflect the situation in 
homologous mkk gene families where the positions of exon/ intron boundaries are usually 
not conserved. All introns in emmkk2 appear with the canonical GT at splice-donor and AG 
at splice acceptor sites.  
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Fig. 3.26: cDNA of emmkk2 with deduced amino acid sequence. The two possible ATG start 
codons are highlighted in red. The stop codon is marked by asterisks and the putative polyadenylation 
signal sequence (ATTAAAA) is accentuated by the line above the sequence. The position of introns in 
the genomic sequence is indicated by arrows. The Ser/ Thr kinase domain (in blue letters) was 
identified between  Ser157 and Val457 by SMART, the putative 14-3-3 protein interacting motif 
‘HTSTSS’ (green) and the MAPK interacting motif ‘RRSSIRF’ (green) by the ELM software tool. 
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Fig. 3.27: Amino acid sequence alignment of EmMKK2 and EmMKK1 with MAP kinase kinases 
from humans (HsMKK6; P52564 and HsMEK1; Q02750) and D. melanogaster (DmMKK3; O62602 
and DmSOR1; Q24324). Shading with a threshold set for 60% indicates similar residues (blue) and 
identical residues (black). Homologies of aligned proteins to both Echinococcus MAPK kinases are 
listed below the alignment (% identities/ % similarities). Highly conserved residues among all 
eukaryotic protein kinases are marked by asterisks above the sequences [105]. The conserved motifs 
of protein kinases Gly-x-Gly-x-x-Gly-x-Val at the N- terminus and His-Arg-Asp-Leu/Val-Lys-x-x-Asn 
known as the catalytic loop are marked. In subdomain VII, the conserved ‘DFG’ triplet is marked as 
start for the activation loop (line above), which ends with the conserved ‘APE’ triplet in subdomain VIII 
[105].  At the C-terminus, the consensus sequence for protein serine kinases His-x-a-h is highlighted, 
whereas ‘a’ indicates any aromatic and ‘h’ any hydrophobic residue [105].Conserved serine residues 
predicted to be phosphorylated by upstream kinases are highlighted with an encircled ‘P’.  
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Tab. 3.3 : Genomic structure of emmkk2. The emmkk2 gene codes on two contigs (no. 803 and 804 
of the first assembly) and comprised six exons (I-VI; 47-526 bp). The encoded ORF is interrupted by 
five introns at corresponding triplets coding for indicated AA. All exon/ intron boundaries carry the GT 
at the splice acceptor and the AG motif at the splice donor site. 
  
 
 
 
3.5.2 Expression of emmkk2 in E. multilocularis larvae  
 
RT PCR was performed to investigate emmkk2 expression in E. multilocularis larval stages 
which are involved in the infection of the intermediate host. Specific transcripts were detected 
in metacestode as well as in protoscoleces before and after activation by low pH and bile 
salts mimicking the passage through the digestion tract of the final host. Additionally, it was 
analysed whether emmkk1 and emmkk2 are co-expressed. The expression of both genes 
relative to the expression of the housekeeping gene elp was investigated using a semi-
quantitative PCR approach [73, 76, 77]. Furthermore, expression of one putative interaction 
partner, a previously identified 14-3-3 orthologue of E. multilocularis, was assessed (see also 
section 3.5.3). As indicated in Fig.3.28, emmkk1 was considerably less expressed in 
metacestode vesicles and in protoscoleces upon activation than emmkk2. Moreover, 
emmkk2 showed an increased expression in both protoscolex preparations. Em14-3-3 
expression was detected in metacestode and resting protoscoleces whereas no expression 
was observed for activated protoscoleces (Fig. 3.28). This confirmed a result previously 
obtained by Siles Lucas et al. [121]. 
 
 
 
 
 
 
Fig. 3.28: Expression of emmkk2 in 
E. multilocularis larvae. Indicated 
are semi-quantitative RT-PCR 
analyses of Echinococcus gene 
expression in in vitro cultivated 
metacestode vesicles (MV) and 
protoscoleces in non-activated form 
(P) and after activation with low 
pH/pepsin and bile salts (Pact). cDNAs 
of corresponding larval stages were 
used as template in a serial of 10-fold 
dilution steps (indicated by triangles) 
for PCR setups specific for the 
housekeeping gene elp as internal 
standard [73, 76, 77], emmkk2, 
emmkk1 and em14-3-3.  
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3.5.3 Interaction studies between EmMKK2 and potential members of the E. multilocularis 
MAPK cascade 
 
Based on the homology of EmMKK2 to MAPK cascade members, interaction for several E. 
multilocularis factors was carried out using yeast two hybrid. Fusion constructs for EmMPK1, 
EmMPK2, EmMKK1, EmMKK2 , EmRAF and Em14-3-3 with the GAL4 DNA-binding domain 
or the GAL4 trans-activation domain were co-transfected into yeast strain AH109 [98, 121, 
122]. For protein-protein interaction under high stringency conditions, double transfectants 
were selected on leucin-tryptophan-histidin-adenin-deficient medium (Fig. 3.29 A). Individual 
yeast colonies were picked and plated repeatedly on quad minus medium for 48 h to 
eliminate false positive clones. In these exerpiments, EmMKK2 and EmMPK1, the Erk 
orthologue of the parasite, strongly interacted. In addition, EmRAF representing the putative 
upstream kinase of E. multilocularis MKKs interacted with EmMKK2. In line with the above 
structural data showing that EmMKK2 contained a consensus motif for interactions with 14-3-
3 proteins (see section 3.5.1), EmMKK2, but not EmMKK1 interacted with Em14-3-3 in the 
yeast two hybrid. The interaction of EmMKK1 with EmRAF as well as the absence of 
interaction with EmMPK1 confirmed the results of Y2H analysis conducted by Spiliotis [98]. 
No homo-dimerization was observed for all factors analyzed. In addition, none of the 
Echinococcus MKK interacted with the p38 orthologue EmMPK2. This result was interesting 
in so far as that human MKK3/6 homologues interact with p38 MAPK isoform α to which 
EmMKK1 displays highest homologies. 
To verify the interaction between EmMKK2 and EmMPK1, co-immunoprecipitation with 
ectopically expressed and purified fusion proteins was performed. EmMKK2 fused to a V5 
epitope and thioredoxin tag was immobilized via anti-thioredoxin antibody on agarose G 
beads and incubated with EmMPK1 GST fusion protein. The interaction of EmMPK1 and 
EmMKK2 was detected with both the anti-GST-antibody and anti-Erk antibody via Western 
blot (Fig. 3.29 B). No signal was detected using the anti-phospho-Erk antibody indicating, as 
exspected, that the interaction between EmMKK2 and EmMPK1 is independent of EmMPK1 
phosphorylation at the TEY motif. 
In conclusion, these interaction analyses identified EmMKK2, the parasite MKK1 homologue, 
as a component of the Echinococcus MAPK cascade. In this cascade, EmMKK2 acts as 
tranducer between the upstream factor EmRAF and the downstream factor EmMPK1. For 
EmMPK2, no activating kinase could be identified by this approach.  
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Fig. 3.29: Interaction analyses of MAPK cascade members from E. multilocularis. (A) Listed are 
results of yeast two hybrid protein-protein interaction assays under high stringency conditions of 
experiments with fusion constructs for EmMKK1, EmMKK2, EmRaf, EmMPK1, EmMPK2 and Em-14-
3-3 with activation domain (pGADT7) or DNA-binding domain (pGBKT7) of yeast transcription factor 
Gal4. Co-transfected yeast cells of the strain AH109 were selected on leucine and tryptophan deficient 
agar plates. The correct expression of fusion proteins was anaylsed by Western blot (data not shown). 
Selection for interaction took place under high stringency on quad drop out medium. As controls, the 
expression plasmids of the large T- antigen of virus SV40 as pGADT7 construct with tumour 
suppressor p53 in pGBKT7 (positive control) and T-Antigen with lamin C in pGBKT7 (negative control) 
were co-transfected. Moderate growth is indicated by one ‘+’, good growth by ‘++’. No growth by ‘-‘. 
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(B) Co-immunoprecipitation of EmMPK1 with EmMKK2. After heterologous expression in E. coli and 
subsequent purification of EmMPK1 as GST fusion protein and EmMKK2 as fusion protein with V5 
epitope and thioredoxin tag, EmMKK2 was bound by anti-thioredoxin antibody to agarose G beads. 
Subsequent to repeated washing steps, GST-EmMPK1 was added. After washing again, the beads 
were transferred into 2x stop mix and boiled for five minutes. The samples were spun down and the 
supernatant separated on 12% polyacrylamid gel. Precipitated proteins were analysed via Western 
blot experiments using the anti-V5 antibody, the anti-GST antibody and the anti-Erk1/2 antibody as 
indicated. As negative controls, EmSkip  was used as GST fusion protein and EmNIP as fusion with 
V5 epitop and thioredoxin tag [89, 91]. (C) In vitro activity assay of the MAPK cascade. EmRas 
activated or non-activated EmRaf as His-tagged protein were incubated together with EmMKK2 as V5 
fusion protein and GST-EmMPK1 with or without ATP [98, 123]. The protein content of the samples 
were separated by PAGE and examined by Western blotting using the indicated antibodies directed 
against the tags as well as the dual-phosphorylation motif pT-E-pY of Erk-like MAPKs.  
 
 
 
3.5.4 In vitro activity of the parasite MAPK cascade 
 
Due to the results from the interaction analyses it was investigated whether EmRAF, 
EmMKK2 and EmMPK1 constitute a functional MAPK cascade. EmRas carrying an 
activating mutation was co-expressed with EmRaf in insect cells to obtain the parasite MKKK 
in an activated form (EmRaf*). Following purification, EmRAF* was incubated with EmMKK2 
and EmMPK1, each separately expressed in E. coli and purified, to perform an in vitro 
activity assay. Phosphorylation of EmMPK1 was then measured via Western blot using the 
anti-phospho-Erk antibody. To ensure the specificity of this in vitro assay, I omitted either one 
component including ATP in the reaction. As indicated in Fig 3.29 C, EmMPK1 was 
phosphorylated only in the presence of ATP and the complete protein contingent. This 
indicated that EmRas activated EmRAF, which in turn lead to the phosphorylation of 
EmMKK2 subsequently leading to the activation of EmMPK1. Thus, the Erk-like MAPK 
module in Echinococcus is formed by EmRAF, EmMKK2 and EmMPK1. 
 
 
 
3.6 Analysing and targeting the EGF signaling pathway of E. multilocularis 
 
3.6.1 Phosphorylation of Elp in response to host EGF and the effects of inhibitors 
 
Members of the ERM protein family are involved in the regulation of cell morphology via 
acting as molecular linkers between the actin cytoskeleton and the cytoplasmic membrane. 
This involves phosphorylation of ERM proteins at a conserved C-terminal motif in growth 
factor (e.g. EGF) dependent ways [124-126]. To investigate whether a similar mechanism is 
acting on the E. multilocularis ERM orthologue Elp, experiments concerning Elp 
phosphorylation in intact metacestode vesicles upon exogenous stimulation through host 
EGF were carried out. As shown in Fig. 3.30., phosphorylation of Elp is no longer detectable 
once metacestode vesicles from co-culture were incubated for 4 days in the absence of host 
serum and feeder cells (i.e. 'serum starving' conditions). However, when during serum 
starvation host EGF (100 nM) is present, Elp phosphorylation is as intense as in vesicles 
from co-culture. This suggests that the ERM orthologue of the parasite is regulated via 
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phosphorylation through a so far unidentified kinase in an EGF dependent signaling cascade. 
Concerning the question, which molecules could be involved, metacestode larvae were 
treated with PP2 as inhibitor of Src kinases and leflunamide as anti-proliferative agent and 
broad-range inhibitor of tyrosine kinases [127, 128]. After 2 hours, metacestode vesicles 
were harvested and examined for Elp phosphorylation. As depicted in Fig. 3.30 B, the 
phosphorylation of Elp was completely blocked upon treatment with PP2.  In the case of 
leflunamide, Elp phosphorylation was still detectable, albeit at lower level compared to the 
DMSO control. In addition, the influence of both inhibitors on EmMPK1 phosphorylation was 
analysed. For both inhibitors, the phosphorylation of EmMPK1 was minimally diminished 
compared to the control (Fig. 3.31 B).  
In summary, these results indicated that exogenous serum derived factors, among them host 
EGF, stimulated Elp phosphorylation. On the assumption that PP2 and leflunamide were 
able to target the same classes of worm kinases like in mammalian cells, tyrosine kinases, in 
particular members of the Src family could be responsible in the growth factor activation of 
Elp. Furthermore, no significant effects of PP2 and leflunamide on Erk1/2 like MAPK 
signaling were observed.  
 
 
 
 
 
Fig. 3.30: Growth factors cause Elp phosphorylation.  Indicated are Western blot analyses of 
metacestode lysates in turn of PAGE. Whole amount Elp was detected with the anti-EM10 antibody 
and as phosphorylated protein with the anti-phospho-ERM antibody. (A) Before co-cultivated 
metacestode vesicles in rich medium were subsequently incubated under low serum condition in the 
presence or absence of 100 nM EGF. (B) The larval material was kept rich medium supplemented 
with 200 µM PP2, 300 µM leflunamide or with the inhibitor dissolvent alone.  
 
 
 
3.6.2 Activation of EmMPK1 in response to host EGF  
 
The influence of host serum or the integrity of metacestode vesicles on EmMPK1 activation 
has been examined by Spiliotis et al. [98]. The results demonstrated a positive effect of 
mammalian serum on the phosphorylation of EmMPK1. A potent inducer of the MAP kinase 
cascade and, thus, of ERK phosphorylation in mammalian cells is EGF via binding to the 
EGF receptor [129]. Since EGF is present in mammalian serum [130], the question arose 
whether the phosphorylation state of EmMPK1 in metacestode vesicles can be altered in 
response to exogenous host EGF (Fig. 3.31). Physically intact metacestode vesicles from in 
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vitro culture were initially incubated for 4 days in medium containing 0.2 % FCS in the 
presence or absence of 100 nM human EGF. After the incubation, phosphorylation of 
EmMPK1 was undetectable in the absence of EGF and detectable in the presence of EGF 
(Fig. 3.31 A). Second, the metacestode vesicles were kept for 4 d in low serum 
concentrations and subsequently stimulated for 30 min with EGF (Fig. 3.31 B). 
Phosphorylation of EmMPK1 could be reconstituted by adding host EGF as well as serum to 
a final concentration of 10%. These findings reflected the starting situation of phosphorylated 
EmMPK1 in axenically cultivated and growing metacestode vesicles. These experiments 
indicated that intact E. multilocularis metacestode vesicles are responsive to exogenous host 
EGF and that the stimulation triggers the parasite’s MAPK cascade as shown by increased 
phosphorylation of the parasite’s ERK-like kinase. 
An important question concerns the in vivo relevance of the EGF effect on the Echinococcus 
MAP kinase cascade. E. multilocularis could, indeed, come into close contact with host EGF 
during an infection since this cytokine is produced by a wide variety of host cells [44, 131, 
132]. In the liver, EGF is mainly produced during regeneration after hepatectomy or in 
response to chemical injury [131, 133]. A possible scenario is that hepatocytes are injured 
either directly by the parasite or indirectly through the host immune response around the 
metacestode, upon which the liver tissue responds with regeneration and the release of 
EGF. Therefore, the question arose whether the feeder cells in the co-culture system 
synthesize EGF. The expression of EGF has been validated by a PCR approach with gene 
specific primer and RH- cDNA as template (data not shown). 
 
 
 
 
 
 
Fig. 3.31: Phosphorylation of EmMPK1 in response to host EGF. Depicted are Western blot 
experiments of vesicle lysates using the anti-Erk1/2 and the anti-phopsho-Erk antibodies detecting 
overall EmMPK1 and phosphorylated EmMPK1, respectively after separation on 12% acrylamid. (A) 
Intact metacestode vesicles (MV) (axenically cultivated) were kept in medium pre-conditioned with 
hepatocytes (RH-) containing 10% FCS (lane 1), 0.2% FCS (lane 2) or 0.2% FCS and 100 nM host 
EGF for 4 d. (B) MVs had been incubated for 4 d in medium with 0.2% FCS (lane 2) and were then 
placed placed for 30 min into medium containing 10% FCS (lane 3) or 0.2% FCS/ 100 nM EGF (lane 
4). Lane 1 shows MVs before incubation in 0.2% FCS. 
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3.6.3 Enhanced proliferation of E. multilocularis in response to host EGF 
 
In addition to the activation of the MAP kinase cascade in cultivated metacestode larvae, 
host EGF was tested as putative inducer of parasite proliferation. The mitotic activity of the 
metacestode was determined upon EGF stimulation through detection of incorporated 5-
bromo-2-deoxyuridine (BrdU) into newly synthesized DNA [134]. Axenically cultivated 
vesicles were transferred into normal culture medium containing 10% or 0.2% FCS. After 4 
days, the metacestode vesicles were stimulated for 3 h with 50 and 100 nM of either human 
EGF or TGF-α. At the same time, the medium was supplemented with BrdU to a final 
concencentration of 1 mM. Following isolation, the genomic DNA (0.1, 0.5 and 1 µg) was 
blotted onto nitrocellulose. DAPI staining was performed to confirm that equivalent amounts 
of DNA have been applied to the blot. Subsequently, de novo DNA synthesis was measured 
by immuno-staining using the anti-BrdU antibody. Co-isolated RNA has been removed to 
avoid cross-reactivity of the antibody to endogenous uridine.  
As shown in Fig. 3.32, significantly more BrdU was incorporated by the parasite in the 
presence of 50 nM EGF for both low and high serum conditions. Interestingly, a 
concentration of 100 nM EGF still led to increased BrdU incorporation but to a lesser extend 
that in the case of 50 nM EGF. In the case of TGF-α, significant stimulation was also 
observed, but only for a concentration of 50 nM. 
 
 
Fig. 3.32: Mitotic effects on 
metacestode larvae upon 
stimulation with host growth 
factors.  
In vitro cultivated metacestode 
vesicles were incubated in the 
presence of BrdU under low (A) 
and high (B) serum conditions and 
subsequently stimulated with the 
indicated concentration of host EGF 
and TGF-α.  The genomic DNA of 
metacestode vesicles was slot-
blotted following isolation onto 
nitrocellulose and the incorporation 
of BrdU into the newly synthesized 
DNA was detected by 
immunostaining using the anti-BrdU 
antibody. The transferred DNA 
content was confirmed with DAPI 
staining. (C) Quantification of the 
proliferation increase in stimulated 
metacestode vesicles. The intensity 
of the bands were quantified and 
the values normalized against non-
stimulated control using NIH 
ImageJ software. 
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3.7 In vitro treatment of metacestodes with tyrosine kinase and MAPK cascade inhibitors 
  
To test whether small molecule compounds originally designed to inhibit human MAPK 
cascade factors might also affect the respective parasite orthologs and thus inhibit E. 
multilocularis growth and development, in vitro inhibition studies were carried out. Due to the 
limitations of co-culture models (indirect effects of drugs on mammalian feeder cells), 
axenically cultivated vesicles were used for these experiments. 
First, BAY439006 (RAF inhibitor) as well as M-INH and PD184352 (MEK inhibitors) were 
tested for inhibition of EmMPK1 phosphorylation [135, 136]. As indicated in Fig. 3.33, all 
three compounds blocked EmMPK1 phosphorylation when the vesicles were kept for 2 h in 
DMEM 10 % FCS in the presence of 100 µM of each drug. Long-term cultivation for 4 weeks 
(exchange of medium including inhibitors was performed 4 d), however, did neither result in 
damage of vesicles nor to an increase of alkaline phosphatase activity in the supernatant of 
cultivated vesicles. Second, metacestode vesicles were treated with PD168393 and 
PD173074, direceted against members of the EGF- and FGF-receptor families, respectively, 
in concentrations between 1 nM up to 50 µM (final concentration) [94, 95, 137-139]. Since 
activity assays for EmER and EmFR are not yet established, EmMPK1 phosphorylation was 
used as read out. However, under these conditions no effects were observed on EmMPK1 
phosphorylation (short term incubation), not on vesicle viability or AP acitivities in the 
supernatant (4 weeks incubation). 
Finally, although the Src kinase inhibitors PP2 and leflunamide clearly inhibited Elp 
phosphorylation in response to EGF (see above), these drugs did not affect EmMPK1 
phosphorylation (Fig. 3.33) nor did they exert effects on vesicle viability during long-term 
cultivation (each 50 nM- 500 µM final concentration).  
In summary, the activation of the E. multilocularis Erk-like MAPK cascade could be blocked 
by adding inhibitors originally designed against mammalian Raf and MEK factors to 
metacestode vesicles. Albeit these inhibitors lead to a decreased EmMPK1 activity as 
confirmed by Western blotting, a negative effect on parasite survival could not be detected.  
 
 
 
 
 
Fig. 3.33: Inhibition of the parasite MAPK cascade in the in vitro cultivated metacestode larvae. 
Depicted are Western blot experiments of vesicle lysates using the anti-Erk1/2 and the anti-phopsho-
Erk antibodies detecting overall EmMPK1 and phosphorylated EmMPK1, respectively after separation 
on 12% acrylamid. Axenically cultivated metacestode vesicles were kept for 2 h in rich medium 
supplemented with DMSO and with or without RAF inhibitor BAY439006, MEK inhibitors PD184352 
and M-INH (100 µM each), 200 µM PP2 or 300 µM leflunamide.  
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3.8 Influence of various host growth factors on vesicle regeneration 
 
An in vitro system for long-term E. multilocularis primary cell cultivation has recently been 
introduced [13]. In this system, Echinococcus cells which derived from metacestode vesicles 
fully regenerated viable and intact vesicles in the presence of host feeder cells or 
hepatocyte-conditioned medium, indicating an important role of secreted host factors on 
parasite regeneration [84, 85]. In the present work, experiments were carried out to test 
whether host insulin, EGF and/or FGF could play a role in parasite regeneration. E. 
multilocularis primary cells were isolated according to a previously established protocol [13] 
and kept in the presence of medium containing 1% FCS with or without growth factors. As 
shown in Fig 3.34 B, primary cells kept for 21 days in 1% FCS proliferated and formed cell 
aggregates with central cavities, indicating parasite regeneration [13]. In the presence of 1 
nM host insulin, a significant effect on vesicle regeneration was observed which occurred 
faster and involved the formation of larger cell aggregates (Fig. 3.34 C). In addition, central 
cavities within cell aggregates were significantly larger than in cultures without additional host 
insulin. Upon co-incubation with host EGF (50 nM) as well as acidic or basic FGF (both at 1 
nM), aggregate size and central cavity diameters were similar to controls (Fig. 3.34 D, E, F). 
It appeared, however, that more aggregates were formed under the influence of these host 
factors.  
Since EGF, FGF and particularly insulin apparently had an influence on vesicle regeneration, 
respective signaling pathways were further investigated. Echinococcus cells were incubated 
for long-term in the presence of drug compounds known to inhibit the putative RTKs of the 
respective cytokine signaling pathways in human cells. Among these was the cell permeable 
pyridopyrimidine compound PD173074 which reversibly blocks (in nM range) the activities of 
FGF and VEGF receptor in vitro by ATP competitive binding. When added in higher 
concentrations (µM range), this substance also inhibits members of the insulin and EGF 
receptor families [137, 138]. The quinazoline derivate PD168393, on the other hand, 
operates as cell permeable, irreversible and selective inhibitor of EGFR by binding to the 
intracellular catalytic domain [139]. Both compounds were selected on the basis of homology 
comparison of the two parasite kinases EmFR and EmER to human RTKs. Both EmFR and 
EmER displayed in their catalytic domains residues which were putatively involved in drug 
binding. For example, Cyt773 in the ATP binding pocket in EGFR is present in EmER as 
residue Cyt1084  and therefore a putative interacting residue for PD168393 [139]. For the 
experiment, freshly isolated Echinococcus primary cells were cultivated in pre-conditioned 
medium supplemented with PD173074 and PD168393 each at 50 µM final concentration and 
the assembly of aggregates was monitored for 4 weeks. However, an effect on primary cell 
regeneration could not be measured for PD173074 and PD168393 despite the homology in 
the respective target structures. Like the DMSO treated control group, the primary cells 
formed aggregates, central cavities and new vesicles in the presence of PD173074 and 
PD168393. Furthermore, after 3, 12, and 24 h treatment, phosphorylation of EmMPK1 
remained unchanged (data not shown).  
Treatment of primary cells with the cell permeable insulin receptor tyrosine kinase inhibitor 
HNMPA-(AM)3, however, clearly affected regeneration. On in vitro cultivated human cell 
lines, the ATP non-competitive HNMPA-(AM)3 revealed inhibitory capacity on Tyr kinases 
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over Ser kinases and was proved to block the auto-phosphorylation on Ser1305/Ser1306 of 
human InsR [140, 141]. Inhibitory activity against PKC and PKA was not reported, however, 
the blocking of insulin-stimulated glucose oxidation [141]. In Echinococcus primary culture, 
the presence of 25 µM HNMPA-(AM)3 for three weeks prevented regeneration of vesicles 
(Fig. 3.35 A). The cells remained as single cells and occassionally only small clusters of cells 
were formed. Primary cells which were cultivated in rich medium containing the inhibitor 
dissolvent DMSO, were capable of forming cell aggregates and central cavities within three 
weeks. The cultivation under same conditions with addition of insulin resulted in the above 
described large agglomeration of aggregates and in large size vesicles. The combined 
treatment of HNMPA-(AM)3 and insulin led to an improved cell clustering than in the 
presence of the inhibitor alone, but the cells never reached the level of aggregation than in 
the absence of inhibitor (Fig. 3.35 A).  
Since it has been demonstrated that insulin stimulated EmMPK1 phosphorylation could be 
inhibited in the presence of HNMPA-(AM)3 in in vitro cultivated metacestode larvae [93], the 
status of EmMPK1 phosphorylation was examined in Echinococcus primary cells. Freshly 
isolated primary cells were kept in rich medium as well as under serum starvation conditions 
and treated with 0.5 µl/ ml or 2 µl/ ml insulin (final concentration 1 nM and 4 nM, respectively) 
1 nM) and/or 25 µM HNMPA-(AM)3 for 20 and 40 minutes as well as 4, 8 and 24 h. The 
samples were subsequently prepared for Western blot experiments detecting total EmMPK1 
and pT-E-pY phosphorylated EmMPK1. For none of the examined experimental condition, an 
alteration of EmMPK1 phosphorylation was detectable as exemplary shown in 3.35 B. 
Moreover, the presence of insulin did not result in an increased phosphorylation under serum 
starving condition as has been reported for metacestode vesicles. The treatment of primary 
cells with the tyrosine kinase inhibitor HNMPA-(AM)3 did not affect EmMPK1 phosphorylation 
as depicted in 3.35 B. Interestingly, by examining treated primary cells in Western blot 
analyses using the anti-Erk 1/2 antibody, an additional band representing a so far unknown 
protein of estimated 120kDa consistently appeared. This signal disappeared when primary 
cells were cultivated with HNMPA-(AM)3 under serum starving condition as shown in Fig. 
3.35 B. In addition to this, a protein of approximately 70 kDa (question mark in Fig. 3.36 B) 
was detected by the anti-phospho-Erk antibody (but not by the anti-Erk antibody) exclusively 
under high serum conditions. This protein was further investigated as outlined in section 3.9.  
Although the 120 kDa protein which interacted with both antibodies could represent an as yet 
uncharacterized 'big MAPK' (such as Erk5) orthologue in the parasite, no indications for such 
a kinase was obtained by screening genomic contigs. Hence, the molecular nature of this 
cross-reacting protein is presently unknown. 
As demonstrated in this section, treatment of Echinococcus primary cells with host cytokines 
affected the developmental process in various manners. The presence of host EGF in 
primary culture led to smaller cell aggregates which, however, occurred in higher number, 
indicating that EGF enhanced the proliferation of primary cells. I observed a comparable 
outcome by treatment with acidic and basic FGF. Remarkable was the influence of insulin, 
which resulted in the strongest stimulation of vesicle regeneration. In fact, in the presence of 
insulin, primary cells aggregated to large size, which were mainly associated whith each 
other and resulted in large size vesicles. The attempts to prevent the assembly of 
Echinococcus primary cells by targeting the respective signal receptors were not successful 
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with one exception, the treatment with the insulin tyrosine kinase inhibitor. In the case of 
EGF- and FGF-receptor inhibitors, this might be due to diminished affinities of the drugs to 
EmER and EmFR. Concerning the influences on protein level, neither the host cytokines nor 
the corresponding inhibitors of the signal pathways led to alterations of EmMPK1 
phosphorylation.  
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Fig. 3.34: Influence of selected host growth factors on Echinococcus primary cell cultures. 
Primary cells were cultivated in medium containing 1% FCS (directly after isolation (A)) and cultivated 
for 21 d in the absence (B) or presence of additional growth factors (C-H). The medium supplemented 
with the growth factor was refreshed every fourth day. Shown are primary cells cultivated in the 
presence of 1 nM host insulin (C), 50 nM EGF (D), 1 nM aFGF (E), 1 nM bFGF (F), insulin together 
with EGF (G) and EGF together with acidic and basic FGF (H) at day 21.  
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Fig. 3.35: Treatment of Echinococcus primary cells. (A) Freshly isolated primary cells were 
incubated in rich medium supplemented with DMSO, DMSO and insulin, HNMPA-(AM)3 as putative 
inhibitor of the Echinococcus insulin receptors or HNMPA-(AM)3 combined with insulin. Shown are 
primary cells after three weeks with the designated treatment. (B) After 3 h treatment, which was 
carried out as indicated on top, primary cells were processed for Western blot approach. Detection 
was performed with the anti-Erk1/2, anti-phospho-Erk and the anti-Em10 antibodies as indicated to the 
left.  
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3.9 EmMPK3 – a serum sensitive MAPK  
 
As already mentioned, stimulation of Echinococcus primary cells with host cytokines or 
serum did not affect the phosphorylation of EmMPK1 on the T-E-Y motif which is contrary to 
the situation in intact metacestode vesicles (chapters 3.6 and 3.8). By Western blot analyses 
on primary cells, however, an additional protein of approximately 70 kDa was detected with 
the anti-pT-E-pYantibody when the cells were kept under high serum conditions. The 
appearance of the respective protein in response to serum stimulation was verified in a 
additional experiment. Primary cells were stimulated by adding 10% serum to culture 
medium for 3 h following isolation and incubation in the absence of serum for one day. As 
depicted in Fig. 3.36, a clear signal representing a protein of ca. 70 kDa was detected upon 
stimulation with serum. The protein was recognized by the phospho-specific antibody for Erk 
MAPK, which is directed against the pT-E-pY motif. In silico analyses of the Echinococcus 
genome were performed using the BLAST tool with the activation loop of EmMPK1 and the 
human Erk MAPK as queries. Only two factors containing the T-E-Y motif were identified. 
One was the already characterized Erk-like kinase EmMPK1. The second factor was a 
recently described kinase, EmMPK3, which displayed highest homologies to Erk7/Erk8 
family members [97]. 
By repeating TBLASTN analysis with the EmMPK3 sequence against the genome data base, 
the protein sequence of 625 AA was confirmed and yielded a calculated MW of 69 kDa. No 
further factors with T-E-Y triplet in the context of a Ser/Thr kinase activation loop were 
recorded. Hence, the protein of around 70 kDa detected with the anti-pT-E-pY antibody upon 
serum stimulation could indeed be EmMPK3. It was not to be expected that EmMPK3 was 
detected with the anti-Erk1/2 antibody since EmMPK3 does not contain the oligopeptid 
(PFTFDMELDDLPKERLKE LIFQETARFQPGAPEAP) against which the antibody is directed.  
 
 
 
 
Besides structural analyses, functional analyses on EmMPK3 were performed in this work. 
First, I examined the interaction of EmMPK3 with the two MKKs of Echinococcus. After 
cloning of the EmMPK3 ORF into yeast expression vector pGBKT7 to obtain translational 
fusion products with the DNA-binding domain of the Gal4 transcription factor, co-
transfections of yeast strain AH109 were carried out together with pGADT7 plasmids coding 
Fig. 3.36: Stimulation of Echinococcus 
primary cells with serum. Freshly isolated 
primary cells were incubated in medium without 
serum for 24 h and afterwards stimulated with 
10% FCS for 3 h. A Western blot analysis of 
these cells was realized after sample separation 
on acrylamid gel using the anti-Erk1/2, anti-
phospho-Erk and the anti-Em10 antibodies as 
indicated to the left. 
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for EmMKK1 and EmMKK2 fusion proteins as listed in Tab. 3.4. Co-transfected clones were 
incubated on agar plates to identify protein-protein-interaction under low and high stringency 
condition. Under neither condition, an interaction of EmMPK3 was detected with EmMKK1 or 
with EmMKK2 (Tab. 3.4).  
Second, EmMPK3 was ectopically expressed as fusion protein with V5 and hexahistidin tag 
and subsequently purified under native condition to investigate enzymatic activity in vitro. For 
this purpose, EmMPK3 was incubated in the presence of radioactively labelled ATP and the 
common kinase substrate myelin basic protein (MBP). As displayed in Fig. 3.37, the 
recombinantly expressed EmMPK3 possessed enzymatic activity as determined by 
incorporation of γ- 32P into MBP. The phosphorylation status of EmMPK3 after expression in 
E.coli was further investigated in Western blot experiments. Here, EmMPK3 was detected 
with the anti-V5 antibody at the expected size of 75kDa. Moreover, recombinant EmMPK3 
was recognized by the human anti-phospho-Erk antibody (Fig. 3.37) indicating the 
phosphorylation on T-E-Y. 
 
 
 
 
Tab. 3.4: Protein-protein interaction analysis of EmMPK3 with MKKs of the parasite. Tabulated 
are yeast two hybrid results for high stringent interaction with generated fusion constructs of EmMKK1, 
EmMKK2 and EmMKP3 with the activation domain (pGADT7) or the DNA-binding domain (pGBKT7) 
of yeast transcription factor Gal4. Co-transfected yeast cells of the strain AH109 are selected on 
leucine and tryptophan deficient agar plates. Correct expression of the fusion proteins was analysed 
by Western blotting (data not shown). As controls, expression plasmids of the large T- antigen of  
SV40 as pGADT7 construct with tumour suppressor p53 in pGBKT7 (positive control) and the T-
Antigen with lamin C in pGBKT7 (negative control) were co-transfected. Moderate growth is indicated 
by one ‘+’, good growth by ‘++’. No growth by ‘-‘.  
 
 
 
 
Fig. 3.37: Heterologous expression and in 
vitro activity of EmMPK3. Ectopically expressed 
and purified EmMPK3 as fusion protein with V5 
epitop and hexahistidine tag was separated by 
PAGE. Western blot detection was performed 
with antibodies against the V5-epitope (top) and 
the pT-E-pY motif of Erk MAPKs (middle). The 
MPK3 activity assay was performed as done for 
EmMPK2 (section 3.1). Incorporation of 32P into 
the common MAPK substrate myeline basic 
protein (MBP) is shown below. Marker sizes are 
indicated beside the blots.   
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3.10 Activity assay for EmER, the EGF receptor of E. multilocularis - Preliminary data 
 
Several effects of human EGF on the parasite’s signaling pathways were observed so far 
(see section 3.6). Despite the structural characterization of E. multilocularis EGF receptor 
homologue EmER,  it is, however, not yet clear whether EmER indeed functions as a direct 
sensor of host EGF [95]. Because of this, the signaling pathway triggered upon activation of 
EmER and its potential role as a receptor for host ligands were analyzed. Towards this end, I 
produced expression constructs for wildtype EmER and chimeras with both the amino and 
the carboxyl terminal part of human EGF receptor ErbB-3 (P21860) and ErbB-1 (EGFR; 
P00533). In human cell lines HEK293 and BA/F3 expressing the constructs, it should be 
possible to measure the EmER activity as phosphorylation of the downstream Erk MAPK or 
as tyrosine phosphorylation of the receptor itself upon EGF stimulation. In particular, the 
BA/F3 cell line should be suitable for these analyses due to the absence of endogenous EGF 
receptor. HEK293 expression of the constructs were first investigated in Western blot 
analysis using antibodies recognizing the fused myc and HA tag of expression vector 
pSecHygro A. Unfortunately, no expression of wildtypes EmER or the ErbB1 and ErbB3 
chimera was observed. 
However, constructs were employed in an activity assay using Xenopus oocytes for 
expression in cooperation with C. Dissous (Institute Pasteur, Lille). Xenopus oocytes have 
been established as a suitable model for investigating receptor tyrosine kinase activation and 
transduction cascades. They are physiologically arrested at the G2-M transition of the first 
meiotic prophase. This blockade can be abolished upon activation of receptor tyrosine 
kinase-dependent pathways. The activation of Ras triggers the MAPK cascade and leads to 
phosphorylation of the MAP kinase, which is necessary and sufficient to induce meiosis as 
indicated by oocyte germinal vesicle breakdown [142, 143]. Fourteen Xenopus oocytes each 
were transfected with translational expression constructs for full-length EmER as well as 
chimera of the N-terminal half of EmER and the C-terminal half of ErbB3 (including the 
transmembrane domain) and were subsequently stimulated with human EGF. Human EGFR 
and S. mansoni EGF receptor SER served as controls [142]. A vesicle breakdown was 
observed only in eight of fourteen oocytes (57%) expressing EmER (Tab. 3.5). An 
explanation for this result might be that the transduction machinery of the Xenopus oocytes 
does not fully interact with the Echinococcus receptor. A vesicle breakdown did not occur in 
the set ups with the chimera. This result was expected, since ErbB3 lacks a functional kinase 
domain [43]. Since ErbB3 homodimers are neither capable to activate the MAPK pathway 
nor to sense EGF and the heterodimers of ErbB3 and one of the other EGF receptor 
homologues (EGFR, ErbB2 or ErbB4) are only activated by neuregulins, constructs for 
ErbB3 expression represent suitable negative controls.  
 
 
 
Tab. 3.5: EmER activity in Xenopus oocytes. 
Vesicle breakdowns were measured as 
indication for receptor activity after ectopic 
expression of EmER (full length) and chimera of 
N-terminal extracellular domain of EmER and C-
terminal part of ErbB3 upon stimulation with 
human EGF. 
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4. Discussion 
 
For metazoan organisms, cell-cell-communication is imperative to organize a broad range of 
developmental processes. Commonly involved are lipophilic or water-soluble hormones 
activating the signal receiver, i.e. intracellular or trans-membrane receptors, which activate 
intracellular signaling networks to convert the extracellular signals into an appropriate cellular 
response. This principle developed very early in the evolution of the animal kingdom and is 
therefore present in E. multilocularis and its hosts. Due to conservation of several families of 
growth factors and hormones as well as their cognate receptors, hormonal crosstalk between 
parasite and its host might represent a system through which parasite development is 
regulated depending on the status of the host. Despite the high degree of homology in 
invertebrate and vertebrate signaling systems, cestodes and mammals developed 
independently long enough so that several differences in their signalling cascades have 
accumulated. These differences could be exploited for the development of novel 
anthelminthic drugs. 
In the present work, I investigated peptide growth factor signaling pathways which are likely 
involved in proliferation and differentiation processes of the parasite. This assumption is 
based on preliminary data showing that Erk1/2 like MAPK cascade regulates the growth of E. 
multilocularis but mostly on the findings that mutations in homologous mammalian pathways 
often lead to the formation of cancer [41, 98]. 
Hence, a wealth of data, particularly concerning the biochemistry of the factors involved and 
on small molecules to inhibit their activities is already available. Employing inhibitors of 
serine/ threonine and tyrosine kinases, I examined the role of respective kinases in the 
development of Echinococcus. In a second step, structural and functional differences 
between human and its echinococcal homologue were worked out. 
 
Targeting EmMPK2- the p38 orthologue of E. multilocularis  
 
Among the analysed Echinococcus factors, I suggest EmMPK2, the p38 orthologue, as the 
most promising target for AE treatment. Several lines of evidence clearly indicate that 
EmMPK2 is a functionally active member of the p38 MAPK subfamily. EmMPK2 displays 
clear homologies to p38 MAPKs from phylogenetically different organisms and contains a T-
G-Y motif in the activation loop which is a the hallmark of this subclass of MAPKs. The exon-
intron structure of the encoding gene, emmpk2, is highly similar to that of mammalian p38 
MAPK genes and differs from genes encoding Erk- or JNK/SAPK-like proteins. EmMPK2 is 
capable of auto-phosphorylation at the dual-phosphorylation T-G-Y motif that is recognized 
by an antibody originally raised against human p38 MAPK. Recombinantly expressed, 
purified EmMPK2 phosphorylated MBP, a common substrate of MAPKs. The enzymatic 
activity of EmMPK2 could be blocked by pyridinyl imidazoles specifically designed to inhibit 
human p38 MAPKs. Genomic analyses further indicate that EmMPK2 is the only member of 
the p38 MAPK family in E. multilocularis. Due to the important role of p38 MAPKs in cellular 
signaling of animal cells, the constitutive expression of emmpk2 is not surprising, at least in 
the larval stages that are involved in the infection of the intermediate host (including primary 
cells, which give rise to metacestode vesicles). Compared to metacestode vesicles and 
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activated protoscoleces, a somewhat lower level of phosphorylated EmMPK2 was detected 
in resting protoscoleces. As will be discussed below, one of the functions of EmMPK2 could 
be, like in the case of other p38 MAPKs, the induction of stress responses. The lower levels 
of phospho-EmMPK2 in resting protoscoleces might therefore be due to the fact that this 
stage is located within metacestode vesicles and thus relatively well protected from the 
host’s immune response (having the metacestode’s germinal and laminated layers as first 
lines of defense). On the molecular level, it remains to be established whether the lower 
phospho-EmMPK2 levels in resting protoscoleces are due to diminished translation of the 
protein, to differences in the activity of upstream regulators, or to lower auto-phosphorylation 
activity. However, based on the robust auto-phosphorylation activity of EmMPK2 after 
ectopic expression and the fact that an interaction with the only two upstream MAPK kinases 
could not been identified (see below), translational effects are most likely involved. As an 
alternative, corresponding dual-specific phosphatases, which are present in the parasite’s 
genome, could have elevated activities in the resting protoscolex. 
One of the most important findings of this study is that EmMPK2 displays a significantly 
higher basal activity (towards MBP and towards itself as a substrate) than p38 MAPK 
orthologues from humans. Although I have only tested the physiologically most important 
human isoform p38-α, no other isoform (β, γ, or δ) has been reported to display a basal 
activity higher than that of p38- α [61, 144]. The molecular basis of the high basal activity of 
EmMPK2 is unknown at present. Overall, the protein displays significant homologies to 
human p38 MAPKs but also contains many amino acid exchanges which could affect folding 
and thus basal activity, the interaction with upstream regulators and the responsiveness to 
extracellular signals. Interestingly, when screening the yeast p38 MAPK orthologue HOG1 
for activating mutations, Bell et al. and Diskin et al. identified several hyperactive forms that 
carried exchanges within domains that are important in forming the interface for p38 MAPK 
dimerization [107, 109, 145]. When introduced into human p38 MAPKs, exchanges in three 
of these residues (D176A, Y323S, Y323L, F327L, F327S in p38-α) also led to constitutively 
hyperactive forms [61]. In EmMPK2, the residues at corresponding positions are N177 
(instead of D), L324 (instead of Y) and L328 (instead of F) (Fig. 3.1). In EmMPK2, two of these 
three residues are similarly exchanged at positions 324 (L instead of Y) and 328 (L instead of 
F). Although EmMPK2 carries N at position 177 (instead of D) which differs from the 
corresponding exchange in hyperactive mutants (D176A), an involvement of this residue in 
EmMPK2 hyperactivity is nevertheless possible. Hence, it appears that mutations which have 
to be introduced into yeast and mammalian p38 MAPKs to yield constitutively hyperactive 
forms, are already present in the wild-type form of EmMPK2.  
Questions concerning the cellular function of EmMPK2 and its participation in signaling 
pathways in E. multilocularis cannot be conclusively answered at present. At least on the 
basis of the inhibitor studies (see below), an important role of the kinase in parasite viability 
is apparent. When investigating the influence of different stress conditions (e.g. hydrogen 
peroxide, paraquat or DMSO as producers of reactive oxygen intermediates) on EmMPK2 
activity, only a slight increase in phosphorylation upon physical disruption of metacestode 
vesicles was observed. This could indicate a role in osmotic stress regulation but surely 
requires further investigation. Likewise unclear is whether EmMPK2 is regulated in a similar 
fashion as p38 MAPKs in other organisms.  
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Up to now, three different ways of p38 MAPK activation have been reported of which two are 
unlikely to occur in E. multilocularis. These are the activation through phosphorylation at a 
non-canonical activating residue, Y323 in p38-α, which occurs in mammalian T cells upon 
activation of the T cell antigen receptor (TCR) and the TGF-β-dependent activation involving 
direct interaction between p38-α and TAB1 (Transforming growth factor-β-activated protein 1 
(TAK1)-binding protein) [146]. Since EmMPK2 carries a leucine at the respective position 
(L324) and flanking residues which do not match the sequence stretch in the human 
counterpart, a regulatory mechanism through a TAB-1 homologue is virtually unlikely. 
Furthermore, genes coding for TAB-1 or TCR homologues are not present in the parasite’s 
genome. The best studied pathway for p38 MAPK activation is dual phosphorylation at the T-
G-Y motif by upstream MKKs [146]. For these interactions, however, the conserved 
aspartates of the common docking domain are highly important and at least one of these 
residues is replaced by Asn in EmMPK2 (Fig.3.1) [110]. A similar exchange in the Drosophila 
MAPK, Rolled, renders the insect enzyme constitutively active and severely weakens the 
interaction with regulators such as MKKs or phosphatases [145]. Since the two different 
members of the MKK family in E. multilocularis EmMKK1 and EmMKK2 did not interact with 
EmMPK2 in yeast two-hybrid and in activity assays, it is indeed possible that EmMPK2 is 
only under very limited control by upstream regulatory pathways. This is further supported by 
analyses in which effects of growth factors such as EGF, insulin, TGF-β or bone 
morphogenetic protein on the EmMPK2 phosphorylation state, when added exogenously to 
metacestode vesicles, were never observed although, under similar conditions, the Erk-like 
MAPK EmMPK1 is clearly activated, at least by EGF-treatment (discussed below). 
Taken together, all structural and functional data suggest that the accumulation of activating 
mutations, particularly the leucine residues and the alteration of the common docking 
domain, rendered EmMPK2 a constitutively active MAPK. Hence, EmMPK2 may be 
regulated by alternative mechanisms, but its activation at least seems not to be under direct 
control by upstream MKKs.  
Therefore, EmMPK2 phosphorylation at the conserved T-G-Y motif should solely depend on 
EmMPK2 auto-phosphorylation activity.  This is supported by the data in which the treatment 
of metacestode vesicles or primary cells with p38 MAPK inhibitors led to complete de-
phosphorylation of EmMPK2. In this context, it still remains to be established whether 
EmMPK2 auto-activity leads to dual-phosphorylation of both T181 and Y183, as has been 
reported for TCR-activated p38-α or only to the phosphorylation of T181, as observed for 
hyperactive L16-loop mutants of HOG-1 and human p38 MAPKs [109, 147]. In principle, the 
data support both scenarios since antibodies against the dual-phosphorylated pT-G-pY motif 
of p38 MAPKs very frequently also recognize mono-phosphorylated pT-G-Y and a similar 
situation cannot be excluded for my experiments with EmMPK2 [109]. For the model of 
EmMPK2 being a constitutively hyperactive p38 MAPK, on the other hand, this distinction 
seems not to be critical since it has already been firmly established that threonine-, but not 
tyrosine-phosphorylation within the T-G-Y motif is necessary for obtaining hyperactive forms 
of the enzyme [109]. 
The biochemical analyses showed that EmMPK2 can be effectively inhibited by the p38 
MAPK inhibitors SB202190 and, in particular, by ML3403. Both substances are cell-
permeable pyridinyl imidazole compounds that act on p38 MAPKs in an ATP-competitive 
  4. DISCUSSION 
  - 76 - 
manner [112, 148]. While SB202190 belongs to the first generation of pyridinyl imidazole 
inhibitors, which exhibit severe liver toxicity through interference with hepatic cytochrome 
P450 enzymes, the toxic side effects have been minimized in second generation inhibitors 
such as ML3403 [148]. In studies on the widely used model compound SB203580, it has 
previously been shown that two residues in the ATP-binding pocket of target kinases, M109 
and K53 of p38-α, are in direct contact with pyridinyl imidazoles and contribute decisively to 
inhibition [144, 149]. In EmMPK2, these two residues are invariably present (M110 and K54). 
Furthermore, it is known that target specificity is mainly conferred through one single residue, 
T106 in p38-α [144]. Mutation of this residue in p38-α  renders the enzyme insensitive to 
pyridinyl imidazole inhibitors while introduction of the residue into Erk- or JNK/SAPK-like 
MAPKs leads to sensitivity towards this class of compounds [144, 150]. In EmMPK2, this 
residue is present at the corresponding position (T107) which, together with the presence of 
M110 and K54, explains the sensitivity of EmMPK2 towards pyridinyl imidazoles. In EmMPK1, 
on the other hand, T107 is replaced by D102, which is in concordance with the presented data 
showing that the Erk-like MAPK of the parasite is not affected by p38 inhibitor treatment [98]. 
Apart from the three residues mentioned above, structural studies by Gum et al. revealed ten 
additional residues that are involved in p38-α inhibition through SB203580, the exchanges of 
which either lead to higher or lower affinity between enzyme and drug [149]. Four of these 
are different between EmMPK2 and human p38-α (Fig. 3.1). Different pyridinyl imidazole 
compounds display a wide variety of activities towards the four human p38 MAPK isoforms 
(SB203580 strongly inhibits isoforms p38- α and β, but not γ and δ), depending on amino 
acid residue exchanges in critical position. Considering that, it should be possible to obtain, 
by chemical modification of ML3403, compounds that display high activity against EmMPK2 
while being only weakly active on human p38 MAPKs [144]. Based on the EmMPK2 activity 
assay established in this work, screening assays can be realized in which different pyridinyl 
imidazoles are tested for high affinity towards EmMPK2 while exerting diminished inhibitory 
activity towards human p38 isoforms. 
Both p38 MAPK inhibitors tested in this study, but particularly ML3403, proved to be effective 
in inactivating in vitro cultured larvae, metacestode vesicles and evaginated protoscoleces. 
Due to difficulties in handling protoscoleces in vitro, the effect of ML3403 on this larval stage 
could not be readily quantified. Nevertheless, I could record toxic effects on these larvae in 
response to ML3403, which were clearly inactivated after two weeks. The metacestode 
representing the larval stage which is mainly to be addressed during AE treatment, was 
much more sensitive towards the inhibitors. Here, after 4 days of ML3403 treatment at 
concentrations of 0.5 to 5 µM, which showed no effects on cultured mammalian cells that 
express p38-α, more than 50% of metacestode vesicles lost structural integrity and displayed 
no further capacity to regenerate novel vesicles. It was unexpected that much higher doses 
of the drug had to be given to see effects in the alkaline phosphatase (AP) assay since, in 
former studies using benzimidazoles or nitazoxanide as drugs, this method proved to be very 
sensitive [33, 113]. However, at least in mammalian cells it is well established that AP 
expression is controlled through the p38 MAPK pathway and a similar scenario cannot be 
ruled out in E. multilocularis [151, 152]. Consequently, ML3403 treatment and the inhibition 
of EmMPK2 could have led to decreased overall levels of the enzyme in metacestode 
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vesicles so that significant activities in the supernatant were only detectable after killing of 
many parasite cells in the presence of 1 mM of the drug.  
As yet it is not clear whether the elevated sensitivity of E. multilocularis towards ML3403, 
when compared to cultured mammalian cells, is due to better binding of the drug to EmMPK2 
than to mammalian p38 MAPKs. Once comparable activity assays are available, this topic 
has to be analysed. However, I would assume that the difference lays in the basal activity of 
EmMPK2 and mammalian p38 MAPKs, which renders the parasite more sensitive. While the 
mammalian isoforms are only activated under certain stress conditions or in response to 
specific cytokines, the parasite’s cell physiology seems to be highly adapted to constitutive 
p38 MAPK activity, which could result in high sensitivity if parts of this activity are knocked 
down by specific drugs. If EmMPK2 is also constitutively activated during in vivo infections, 
which must be assumed, ML3403 could already be an effective drug for AE treatment. At 
least in Toxoplasma gondii infected mice, curative, long-term treatment with second 
generation p38 MAPK inhibitors did not show detrimental effects on host viability or immune 
responses [153]. Furthermore, orally administered doses of ML3403 that led to plasma 
concentrations of the drug in the range between 0.5 and 5 µM were well tolerated by the 
animals [112]. In future studies it should therefore be worthwhile to investigate the effects of 
ML3403 on parasite larvae during infections of laboratory hosts. 
It also appears interesting to extend the pyridinyl imidazole studies on other cestodes. This 
will not only reveal their potential lethal influence on these parasites, but also be useful to 
understand the general function of p38 MAPK orthologues in helminths other than E. 
multilocularis. It would be interesting to study the influence of ML3403 on E. granulosus 
larvae from which the target structure appears with subtle change, but the proliferation of the 
lesions during infection clearly differ (exogenous versus endogenous budding, see section 
2). For these experiments, microcyts cultivated in vitro could be used to investigate if 
pyridinyl imidazole also inactivate E. granulosus larvae. In addition, the effects of ML3403 on 
recombinant EgMPK2 could be analysed and activity assays for EgMPK2 could be 
established as done for EmMPK2. The question why SB202190 and ML3403 did not affect 
the integrity of metacestode larvae of T. crassiceps remains unanswered yet. On reason 
might be structural differences in the p38 MAPK orthologues of E. multilocularis and T. 
crassiceps as indicated by different protein sizes and certain differences in the primary 
structure. It is unlikely, however, that morphological differences between the metacestodes of 
E. multilocularis and T. crassiceps are responsible for the different sensibility to pyridinyl 
imidazoles. Due to the absence of a laminated layer in T. crassiceps, drug accessibility 
should even be better than in the case of E. multilocularis.  
Several structural and functional data of this work clearly show that EmMPK2 is specifically 
inhibited by pyridinyl imidazoles. It can, however, not be excluded that the second 
Echinococcus kinase with structural homologies to p38 MAPK, EmSSY, is also affected by 
this class of compounds. EmSSY shares 63% identity with EmMPK2 and was clearly 
identified as Ser/Thr kinase of the MAPK family based on the presence of ATP-binding 
domain, catalytic and activation loop and CD site (Fig.3.21). Contrary to all other known 
members of the MAPK family, however, EmSSY contained an S-S-Y motif in the activation 
loop instead of the typical T-X-Y. Expression analysis revealed that the encoding gene, 
directly located upstream of the emmpk2 locus, is expressed in form of two transcripts in the 
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echincoccal larval stages resulting in two proteins of 486 and 356 AA (named EmSSY-a and 
EmSSY-b varying in the N-terminal region). Due to the presence of introns at positions which 
correspond to the introns of the emmpk2 gene and the location upstream of emmpk2, emssy 
might have been created by gene duplication of the emmpk2 locus. Since the expression of 
emssy was clearly demonstrated, it can be excluded that emssy represents a pseudogene. It 
would therefore be of general interest to analyze the function of EmSSY. If EmSSY-a and b 
are functional MAPKs, the question arises how they are regulated and which are their 
downstream targets. On the one hand, the EmSSY isoforms both contain a conserved 
common docking domain which mediates interaction with regulatory factors such as MKKs 
and phosphatases. It is not known, on the other hand, whether a S-S-Y motif (instead of T-G-
Y) is recognized by MKKs and corresponding phosphatases. Hence, from the biochemical 
point of view, the EmSSY isoforms would be of considerable interest. Likewise interesting 
would be whether EmSSY is a constitutive hyperactive form like EmMPK2. Two of the 
corresponding residues turning the human MAPK into hyperactive mutants upon exchange 
are naturally present in EmSSY (L433, L437). Thus, EmSSY might be a constitutive p38-like 
MAPK. It remains uncertain, if EmSSY and EmMPK2 have similar functions or even 
overlapping functions. Nevertheless, the question arises whether the pyridinyl imidazole 
compounds could inhibit EmSSY. Concerning this, seven of the residues which contribute to 
pyridinyl imidazole binding in mammalian are invariably present in EmSSY [149]. These are 
even more corresponding residues as in the case of EmMPK2, which has been proven to be 
sensitive towards the p38 inhibitors. Thus, EmSSY might be sensitive towards the p38 
inhibitors, too. 
 
Targeting growth factor signaling pathways of E. multilocularis  
 
In humans, key players in tumour formation are the Ser/Thr kinases of the Erk1/2 MAPK 
cascade, which is activated in response to growth factors like EGF [129]. Since the E. 
multilocularis metacestode expresses a member of the EGF receptor family, EmER, and 
since EGF is present in serum which is necessary to support parasite growth, the question 
arouse whether exogenous EGF could stimulate the parasite's Erk-like MAPK cascade 
through EmER [95, 98]. In this work, several results were presented which support this 
hypothesis. 
First, EGF stimulated the phosphorylation of the echinococcal ERM homologue Elp in intact 
metacestode vesicles in vitro. ERM proteins act as regulatory link between the actin 
cytoskeleton and the plasma membrane. While their C-terminal domain (C-ERMAD) directly 
binds to filamentous actin, the N-terminal domain (N-ERMAD) either directly or indirectly 
interacts with membrane-associated receptors. They are involved in several processes like 
microvilli formation, membrane trafficking and ruffling, cell-adhesion and cell-motility and 
occur in an inactive and active form [75]. In the inactive state, which is found in the cytosol, 
the intramolecular interaction of C-and N-ERMAD prevent the interaction with binding 
partners and thereby the translocation to the plasma membrane. One mechanism to regulate 
the interaction of ERM proteins is the conformational change upon PIP2 binding to N-ERMAD 
and the subsequent phosphorylation of a crucial threonine residue within the C-ERMAD by 
Rho, Cdc42, and, presumably, also Rho kinases [154, 155]. Activated ERM proteins are 
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further capable to bind GEFs that in turn activate Rho. Taken together, ERM proteins are 
competent to indirectly activate Rho family members by interaction with positive and negative 
regulators [75].  
Previous investigations by Hubert et al. (1999) already demonstrated that Elp fulfills similar 
cellular functions in E. multilocularis as the members of the ERM family in mammals. In the 
present study, it was clearly shown that Elp is phosphorylated at a conserved C-terminal Thr 
residue (Thr540, see supplements Fig. 6.1) upon incubation of metacestode vesicles with host 
EGF. This indicates that that the parasite ERM factor might also be regulated in a similar way 
as the mammalian orthologs [75, 156]. Like in the case of mammalian ERMs, this might be 
mediated by parasite orthologs of Cdc42, Rho, and PKC, for which genetic information is 
present in the genome [125, 155, 157]. On the other hand, several modifications such as the 
EGF dependent phosphorylation of Tyr145 and Tyr353 in ezrin, which is involved in the 
induction of morphological changes and cell survival, seem to be absent in Elp since the 
respective Tyr residues are not present.    
Since the activation of Elp was clearly suppressed upon vesicle treatment with PP2 and the 
less stringent inhibitor leflunamide, tyrosine kinases, particularly of the Src kinase family 
seem to be involved in the activation mechanism. An Src-dependent phosphorylation of ezrin 
in response to EGF receptor activation has been already reported in human cells [158, 159].  
However, this activation occurred at a tyrosine residue (Tyr145) which is not conserved in Elp. 
Hence, it is rather likely that parasite Src kinases activate cellular mechanisms which result 
in Elp phosphorylation at the conserved C-terminal Thr residue. A possible candidate for this 
type of regulation would be PKC, which is expressed by the parasite. In mammals, PKC is 
known to be regulated through Src kinases [160]. Furthermore, PKC is known to 
phosphorylate ERM family members at the conserved Thr residue in the actin binding 
domain [157]. To clarify the situation, it would be worthwhile in future studies to also test the 
effects of PKC inhibitors on Echinococcus EGF signaling. The MAPK cascade of the parasite 
did not seem to be effected by PP2 and leflunamide as demonstrated by phospho-EmMPK1 
staining. These findings are in line with data on the ERM activation upon EGF stimulation in 
human cells [161, 162].  
Despite the fact that Elp phosphorylation was clearly suppressed upon treatment with PP2 
and leflunamide, long-term incubation of metacestode vesicles in the presence of these 
compounds did not result in vesicle inactivation. However, Src kinases do not appear as 
promising target candidates to kill the parasite.  
 
Second, it could be shown that DNA de novo synthesis is clearly increased upon stimulation 
of metacestode larvae with host EGF and TGF-α. Mitogenic effects of EGF and TGF-α have 
been frequently reported for normal and cancer cells [42, 163]. Since EGF and TGF-α are 
produced by a variety of host cells including hepatocytes, in particular during regeneration of 
liver tissue, it can be assumed that the metacestode is exposed to host EGF and TGF-α 
during an infection in vivo [44, 131-133, 163]. It is further conceivable that the infiltrative 
growth of the larvae into the surrounding host tissue triggers the host immune response 
inducing liver injury upon which the production of EGF is upregulated. The proliferative 
effects of EGF and TGF-α on metacestode cells were more apperent when the cysts were 
kept under starvation conditions. This might be explained through the presence of cytokines 
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in serum. In addition, EGF was a stronger inducer than TGF-α. The findings implicate that 
EmER might be a receptor with the higher affinity for EGF than for TGF-α. Similar effects 
have been reported for EGF signaling in hepatocytes [163]. Furthermore, it is noteworthy 
that, at least in vitro, lower EGF concentrations exerted a stronger effect on Echinococcus 
proliferation than higher cytokine concentration.  
Like in the case of mammalian EGFR, this could be due to the presence of different high- 
and low-affinity binding sites for EGF in EmER [164]. In several human cell systems it has 
previously been demonstrated that proliferation and apoptosis are differentially regulated in a 
concentration and time-dependent manner through differential binding of EGF to different 
sites in EGFR [165]. Since only two concentrations and one time point were investigated for 
proliferative effects, it would be interesting to extend the experimental settings studying the 
impact on the proliferation capacity and the involvement of pro-apoptotic pathways. Further, 
the metacestode vesicle is built up of various cell types, which probably respond in distinct 
ways to EGF dependent stimulation.  
The results of the proliferation studies conclusively indicate that intact metacestode vesicles 
respond with an increased proliferation rate to stimulation with host EGF and TGF-α. The 
DNA de novo synthesis in response to growth factors could be a downstream effect of, at 
least, three different pathways, the parasite equivalent of the Erk1/2 MAPK module, the PKB/ 
Akt and the PI3K pathway. A role of the latter two cannot be excluded, but the Erk1/2 like 
MAPK pathway is definitively involved and is discussed in the following. 
In this work, it could be shown that EmMPK1 is activated in response to host EGF. For the 
mammalian homologue, two mechanisms of activation are known. In one of these, RTKs 
transduce the extracellular signal to Erk1/2 via Ras, while the second occurs via G-protein 
coupled receptors, which activate Raf directly and independently of Ras. Albeit it could not 
be clearly shown that EmER represents the molecule sensing exogenous EGF, the data 
presented in this work strongly support that EmER triggers a signaling cascade which 
induces the phosphorylation and activation of EmMPK1. Prior to the present study, only 
EmRAF and EmMPK1 had been identified as putative components of the echinococcal 
MAPK cascade. The previously identified Ser/Thr kinase homologue EmMKK1 did not 
represent the MKK which links EmRaf to EmMPK1 [86, 98, 122]. Its homology to MKK3/6 
family members rather indicates an involvement in JNK/SAPK-like MAPK signaling. With the 
identification and characterization of EmMKK2 in this work, the missing component of the 
Erk-like MAPK cascade could be found, which is supported by several structural and 
functional data. EmMKK2 possesses a Ser/Thr kinase domain between S157 and V457 
displaying clear homology to other members of the MKK family. In detail, the primary 
structure within the activation loop shares most of the amino acid residues with MKK1/2 
homologues from different phylogenetic origins. Most critically, with S315 and S319, two Ser 
residues are conserved which are homologous to S218 and S222 in mammalian MEK1/2 and 
modified by the upstream activator Raf. Furthermore, EmMKK2 contains an extension (A362 - 
A403) that corresponds to the proline-rich insertion (P265 – P302) of human MEK1 and MEK2. 
EmMKK2 contains a MAPK interaction motif and a ‘HTSTSS’ motif allowing the interaction 
with 14-3-3 proteins. On expression level, it could be shown that emmkk2 is transcribed but 
in contrast to the situation in humans, most probably only as a single splice variant. The 
identification of transcripts of emmkk2 and its potential upstream and downstream interaction 
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partner emraf and emmpk1, in metacestodes as well as non-activated and activated 
protoscoleces provided the first support that the encoded proteins could be part of a single 
MAPK module. Clear evidence for this was further provided by the in vitro interaction and 
activity assays. 
Furthermore, EmMKK2 binds Em14-3-3 in vitro. 14-3-3 proteins are scaffolds for the Erk 1/2 
MAPK pathway, but 14-3-3 proteins interact usually with the upstream signaling pathway on 
the level of Raf [58, 166]. The interaction of a MEK and a 14-3-3 protein has not been 
reported yet. The expression analysis indicates a decreased level of expression of em14-3-3 
during the developmental transition from metacestode to activated protoscolex confirming the 
result of Siles-Lucas et al. who reported the stage-specific expression of Em14-3-3 [121]. 
During the analyses of Spiliotis, neither an interaction of EmMKK1 with EmRaf nor of EmRaf 
with 14-3-3 could be detected although in both cases the structural requirements were met 
[86]. In addition, EmMKK1 lacks a 14-3-3 interaction motif. Quite interestingly, EmMKK2, 
which possess this motif, interacted with Em14-3-3 (this work). This unusual interaction 
needs to be further analyzed. Nevertheless, together with the failure to identify an interaction 
between EmRaf and Em14-3-3, this might indicate a different scaffolding mechanism in the 
parasite’s signaling cascade. 
As outlined in section 3.5.1, the ELM software tool predicted the heptapeptide ‘RRSSIRF’ in 
the C-terminal part of EmMKK2 as potential MAPK interaction motif (KIM) [120]. However, 
such a C-terminal location of the motif which mediates binding to MAPKs would be very 
unusual since KIMs have mostly been reported to be N-terminally located [58, 110, 167-169]. 
With regard to the amino-acid alignment of the MEK homologues, I like to suggest the 
K45RQVTIQNLDL55 sequence close to the N-terminus as actual MAPK docking motif of 
EmMKK2.  
Several functional studies concerning human MEK1 have shown that the replacement of S218 
and S222 with phospho-mimetic residues (D218, D218D222, E218E218) results in constitutively 
active mutants [170-172]. Interesting experiments would be to use constitutive active 
EmMKK2 mutants to analyse the growth behaviour of the E. multilocularis upon transfection 
of primary cells.   
Members of the MEK1/2 family contain a unique, proline-rich insert C-terminal to the kinase 
domain which is important for the regulation of these kinases through Raf-independent 
mechanisms. This insert contains several conserved phosphorylation sites and the two 
threonine residues within the proline-riche insertion (Thr286, Thr292 and Thr386) in human 
MEK1 that are targeted by MAPKs, CDC42 and proline-.directed kinases. In most cases, 
phosphorylation at these sites is inhibitory and results in a dissociation of formed MEK-Raf-
Ras complexes [173]. While this insert is clearly present in EmMKK2 (F427-A486), it is absent 
in EmMKK1, which further supports the notion that EmMKK2 acts within the Erk-like MAPK 
cascade of E. multilocularis. Interestingly, although the conserved threonine residues are 
also invariably present in EmMKK2, the insert region in the Echinococcus proteins contains 
very few proline residues. It is therefore likely that EmMKK2 is also regulated by 
Echinococcus kinases different from EmRaf, although the precise regulatory mechanisms 
require further biochemical analyses.   
Another point in which human and parasite MKK1 homologues apparently do not correspond 
is the NES. By ELM and SMART analysis, a NES has not been identified in EmMKK2, which 
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is present in human MKK1 but not in human MKK2. The NES is nessesary for the cytosolic 
localization of MKK1 that keep Erk1/2 in the cytosol until its activation and subsequent 
translocation into the nucleus [55].  Since one of the functions of human MKK1 is the 
regulation of the MAPK cascade, the regulation of the echinococcal MAPK cascade 
comprising EmRaf, EmMKK2 and EmMPK1 is one of the topics to be analyzed in the future. 
 
The identified stimulatory effect of host EGF, acting via the conserved MAPK module, let to 
the analyses whether this cascade could be a promising target for the development of anti-
Echinococcus drugs. As demonstrated, the activation of EmMPK1 could be blocked upon 
treatment of in vitro cultured cysts with BAY43-9006 and PD184352, two known anti-
tumourgenic compounds, and M-INH. All three drugs were able to inhibit the EmMPK1 
activation more or less to the same extent.  
The bisarylurea compound, BAY439006, is a multi-kinase inhibitor and blocks the activity of 
Raf-1, B-Raf, and the vascular endothelial growth factor receptors in various cell lines and in 
animal models. In spite of its application in various studies, the blocking mechanism is still 
not understood. Nevertheless, the anti-cancer activity of BAY439006 has been attributed to 
both the inhibition of tumour cell proliferation and angiogenesis, particulary in cancer types 
which involve Ras/Raf mutants or overexpression of RTK leading to enhanced Erk1/2 MAPK 
module activation [135, 174]. Although the exact target in the parasite’s signaling pathway 
has not been determined, the inhibitory effect of BAY439006 on the activity of EmMPK1 
could clearly be demonstrated. 
The MEK inhibitor compound M-INH also interferes with the human MAPK cascade. The 
assumption that M-INH targets EmMKK2 as the echicococcal homolog of MEK1 might 
explain the absent EmMPK1 phosphorylation upon the treatment of metacestodes in vitro. 
Further inhibitory effects on EmMPK1 phosphorylation could be demonstrated by applying 
PD184352. The non-ATP competitive PD184352 has been characterized as a highly 
selective inhibitor of human MEK1 in several studies and is the first MEK-targeted compound 
which entered clinical trails [175]. Using yeast genetic screens of randomized human MEK 
mutants, six residues have been identified the exchange of which resulted in a reduced 
sensitivity for PD184352. Only one MEK1 mutant (L115P) was fully insensitive. Four of the 
respective residues have been localized to a cluster in MEK1 limited between S90 and D136 
while two residues (F53, E203) were localized outside of this cluster. Together, these residues 
form a binding clamp for the MEK-inhibitor that is distinct from the ATP-binding pocket [176]. 
All six residues (F53, I103, L115, H119, G128, E203) are invariantly present in EmMKK2 at the 
corresponding positions (F150, I200, L212, H216, G225, E300). In the region of the inhibitor binding 
clamp, EmMKK2 shares much more homology with human MEK1 than EmMKK1. 
Furthermore, none of above mentioned residues which are important for drug binding is 
conserved in EmMKK1. Thus, it can be assumed that PD184352 selectively inhibits 
EmMKK2, not EmMKK1. These findings support previous results that EmMKK2 is the 
upstream kinase of EmMPK1. Further, recent analysis revealed that MEK1, MEK2 and 
MEK5 (which displays homology to MEK1/2) can be affected by PD184352, but none of the 
other MEK family members, underlining the selectivity of this compound [175, 176]. Since the 
genomic screening of the Echinococcus database did not identify a third gene coding for a 
MKK homologue, it seems very likely that this compound solely inhibits EmMKK2.  
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It is noteworthy that none of the MAPK cascade inhibitors affected the structural integrity of 
vesicles during long-term treatment. Since the presence of the compounds resulted in the 
inhibition of EmMPK1 activity, one may conclude that the Erk1/2-like pathway of the parasite 
is not essential to preserve the vesicle integrity or parasite survival. However, the results 
reveal the involvement of EmMPK1 in the regulation of the parasite’s growth after the 
stimulation with growth factors.   
 
Data obtained in this work indicates that the E. multilocularis MAPK cascade might fulfill 
different roles in established metacestode vesicles when compared to regenerating primary 
cells. On the one hand, host-derived insulin, EGF and FGF had a clear effect on the vesicle 
regeneration process; insulin induced the formation of massive cell aggregates with larger 
central cavities while EGF and FGF led to the formation of a higher number of smaller 
aggregates. The addition of insulin, EGF and FGF to regenerating primary cells did, 
however, not lead to an increased phosphorylation of EmMPK1. This is in clear contrast to 
the effects of exogenous EGF, FGF and, to a somewhat lower extent, insulin on established 
metacestode vesicles in which EmMPK1 phosphorylation was induced [93, 94, 98]. Thus, the 
E. multilocularis MAPK cascade might only be functioning downstream of the respective 
RTKs in established metacestode vesicles while other pathways (e.g. the PIP3K/AKT) might 
be mediating the host-cytokine effects in primary cells.   
A potential role of the PIP3K/ AKT pathway in primary cells is supported by the data of the 
miltefosine/ perifosine experiments. Miltefosine and perifosine target the respective pathway 
in human cells. In particular, they accumulate in cell membranes and interfere with lipid 
associated signal transduction pathways such as the PIP3K/AKT survival pathway and the 
SAPK/JNK pathway [116]. In this work, neither compound affected the viability of intact 
vesicles, but primary cells did not regenerate into vesicles in the presence of these drugs. 
The findings for miltefosine being ineffective to inactivate the metacestode confirmed 
previously published results [177]. Since it could be shown that the derivative perifosine is 
equally ineffective to inactivate the vesicles, both alkylphospholipid derivates appear 
unsuitable for the development of a chemotherapeutic drug against established metacestode 
lesions. Both compounds, however, might be useful to interfere in the formation of 
metastases since the inhibitory effect on regenerating primary cell, i.e. germinal cells, could 
be demonstrated. Furthermore, miltefosine and perifosine could be used to investigate 
mechanisms of PIP3K/ AKT signaling in E. multilocularis. In mammalian cells, the PIP3K/ 
AKT pathway is responsible for an enhanced glucose uptake and survival signals upon 
insulin stimulation. An involvement of this pathway in the echinococcal primary cells may 
explain the enlarged and faster vesicle generation in the presence of insulin.  
Taken together, the presented data strongly suggest that the Erk1/2-like MAPK pathway 
promotes metacestode growth, but not survival. In primary or germinal cells, the pathway 
promoting growth seems to be the PIP3K/AKT-like pathway. Regarding the infectious 
process, the data may indicate that insulin via activation the PIP3K/AKT-like pathway is 
important in the early phase of metacestode establishment while EGF-dependent induction 
of the Erk1/2-like MAPK pathway is involved in metacestode proliferation at a later time point 
of infection.  
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EmMPK3 – an atypical MAPK of E. multilocularis 
 
Another difference in the signaling mechanisms of established vesicles and regenerating 
primary cells involves a third MAPK, named EmMPK3. 
Several lines of evidence presented in this work indicate that EmMPK3 is the parasite’s 
Erk7/8 homologue. First, EmMPK3 shares significant sequence homology with the atypical 
human MAPK Erk8. EmMPK3 contains a Ser/Thr kinase domain with a conserved T-E-Y 
motif as part of the activation loop. As in the case of atypical kinases Erk7 and Erk8, 
EmMPK3 possesses a C-terminal extension and at least five putative SH3 binding boxes 
(PxxP). Second, EmMPK3 did not interact with the parasite’s MKKs in vitro. Third, upon 
ectopic expression and subsequent purification, EmMPK3 was auto-activated as indicated by 
the phosphorylation at the threonine and tyrosine of the T-E-Y triplet. Moreover, the 
recombinant protein phosphorylated MBP, a typical MAPK substrate directly implying 
enzymatic activity.  
The identified features of EmMPK3, however, do not yet allow its classification as Erk7 or 
Erk8 MAPK homologue (see section 2.4.4) since EmMPK3 shares features of both. Rat Erk7 
and human Erk8 MAPKs share approximately 69% overall identity (82% within the kinase 
domain) and both contain an extended C-terminal domain with two SH3 binding boxes. Erk7 
possesses a putative NLS (PARKRGP) in its C-terminal tail and indeed localized to the 
nucleus upon overexpression [66, 178]. Contrary to Erk1/2, Erk7 is localized to the nucleus 
independently of its activation state [66]. An NLS could not be indeed identified for EmMPK3, 
but several stretches with similar amino acid residues are present in the C-terminal tail. One 
of those might serve as NLS for EmMPK3 and be responsible for a putative nucleular 
localization of EmMPK3. Ectopically expressed Erk7 is constitutively active towards various 
substrates and phosphorylated on T-E-Y presumably due an auto-activation mechanism as 
has been revealed in studies using a dominant negative K43R mutant [66]. Furthermore, it 
has been reported that typical activators of Erk1/2, e.g. serum, EGF and okadaic acid, did 
not affect the Erk7 activity. This is in accordance with the role of Erk1/2 in cell proliferation 
and Erk7 as a negative regulator of cell growth. Due to the presence of tyrosine-
phosphorylation sites in the C-terminal tail of Erk7, it has been assumed that Src kinases are 
involved in the regulation of its activity. Further studies have shown that Erk7 activity is 
mainly regulated in a MKK independent manner through modification of the C-terminal 
extension and that its conserved T-E-Y motif is exclusively subject to auto-phosphorylation 
[66, 68]. MKK-independent activation has been desrcibed for Erk8 [67]. Erk8, however, 
exerted a lower level of basal kinase activity than Erk7 and appeared to be sensitive to 
serum. Its activation has been shown to be associated with Src-kinase activity [67]. 
Considering the presented features of EmMPK3, it is apparent that the Echinococcus kinase 
displays biochemical properties of both Erk7 and Erk8. EmMPK3 shares with Erk7 the 
elevated basal activity. This should be further verified involving mutation studies with the 
replacement of K43 by arginine and truncated C-terminal versions of EmMPK3. Furthermore, 
EmMPK3 seems not to be controlled by upstream MKK since it did not interact with EmMKKs 
in yeast two hybrid analyses. In cell culture experiments, EmMPK3 was cleary 
phosphorylated in resonse to serum. This activation of EmMPK3 upon stimulation with serum 
occurred only in primary cells but not in metacestode vesicles. Like Erk7, EmMPK3 was 
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insensitive to EGF, FGFs and insulin but like Erk8 sensitive to serum. Hence, serum factor 
(or serum factors) other than EGF, FGFs or insulin must be responsible for the 
phosphorylation of EmMPK3. The responsible factor for Erk8 activation has not been 
reported yet. It would therefore be worthwhile to study EmMPK3 activation using serum 
fractions for the stimulation of primary cells. 
In conclusion, the data presented clearly showed that EmMPK3 belongs to the 'atypical' 
(Erk7/8) MAPK family and that its phosphorylation is induced in Echinococcus primary 
(germinal) cells in a host-serum responsive manner. Due to the important role of host-factor 
induced germinal cell activation in the pathogenesis of alveolar echinococcosis, further 
studies on regulatory mechanisms which involve EmMPK3 are surely worthwhile. 
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5. Material and methods 
 
5.1 Material 
 
Equipment   
  
Agitation Incubators G25  New Brunswick Scientific, Edison, 
NJ, USA 
Blotting Tanks: Mini Trans-Blot cell (7.5 x 10 cm blotting area) BioRad, Munich 
Cooling Centrifuge RC-5B  Heraeus, Hanau 
DNA – Gel Electrophoresis Chamber  BioRad, Munich 
Gel-Documentation System MidiDOC  Herolab, Wiesloch 
Heating Block, DB-3  Techne, Cambridge, UK 
Incubators Heraeus, Hanau 
Overhead Agitation Wheel  Renner GmbH, Dannstadt 
Power Supplies Power Pack P25 und P24  Biometra, Göttingen 
Protein Separation Chambers: Mini-Protean  BioRad, Munich 
Sequencing Apparatus, ABI Prism™ Sequencer 377  Perkin Elmer, Weiterstadt 
Spectrophotometer  NanoDrop™ 1000 Thermo Scientific, Wilmington, 
USA 
Spectrophotometer GeneQuant Pro Amersham, Braunschweig 
Spectrophotometer U-2000  Hitachi, NY, USA 
Thermocycler Trio-Thermoblock™   Biometra, Göttingen 
Ultrasonication Apparatus: Sonifier®II Desintegrator Modell 250  Branson, Danburg 
Ultra-Turrax T25  Janke&Kunkel/IKA Labortechnik 
  
Consumables   
  
0.5 – 2.0 ml reaction tubes Sarstedt, Nümbrecht 
15 ml sterile tubes and 50 ml centrifugation tubes  Greiner, Nürtingen 
Blotting-Paper Schleicher & Schüll, Dassel 
Cell culture flasks from 25 to 175 cm² Sarstedt, Newton 
Centrifuge Beaker, 15 and 50 ml, Quickseal™ Beckman, Munich 
Positively charged nylon membrane porablot NY plus  Macherey & Nagel, Düren 
Sterile Filters, 150 ml Bottle Top Filter, 0.45 µm Nalgene, NY 
Syringes and Needles, sterile Braun Melsungen AG, Melsungen 
X-Ray film Hyperfim™ -MP  Amersham, Braunschweig 
  
Chemicals, commercially available kits and solutions 
  
Agarose NEEO Roth, Heidelberg 
Agar-Agar, Bacto-Peptone, Yeast Extract, Glucose, Yeast 
Nitrogen Base w/o Amino Acids  
Difco Laboratories, Augsburg 
Amino Acids, Antibiotica Sigma, Deisenhofen 
BCA Protein Assay Pierce  
Benchmark™  Prestainded Protein Ladder Life Technologies 
Broadrange Prestained Protein Marker NEB, Schwalbach 
DNase I, RNase free  Roche 
dNTPs lyophilized Roth, Heidelberg 
ECL Chemiluminescence Kit  Amersham, Braunschweig 
EGF, TGFα, aFGF, bFGF ImmunoTools 
H-Insulin Sigma-Aldrich 
Matchmaker Two Hybrid System 3 Clontech, Heidelberg 
  5. MATERIAL AND METHODS 
  - 87 - 
PBS Dulbecco without Ca2+/Mg2+  
Pfu Turbo Polymerase Stratagene 
Phusion Proof Reading DNA polymerase  Finnzymes 
Protease Inhibitor Complete Roche 
Protease Inhibitors Applichem 
Qiagen PCR Cloning Kit Qiagen, Hilden 
Qiagen Plasmid Midi Kit, QIAprep Spin Miniprep Kit, QIAquick 
PCR Purification Kit, QIAgen Gelextraction Kit 
Qiagen, Hilden 
Restriction Enzymes, DNA Modifying Enzymes and T4 DNA 
Ligase 
NEB, Schwalbach 
RNase  Inhibitor  NEB, Schwalbach 
TOPO-TA Cloning®KIT, Original TA Cloning Kit, pBAD/Thio 
expression Kit 
Invitrogen, Groningen, 
Netherlands 
 
All buffers and solutions were made with distilled water, autoclaved and sterile filtrated, 
respectively. For RNA applications, either DEPC-treated or commercially available RNase-
free water was used. For enzymatic reactions, double distilled and autoclaved water was 
used.  
 
5.2 Oligonucleotides 
 
All oligonucleotides were ordered from Sigma-Aldrich/Sigma-Genosys in lyophilized form and 
were reconstituted with PCR grade water at a final concentration of 50 μM. 
 
vector oligonucleotide   
   
pJG4-5 JG4-5 5' CTTATGATGTGCCAGATTATG 
 JG4-5 nest 5' CTCCCGAATTCGGCACGAG 
 JG45-3' 5' TTGGAGACTTGACCAAACCT 
 JG45-3'nest 5' CTGGCGAAGAAGTCC 
   
pBAD/Thio-TOPO®  pBAD forward 5' GCTATGCCATAGCATTTTTATCC 
 pBAD reverse 5' GACTAAATTAGACATAGTCCG 
 Trx forward 5' G TTCCTCGACGCTAACCTG 
 pBAD up 60  5' CTGATTTAATCTGTATCAGGC 
   
pCR®2.1® TOPO-TA Topo M13 5' CAGGAAACAGCTATGACCAT 
 Topo T7 5' TACGACTCACTATAGGGCGA 
   
pGADT7 Y2H T7 seq 5' TAATACGACTCACTATAGGGC 
 Y2H AD seq 5' AGATGGTGCACGATGCACAG 
   
pGBTK7 Y2H T7 seq 5' TAATACGACTCACTATAGGGC 
 Y2H BD seq 5' TTTTCGTTTTAAAACCTAAGAGTC 
 Y2H BD up 5' TAAGAGAGTCACACTTTAAAATTTGTAT 
   
pDrive pDrive T7 5' TAATACGACTCACTATAGGG 
 pDrive SP6 5' ATTTAGGTGACACTATAGAA 
   
pGEX-3x pGEX-3Xup 5’ CGGGAGCTGCATGTGTCAG 
 pGEX-3Xdw 5’ GGCAAGCCACGTTTGGTGG 
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PinPoint™-Xa3  xa-dw 5’ TGGTCAAGGAGCGTGACG 
 xa-up 5’ GACATATTGTCGTTAGAACG 
   
pSecHygroA T7pSec 5’ TAATACGACTCACTATAGGG 
 BGH reverse   5’ TAGAAGGCACAGTCGAG 
    
cDNA     
   
 CD3 5' ATCTCTTGAAAGGATCCTGCAGG 
 CD3nest 5' CTCTTGAAAGGATCCTGCAGGACT 
 CD3RT 5' ATCTCTTGAAAGGATCCTGCAGGTTTTTTTTTT 
TTTTTTTTTTTTTTTTV   T26,V= G+C+A 
 NUP 5' AGGCAGTGGTAACAACGCAGAGT 
 NUP mod 5' GAGGCAGTGGTAACAACGCAGAGT 
 SMART I 5' AAGCAGTGGTAACAACGCAGAGTACGCGGGGG 
GGG 
 SMART II 5' AAGCAGTGGTAACAACGCAGAGTACGC 
(GGG)RNA 
 UPM long 5' CTAATACGACTCATCATAGGGCAAGCAGTGGTA 
ACAACGCAGAGT 
 UPM short 5' CTAATACGACTCATCATAGGG 
   
gene     
   
em10 em10-15 5' AATAAGGTAATCAGTCGATC 
 em10-16 5' TTGCTGGTAATCAGTCGATC 
   
em1433 1433-dw 5' ATGGCAGCTATCACCTCTTGG 
 1433-up 5’ CTG TGACTTGTCATTCTG 
   
emmkk1 mutMEK dw2 5' CCATATAGCGACAGGTGCCCGTGTTGTCCTG 
GGCCATCCTGTTCTTCAACTCTCCCGACACG 
 mutMEK up2 5' CGTGCGGGAGAGTTGAAGAACGACATGGC 
CCAGAGCAACACGGGCACCTGTCGCTATATGG 
 MKK-dw5 5’ GTAATATCGAGTTCTGGCTGTG 
 MKK-3up 5’ GAGTCATCCATCAGTTCCATG 
    
emmkk2 5' EmSor dw XmaI 5' GGATCCCGGGATGTCGGGTCTGACGGACAG 
 3' EmSor up XmaI 5' GGATCCCGGGCTTTACGAGCAGTAGCAGCG 
 5' EmSor dw 5' GCTGAAGACTGAAATGTCG 
 3' EmSor up 5' GTCCATATTCAAATCGACATTAG 
 SOR-2.M-Nde1 5' CATATGAGCACTGGACCTGTTGATCTC 
 SOR-ohne-EcoR1 5' GAATTCGTATCTTGAGAGCCGCAAG 
 SOR-67bp-Nde1 5' CATATGCTGGAGACCGGTGTGGAC 
 Sor dw1 5' ATGGTGCTGAAGCACGCCGGTCG 
 Sor dw2 5' AATGCCCGAGCCAATTGTGTCCCG 
 Sor up1 5' ATGCATATGTTGGATGTTCCCATCAG 
 Sor up2 5' GAACGCCCCATAAAAGCCGACG 
 Sor up3 5' GAAATTCCTCAATGCGCTCTCGCTGG 
 Sor up4 5' AATTGCCTGAGCCCAGCTCGGAG 
 Sor-Not1-up 5' GCGGCCGCCTTTACGAGCAGTAGCAG 
 Sor-Hind3-dw 5' AAGCTTATGTCGGGTCTGACGGAC 
 5' SOR-dw-67-bp 5' CACCTGGAGACCGGTGTG 
 Sor-M-zwei  5’ ATGAGCACTGGACCTGTTG 
 Sor-ohne-up  5’ GTATCTTGAGAGAGCCGCAAG 
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 MEK-MAN2 5' CCCACRAANGARTTNGCCAT 
 MEK-MAN1 5' CCYACRAARCTRTTNGCCAT 
 MEK-YGA 5' ATCGTCGGNTTYTAYGGNGC 
   
emmpk1 erk dw2 5' GTTGAGTCGCGAGCACACCTG 
 erk up2 5' GGGTCTGCAAATGGGAAGAG 
 ERK dw6 5' GAACGTACCTGGAGCAGTTG 
 ERK C3'spezifisch 5' GTAATTTTACACAATACAAGCAT 
 ERK 3' 5' ACCTGCATCTATAGGCTCAG 
   
emmpk2 Ro3 5' GGCGGTCAAGGGAAGGC 
 Roc6 5' GCAAGAAGGATCTCAAGGATGCG 
 MPK2-PWP1-dw  5' TTAATTAAGCCATGGCCGATGTAAATGAG 
 MPK2-PWP1-up  5' TTAATTAATCACGCGTTGATTGGCG 
 Roco3 5' CGGTCGGCCTCCATGGCCAAGCATCACGTT 
GAATTG 
   
emmpk3 Emmpk3 dw expr 5' GATCATGAACTTGAAAAACATG 
 Emmpk3 up expr 5' GGCAATCCACGGACGTG 
 EmMPK3-ADBD-
BamH1-dw  
5' GGATCCATGTGTGTAGGAGTTTCG 
 EmMPK3-ADBD-
BamH1-CT-dw 
5' GGATCCATCCAGAAAGTGAAATTGTGATGG 
 MPK3-Pst1-N-up 5' CTGCAGCTCGAAATTGGGAAACGTAGTGG 
 MPK3-Pst1-5-3-up 5' CTGCAGCGGCAATCCACGGACG 
 MPK3-K43R-dw 5'-Phospho-GTAGCCTTCAAGAAGATTTTTGATGC 
(HPLC) 
 MPK3-K43R-up 5'-Phospho-ATGCTTATTAAGCCGCTTGTACTTTG 
(HPLC) 
   
emegf EGF-5'RACE nest 5' GTCTCGGCTATGAAGAGCGCGGAG 
   
emer ERin-BamH1-dw  5' CGGGATCCAAGCACCGGATATGAAGGACG 
 ERin-Pst1-up  5' TCCTGCAGAGGTAGTCTTCTGGCTGCAAC 
 EmER-C-dw  5' AATTACAAGGCCAAACGCAG 
 EGR-5'-kpn-pSec 5' GATCGGGGTACCCCAGCTATCCCTTGCCCCAG 
 EmER-N-up 5' GGCCTGATTTCGAGCACG 
 EGR-T-up1 5' CACGGCAAGACTACGAAG 
 ERin-Nde1-dw  5' CATATGAATTACAAGGCCAAACGCAGT 
 ERin-EcoR1-up  5' GAATTCGTAGTCTTCTGGCTGCAAC 
   
hsaerb-b1 ErbB1-C-dw  5' ATCGCCACTGGGATGGTG 
 ErbB1-N-up  5' CATGAAGAGGCCGATCCC 
 ErbB1 5' 5' GCCAAGGCACGAGTAACAAG 
 ErbB1 3' 5' GCTCCAATAAATTCACTGCTTTG 
 ErbB1 5'-Kpn1 5' GTAGTAGGTACCGCACGAGTAACAAGCTCACG 
 ErbB1-3' EcoR5 5' GGATATCTGCTTTGTGGCGCGACCCTTAG 
 Chi N-Emer up 5' GCCCCCACCATCCCAGTGGCGATGGAGGCC 
CTGATTCGAG 
 ErbB1-TM-dw 5' GATGGTGGGGGCCCTCC 
 ErbB1-TM-up 5' CATGAAGAGGCCGATCCCCAG 
 Chi N-ErbB1-dw 5' CTGGGGATCGGCCTCTTCATGAATTACAAGG 
CGCCAAACGCAGTCG 
   
emfr FRin-BamH1-dw  5' GGATCCGTCCCCAACGAATG 
 FRin-Pst1-up  5' TCTGCAGCGAACTTTGACAGTGTAGCG 
 GST-up5' 5' CAGATCCGATTTTGGAGGATG 
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 5'-GST-dw  5' ATGTCCCCTATACTAGGTTATTG 
 3'-GST-FRoverh-up  5' GTGGAGGGTGTTGATGCAGATCCGATTTTG 
GAGG 
 GST-SnaB1-dw  5' TACGTAATGTCCCCTATACTAGG 
 3'FRexD-Avr2-up  5' CCTAGGATGGTGATGGTGATGATG 
 EmFRexD-up  5' GTACTTGAGAGACACTGTGTCATGG 
 EmFRexD-dw  5' CATCAACACCCTCCACCCTTCAG 
 FRexD-His-up 5' ATGGTGATGGTGATGATGGTACTTGAGAGAC 
ACTGTG 
 EmFR-BamH1-Sec-
dw 
5' CGGATCCGCGCAGTGGGCGTCTTC 
 EmFR-Not1-Sec-up 5' CGGGCCGCACCCCTGTAAGAACTTTGACAG 
 FGR up1 5' TCGCGACGTAGGTTCTTCGTCA 
 FGR up2 5' AATGTCCTTGGAGGCGAGGTAGACC 
 FRin-Sfi1-dw  5' GGCCATGGAGGCCCGTCCCCAACGAATG 
 FRin-Xma1-up  5' CCCGGGAGAACTTTGACAGTGTAGCG 
 FR-BamH1-ohne-dw 5' GGATCCACATCAACACCCTCCACCC 
   
embmx bmx-dw1  5' GACAACGAAGTGATTGCTG 
 bmx-up1 5' GTCGTAGAGCTCCTCAAAAG 
 bmx-RACE-up2 5' TGGCGTATATCCTATCCTCGCACTGG 
 bmx-RACE-up1 5' GAGTCCCAGCACGCCTGCATCTTG 
   
hsamapk14 hsamapk14 dw - kpn1 5' ATTGGTACCAACAAGACAATCTGGGAGGTG 
 hsamapk14 up -hind3 5' CAGTTCGAAAAGGGGTGGTGGCACAAAG 
 hsamapk14 dw 5' TTCTACCGGCAGGAGCTG 
 hsamapk14 up 5' GGACTCCATCTCTTCTTGG 
   
hsamapk11 hsaMAPK11dw 5' GCTTTACCGGCAGGAG 
 hsaMAPK11up 5' GCTCAATCTCCAGGCTG 
   
rnotegf rat-egf-dw1 5' GACGTTGATGAGTGCCAG 
 rat-egf-up1 5' GTTCTCCAATATAGCCAATG 
   
rnofgf1 rat-fgf1-dw1 5' GAGGTTCAATCTGCCTCTAG 
 rat-fgf1-up1 5' GTCAGAAGATACCGGGAG 
   
rnofgf2 rat-fgf2-dw1 5' GCTTCCCGCACTGCC 
 rat-fgf2-up1 5' GCTCTTAGCAGACATTGGAAG 
   
rnotgfalpha rat-tgf-alpha-dw1 5' GGCTGCAGTGGTGTCTC 
 rat-tgf-alpha-up1 5' GGCAGTGATGGCCTGCT 
   
 
5.3 Determination of nucleic acid concentration and purity 
 
The nucleic acid concentration was photometrically determined at a wavelength of 260 nm 
using the spectrophotometer GeneQuant Pro or NanoDrop 1000. The purity of the nucleic 
acids was analysed on the basis of the ratios of 260 nm/ 280 nm (for protein impurity) and 
260 nm /230 nm (for salt impurity). For molecular biology application, especially for DNA 
ligation, both ratios were 1.5-2.0. DNA concentration was further estimated by comparing the 
intensity of ethidium bromide staining between a DNA fragment of unknown concentration 
with DNA size marker fragments of known concentrations (SmartLadder, Eurogentec). 
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5.4 RNA procedures 
 
5.4.1 Isolation of total RNA from mammalian cell lines 
 
For isolating total RNA from the immortal cell lines RH- and HEK293, cells grown to 
confluency were washed with 10 ml prewarmed 1x PBS, detached from the bottom of the 
flask with 2 ml trypsine/ EDTA for 10 min at 37°C and then resuspended in 8 ml DMEM 
containing 10% FCS and 1% penicillin/ streptomycin (P/S). The number of viable cells was 
determined by Trypan blue staining using a Neubauer counting chamber. 1 x 106 cells were 
used to inoculate a fresh 75 cm2 cell culture flask containing 20 ml DMEM including 10% 
FCS, 1% P/S. After culture for 2 days at 37°C and 5% CO2, the cells reached approximately 
80% of confluency. At this point of time, the cells were harvested (see section 5.9) and 
pelleted by centrifugation at 4°C (300 rcf, 5 min). The supernatant was discarded and the 
cells were lyzed with 600 μl RLT buffer containing β-mercaptoethanol. All following steps 
were executed according to the manual of the RNeasy Kit (Qiagen). 
 
5.4.2 Isolation of total RNA from E. multilocularis larvae 
 
The metacestode vesicles cultivated under axenic conditions or cultivated in the presence of 
RH- (see section 5.10) were prepared for RNA isolation by washing three times with pre-
warmed 1x PBS. For each isolation, vesicles of an approximate total volume of 1 ml were 
disrupted by resuspending with a 1000 µl pipette and subsequently centrifuged. The pellet 
was either resuspended in RP1 lysis buffer supplemented with 1% β-mercaptoethanol of the 
Qiagen RNA isolation Kit or in P1 lysis buffer (Machery-Nagel NucleoSpin RNA/Protein 
isolation Kit). The subsequent steps were performed according to the manufacturer’s 
recommendations. Total RNA of protoscoleces was gained from in vivo cultivated E. 
multilocularis isolates J31, 7030 or Java after sacrifizing the Mongolian jird (M. unguiculatus) 
in accordance to the manufacturer’s manual of the above mentioned kits. The starting 
material was approximately 10 µl protoscoleces per RNA isolation.  
 
5.4.3 Decontamination of isolated RNA  
 
To obtain genomic DNA free RNA, RNA preparations were treated with 0.2 U/ µl RNase-free 
DNase I (Roche) for 1 h at 37°C in the presence of 0.05 M sodium acetate and 0.05 M 
MgSO4. Following digestion the RNA was purified in accordance to the purification protocol 
for RNA isolation of the RNA isolation kit from Qiagen. 
 
5.4.4 First strand cDNA synthesis 
    
The reverse transcription of total RNA into the first strand of cDNA was done using the oligo-
dT-primer CD3RT and the Reverse Transcriptase from the Omniscript RT-PCR kit (Qiagen). 
The manual’s instruction was modified as follows. To resolve possible RNA secondary 
structures and to allow better annealing of the oligonucleotide, up to 2 µg RNA (ad 12 µl with 
RNase free water) were incubated with CD3RT at a final concentration of 1 µM at 65°C for 
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10 minutes. After cooling to RT, all remaining components were added. The synthesis took 
place at 37°C for 90 minutes. The total reaction volume was 20 µl.  
 
5.4.5 Synthesis of SMART cDNA 
 
The synthesis of the SMART (switching mechanism at 5’end of RNA transcript) cDNA was 
performed with the components of the SMART™ RACE cDNA Amplification kit (Clontech) 
according to the manufacturer’s instructions. This method exploits the property of MMLV- 
reverse transcriptase to add mostly three to five cytidines to the 3’ end of the synthesized 
first strand. The ligation of the SMART primer (SMART I or/and SMART II) binding to these 
single stranded cytidines allows the amplification of unknown 5’ ends via PCR approaches.  
 
 
5.5 DNA procedures 
 
5.5.1 Isolation of chromosomal DNA from the metacestode larval stage with purification 
 
For the isolation of genomic echinococcal DNA, the metacestode vesicles were cultivated as 
described in section 10.5.  After extensively washing with 1x PBS, the metacestode vesicles 
were disrupted by pipetting and subsequently pelleted. The supernatant was removed and 
the pellet was dissolved in lysis buffer (100 mM NaCl, 10 mM Tris-HCl, pH8.0, 50 mM EDTA, 
pH8.0, 0.5 % SDS, 20 μg/ml RNase A; 1.2 ml per 100 mg pellet) supplemented with 0.1 
mg/ml Proteinase K. For total digestion of Echinococcus cells, the samples were incubated 
over night in a 50°C water bath and agitated as necessary. The DNA was extracted by 
phenol chloroform extraction and subsequently concentrated via ethanol precipitation as 
follows. One volume of phenol-chloroform-isoamyl-alcohol (25:24:1) was added to the 
sample solution. Following centrifugation for 25 minutes at 2000 rcf at RT, the upper 
aqueous phase containing the DNA was transferred into a new tube. After repeating the 
extraction step, the DNA was precipitated by addition of 0.1 volumes LiCl (stock 5 M; pH4.5) 
and 2 volumes 96% ethanol. The precipitation mix was incubated over night at -20°C. The 
following day, the DNA was completely precipitated at 20,000 rcf for 30 minutes at 4°C. The 
supernatant was removed and, after a washing step with 70% ethanol, the pellet was dried 
over 24 h at RT. The dried pellet was resuspended in 1x TE buffer (10 mM Tris, 1 mM EDTA 
pH 8.0).  
 
5.5.2 BrdU-Staining  
 
To analyse a potential proliferatory effect of human EGF and TGF-α, the incorporation of 
BrdU into Echinococcus DNA was detected as described previously [134]. In brief, 
metacestode vesicles were cultivated in the presence of 1mM BrdU under starvation 
conditions for 4 days as described in 5.10. Subsequently, the chromosomal DNA was 
isolated and purified by phenol-chloroform-extraction followed by EtOH precipitation as 
described in 5.5.1. The DNA content was determined by photometric analysis and the 
amount of DNA in a total volume of 20 µl was transferred onto a nitrocellulose membrane via 
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slot blotting. The slot blot chamber was connected with a vacuum pump and the 
nitrocellulose membrane tightly clamped. To increase the suction force, the membrane was 
underlayed by approximately 6 Whatman papers. The loading of the samples was carried out 
in the middle of the slot. After the transfer, the membrane was dried at RT and the DNA was 
cross linked with UV. To detect the incorporated BrdU, the membrane was blocked with 1% 
BSA TBST (see section 5.6.7) for 1 h on the seesaw. The incubation with the anti-BrdU 
antibody took place overnight at 4°C. After three washing steps with TBST, a HRP 
conjugated anti-mouse antibody was employed as secondary antibody. After 1 h at RT, the 
membrane was washed three times with TBST. The blot was developed by 
chemiluminescence and the incorporation of BrdU was detected by exposing the membrane 
to an X-ray film. Cross reactivity of the anti-BrdU antibody with uridine of the RNA can be 
excluded due the RNase in the lysis buffer.  
 
5.5.3 DAPI staining of DNA blotted on nitrocellulose membrane 
 
The DNA cross-linked to the nitrocellulose membrane was stained with DAPI nucleic acid 
stain as additionally control for the amount of transferred DNA. For this, the membrane was 
first incubated in 0.2 M Tris pH7.5 for 5 min at RT on the seesaw and then for 30 min 0.2 M 
Tris pH7.5 containing 0.1 M sodium sulfate and 2.5 µg/ ml DAPI. After a washing step with 
distilled water for 5 min, the membrane was repeatedly rinsed in 0.2 M Tris pH7.5 and than 
photographed under UV light. The membrane was enclosed in a box after the DAPI staining 
to avoid the degradation of the light sensitive dye. 
 
5.5.4 Isolation of plasmid DNA from E. coli 
 
The isolation of plasmid DNA from E. coli strains was performed with the QIAprep® Spin 
Miniprep kit and the Plasmid Midi kit (both Qiagen). 
 
5.5.5 Gel electrophoresis of DNA 
 
Depending on the size of DNA fragments, the agarose gel was prepared as 0.7% (for 
fragments larger than 4 kb), 1.0 % (fragments of 0.2 to 7 kb) or 2% (fragments smaller than 
0.2 kb) gel. Corresponding amounts of agarose were dissolved by heating in 1x TAE 
buffer (40 mM Tris, 1 mM EDTA, pH8.0, 0.11% glacial acetic acid ad 1l dH2O pH8.5). After 
the cooling down, the agarose TAE solution was poured into a horizontal gel sleigh where 
loading wells were left by fitting combs. To load the DNA, the samples were mixed with 6x 
agarose buffer containing 0.25% bromo phenol blue, 0.25% xylene cyanol, 40% saccharose 
and 30% glycerol. The separation was done at a voltage of 100 V for approximately 20-30 
minutes. The separation was estimated by running of the two dyes included in the lading 
buffer. In a 1% agarose gel, the bromo phenol blue band and the xylene cyanol correspond 
to a 0.3 kb and 3 kb fragments, respectively. The DNA was visualized by exposing the 
ethidium bromide stained gel (2 mg/l ethidium bromide in 1xTAE) to UV light.  
As marker for the DNA size, SmartLadder (Eurogentec) was utilized.  
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5.5.6 Purification of DNA  
 
After gel electropheresis, the bands of interest were excised and the DNA was extracted with 
the QIAquick® gel extraction kit. PCR amplicons or restriction digested DNA were purified 
using the QIAquick® PCR purification kit or the nucleotide removal kit (all Qiagen) according 
to the manufacturer’s recommendations. 
 
5.5.7 DNA precipitation  
 
To precipitate DNA from a sample solution 0.1 volume of 3 M sodium acetate pH5.2 and 2.5 
volume of 96% ice-cold ethanol were added and mixed well. After incubation for up to 24 h at 
-20°C, the DNA was pelleted by centrifugation (30 minutes, 15,000 rpm, 4°C) and the 
supernatant was removed. After washing with 70% ethanol, the pellet was dried in the speed 
vac or by air. Finally, the DNA was dissolved in H2O or 1x TE buffer (10 mM Tris and 1mM 
EDTA pH8.0). 
 
5.5.8 Sequencing 
 
DNA was sequenced according to the dideoxy method developed by Sanger (1977) in an 
ABI PrismTM Sequencer 377 (Perkin Elmer). DNA sample (400 ng of plasmid DNA or 100 ng 
PCR amplicon) was set up with 5 nM oligonucleotide and 2 µl sequencing mix to a final 
volume of 10 µl. The PCR programme was performed with 25 cycles of 96°C for 10 seconds, 
45°C –60°C for 5 seconds and 72°C for 1 minute. Here, the annealing temperature for the 
specific primer was calculated with the equation Ta [°C] = 4x (G+C) + 2x (A+T) – 5. 
Subsequently, the DNA was precipitated, heated to 90°C for 2 minutes, and separated on 
polyacrylamide. 
 
5.5.9 Amplification of DNA via PCR 
 
Costume-made oligonuceotides with a defined sequence have been designed were amplified 
via polymerase chain reaction (PCR) in the Trio-ThermoblockTM (Biometra). The design of 
the oligonucleotides was usually carried out for annealing temperature of about 58°C 
calculated with the equation Ta [°C] = 4x (G+C) + 2x (A+T). The Taq DNA polymerase (NEB) 
needs approximately 30 seconds and a temperature of 72°C for the synthesis of 500 nt. 
Consequently, the cycling conditions were generally as follows: with an initial denaturation for 
60 seconds at 94°C, 30 cycles of a denaturation, primer annealing and a elongation step (30 
seconds at 94°C, 30 seconds at Ta, 60 seconds/1000 nt at 72°C) and with a final elongation 
for 10 to 30 minutes at 72°C. The PCR mix comprised 1-5 µl template, 2 µl 10x buffer, 0.2 µl 
10 mM dNTPs, 0.2 µl 50 µM oligonucleotide I, 0.2 µl 50 µM oligonucleotide II, 0.2 µl Taq 
DNA polymerase (2 U/µl) ad a final volume of 20 µl. Besides the non-proof-reading Taq DNA 
polymerase (NEB), the proofreading enzymes Pfu (Stratagen), Phusion (Finnzymes) and 
Triple Master (Eppendorf) was used in accordance to the manufacturer’s manuals. 
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5.5.10 Rapid amplification of cDNA ends (RACE) 
  
The rapid amplification of cDNA 5’ and 3’ ends was carried out by either SMART cDNA or an 
already present library cDNA (pJG4-5; [74]). A first PCR was carried out using a gene 
specific primer and a primer complementary to either the 5’ end or the 3’ end of cDNA. For 
the nested PCR, a pair of primers was chosen, which binds between the first pair of primers. 
 
5.5.11 Semi-quantitative RT PCR 
 
Total RNA was isolated from in vitro cultivated primary cells, metacestode vesicles as well as 
activated or non-activated protoscoleces as described above. cDNA was produced using the 
Omniscript RT-PCR kit (Qiagen; Hilden, Germany) and oligonucleotide CD3RT according to 
the manufacturer’s instructions. Ten-fold serial dilutions of the cDNA were then used as 
template for PCRs using primers em10-15 and em10-16 for the constitutively transcribed 
gene elp [76, 81]. Additionally, the primers Roc6 and Ro3 were used for emmpk2, SOR-EEF 
and SOR-IHL for emmkk2, MKK-dw5 and MKK-up3 for emmkk1,1433-dw and 1433-up 
em14-3-3. Cycling conditions were 25 cycles of 30 sec at 94°C, 30 sec at 58°C and 30 sec at 
72°C. PCR products were simultaneously separated on a 1 % agarose gel and stained with 
ethidium bromide. The multiplex PCR experiment was performed under unchanged cycling 
conditions using the primer pairs Roc6 and Ro3 for emmpk2 and em10-15 and em10-16 for 
elp. Control experiments missing one and two primers or template DNA were included.  
 
5.5.12 TA cloning 
 
PCR products amplified with Taq DNA Polymerase (NEB) or the Triple Master DNA 
polymerase (Eppendorf) possess an additional 3’A. This overhang is exploited for cloning 
into the pCR®2.1® TOPO-TA vector or Original TA cloning vector (both Invitrogen), which 
possess a complementary 5’ T overhang according to the manufacturer’s instructions. Both 
vectors allow blue-white screening to discriminate inserts from religated vectors. PCR 
products without the 3’ A were incubated with Taq DNA polymerase and dATP for 1 h at 
72°C to enable TA cloning.  
 
5.5.13 Colony-PCR 
 
The insertion of DNA into the MCS of the corresponding plasmids were analysed via colony 
PCR approach. The respective colony was picked from the agar plate and resuspended in 30 
µl sterile water. 3 µl of the obtained bacteria suspension served as template in the PCR 
setups (see section 5.5.9). The first denaturation time of the cycle programm was extended 
to ten minutes to disrupt the bacterial cells.  
 
5.5.14 Restriction digest of DNA 
 
All DNA restriction digests were carried out in 20 µl reactions with enzymes purchased from 
NEB according to the given specifications.  
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5.5.15 Ligation of DNA fragments 
 
DNA fragments were ligated in 20 µl reactions using T4 DNA ligase (NEB) by incubating over 
night at 16°C. The ligation setup was mixed for a final volume of 20 µl. For ligation reactions, 
plasmid and insert DNA were mixed at a ratio of 1:3 (with 100 ng of plasmid). To avoid re-
ligation in cloning procedures, the cutted vectors were dephosphorylated at the 5’end by 
treatment with antarctic phosphatase or CIP (both NEB). 
 
5.6 Protein procedures 
 
5.6.1 Determination of protein concentration 
 
The protein concentration was determined with the BCA Protein Assay Kit (Pierce). Based on 
the absorbance measured for the protein standards, the protein concentration of the samples 
was calculated. To this end, reagents A and B were mixed in a ratio of 50: 1 to yield the 
working solution. 50 μl of each bovine serum albumin (BSA) standard (50, 100, 200, 400, 
600, 800, 1000 und 1200 μg/ml) and 50 μl of the protein solution (in 1:5 and 1:10 dilutions) of 
unknown concentration were mixed with 1 ml working solution. After a 30 min incubation step 
at 37°C, 150 µl of each sample were transferred into a 96well plate and the absorption at 540 
nm was determined in the ELISA reader Multiscan Ex Primary EIA V.2.1-0 (Thermo). 
 
5.6.2 In vitro activity assay with myelin basic protein as substrate 
 
The enzyme activity of the recombinant MAP kinases Hsp38, EmMPK2 and EmMPK3 was 
determined measuring the transfer of radioactively labelled [γ
32
]-P onto MBP (Sigma-Aldrich). 
Equal amounts of purified protein were incubated in kinase buffer (20 mM HEPES pH7.4, 10 
mM MgCl2, 2 mM EGTA, 1 mM DTT, 100 µM ATP) supplemented with 0.5 mg/ ml MBP, 1 
µM leupeptin, 1 µg/ ml aprotinin, 1 µg/ ml pepstatin A, 1 mM PMSF and 4 µCi [γ-32P]-ATP. In 
some experiments, inhibitor or solvent were also added. After 60 min incubation at 37°C the 
reaction was stopped by adding 2x stop mix (see below) and boiling for 10 min. The samples 
were subsequently separated on 15% polyacryl-amid, blotted onto nitrocellulose membranes, 
and exposed for 48h to x-ray films.  
 
5.6.3 In vitro activity assay for the MAPK cascade 
 
Purified recombinant proteins (20 µl EmMPK1, 10 µl EmMKK2 and 5 µl EmRAF/ EmRAS) 
were mixed and incubated with 60 µl kinase buffer (20 mM HEPES pH7.4, 150 mM NaCl, 10 
mM MgCl2, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mM Na3VO4, 500 µM 
ATP) for 30 minutes at 30°C. Subsequently, the reaction was stopped by adding equal 
volumes of 2x stop mix and the samples were boiled for 5 minutes. After separation on 12% 
poly-acrylamid, the proteins were detected by Western blotting using the corresponding 
antibodies. Control reactions lacked either one of the proteins or ATP. 
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5.6.4 Co-immunoprecipitation 
 
250 µl of the purified protein solutions were mixed with equal volumes of 1x TBST buffer ( 20 
mM Tris HCl pH8, 150 mM NaCl, 1% Triton-X 100) containing 1 mM Na3VO4, 10 mM NaF, 1 
mM PMSF and were incubated for 30 minutes at 4°C under overhead agitation with the anti-
thioredoxin antibody at a final dilution of 1:500. Afterwards, 50 µl of slurry agarose G- beads 
equilibrated with 1x TBST were added. After 4 h, 250 µl of the second protein solution was 
added without changing the conditions. Protein complexes were allowed to form overnight 
and precipitated by centrifugation (1 min, 500 rpm). The supernatant with unbound proteins 
was removed. Unspecific and unbound protein was removed by washing three times with 1x 
TBST. Finally, equal volumes of 1x TBST and 2x stop mix (see below) containing β-MEtOH 
were added and the samples were boiled for 5 minutes. After a short spin, the supernatant 
was analysed by Western blotting.  
 
5.6.5 SDS-PAGE 
 
For the sodium dodecyl sulfate –polyacrylamide gel electrophoresis (SDS-PAGE) the 
separation chamber Mini-Protean (BIORAD) was used. The acrylamid polymerisation of the 
resolving gel was initiated by addition of 40 µl TEMED and 120 µl APS and required an 
incubation of approximately 30 min at RT. For the polymerisation of the stacking gel 40 µl 
TEMED and 70 µl APS were added. Combs with 10 and 15 wells were used. The described 
volumes are sufficient to synthesize six Mini gels (100 mm x 75 mm x 1 mm) of the BioRad 
system. Before loading, the samples were mixed with 2x stop mix and boiled for 5 min. The 
separation took place at 150 V (approx. 60 mA). 
 
Working solutions  
  
PAA 30% Acrylamid/ 0.8% bis-acrylamid (Roth) 
  
4x Lower-Tris 1.5 M Tris-HCl, pH 8.8 
 0.4% SDS 
  
4x Upper-Tris 0.5 M Tris-HCl, pH 6.8 
 0.4% SDS 
  
TEMED N,N,N',N'-tetramethylethan-1,2-diamin (Merck) 
  
APS 16% ammonium persulfate dissolved in H2O 
  
Running buffer 192 mM glycine 
 25 mM Tris base 
 1% SDS 
  
2x stop mix  2 ml 0.5 M Tris-HCl pH 6.8 
 1.6 ml glycerol 
 1.6 ml 20% SDS 
 1.4 ml dH20 
 0.4 ml 0.05% (w/v) bromophenol blue 
 7 µl β-mercaptoethanol/100 µl 
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Resolving Gel Composition: 
       
5% 7.5% 10% 12% 15% 17.5% Resolving gel 
4 ml 6 ml 8 ml 10 ml 12 ml 14 ml PAA 
6 ml 6 ml 6 ml 6 ml 6 ml 6 ml 4x Lower Tris 
14 ml 12 ml 10 ml  8 ml 6 ml 4 ml dH2O 
       
Stacking Gel Composition:  
   1.5 ml PAA   
   2.5 ml 4x Upper-Tris  
   6.5 ml dH2O   
 
5.6.6 Coomassie staining of protein gels 
 
The proteins of the PAA gels were stained for approximately 30 min with coomassie staining 
solution on the seesaw. Bands were visualized by destaining the unspecifically stained gel 
areas. 
 
Coomassie staining solution 0.25% Coomassie R250 
 50% methanol 
 10% glacial acetic acid 
  
Coomassie destaining solution 45% methanol 
 45% H20 
 10% glacial acetic acid 
 
5.6.7 Western blotting 
 
The transfer of the resolved proteins onto nitrocellulose membranes with the Mini Trans-Blot 
Cell (BIORAD) was carried out for 1 h at 350 mA. After the transfer, the nitrocellulose was 
blocked for 1 h at RT in blocking buffer (depending on the antibody) and was incubated with 
the corresponding antibody over night at 4°C on the seesaw. Upon three washing steps for 
10 minutes, the membrane was incubated with the secondary antibody solution for 1 h at RT 
on the seesaw. The washing steps were repeated and the proteins were visualized by 
chemiluminescence (ECL, Pierce) and exposing to X-ray-films. The films were developed 
with a Curix 60 automated developer (Agfa). 
 
Western blotting buffer 192 mM glycine 
  25  mM Tris base 
  20 % methanol 
  
Blocking buffer 5 % skim milk (SM) or 5 % BSA dissolved in 1x TBST (20 mM Tris, 
150 mM NaCl, pH7.5, 0.1% Tween20) 
  
Washing buffer 1xTBS 0.1%Tween20 (TBST) 
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Primary Antibody Dilution Buffer Firma Source 
     
anti-Erk1/2 1:1000 5% SM- TBST Stressgen rabbit 
anti- Erk (pTpY 185/187) 1:1000 5% SM- TBST Biosource rabbit 
anti-elp 1:1000 5% SM- TBST mAb2810 [73] mouse 
anti-ERM 1:1000 5% BSA- TBST Cell Signaling rabbit 
anti-phospho-ERM 1:1000 5% BSA- TBST Cell Signaling rabbit 
anti-MEK 1/2 1:1000 5% BSA- TBST Cell Signaling rabbit 
anti-phospho-MEK 1/2 (S221) 1:1000 5% BSA- TBST Cell Signaling rabbit 
anti-active p38 1:1000 5% TopBlock- or 
BSA-TBST 
Promega rabbit 
anti-phospho-CREB (Ser133) 1:1000 5% BSA- TBST Cell Signaling rabbit 
anti-phosphp-S6 (Ser235/236) 1:1000 5% BSA- TBST Cell Signaling rabbit 
anti-phospho-tyrosine  1:2000 5% BSA- TBST Cell Signaling mouse 
anti-GST  1:1000 5% SM- TBST Santa Cruz 
Biotechnologies 
mouse 
anti-HA 1:1000 5% SM- TBST Santa Cruz 
Biotechnologies 
rabbit 
anti-myc 1:1000 5% SM- TBST Santa Cruz 
Biotechnologies 
mouse 
anti-V5 1:5000 5% SM- TBST Invitrogen mouse 
anti-His 1:1000 5% SM- TBST Cell signaling mouse 
anti–Biotin - HRP 
 
1:5000 5% SM- TBST Cell signaling  
anti-BrdU 1:1000 1% BSA- TBST Sigma-Aldrich mouse 
anti-phospho-histon H3 (Ser10) 1:1000 5% BSA- TBST Cell signaling rabbit 
anti-pospho-MAPKAPK-2 
(Thr334) 
1:1000 5% BSA- TBST Cell signaling rabbit 
anti- MAPKAPK-2  1:1000 5% BSA- TBST Cell signaling rabbit 
 
anti-EGF 1:1000 3% SM –PBS upstate 
biotechnology 
rabbit 
     
Secondary Antibody     
     
anti- mouse IgG – HRP 1:104 blocking buffer Jackson,  
ImmunoResearch 
 
anti–rabbit IgG – HRP 1:5000 blocking buffer Jackson,  
ImmunoResearch 
 
 
5.7 Working with bacteria 
 
5.7.1 Bacteria strains and media 
 
Bacteria Strains   
   
E. coli DH5α Invitrogen F-Φ80dlacZΔM15 Δ(lacIZY-argF) U169 recA1 endA1 
hsdR17(rk-,mk-) phoA supE44 thi-1λ gyrA96 relA1 tonA 
E. coli TOP10 Invitrogen F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endAI nupG 
E. coli BL21 Amersham B F-, ompT, hsdS (rB-,mB-), gal, dcm 
   
Media   
   
Luria-Broth (LB)  Invitrogen  
LB agar plates  LB medium with 1.5% Bacto-Agar 
SOC Invitrogen  
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All bacteria were incubated at 37°C either in LB- liquid medium or on LB-agar plates 
supplemented with antibiotics depending on the transformed plasmid. Usually, 100 μg/ ml 
ampicillin or 50 μg/ ml kanamycin were used. 
 
5.7.2 Chemically competent E. coli 
 
Competent bacteria were prepared using the CaCl2 method as follows. 50 ml LB-medium 
was inoculated with 1 ml O/N culture of the E. coli strain and incubated at 37°C and 225 rpm 
until an OD600 of 0.5 -0.7 was reached (approximately 2-3 h). Subsequently, the culture was 
separated into 2 aliquots, pelleted at 4000 rpm and 4°C for 10 min. The supernatant was 
decanted and the pellet directly placed on ice. Each pellet was carefully resuspended in 12 
ml ice cold 100 mM CaCl2 and the centrifugation step was immediately repeated.  The 
resulting pellet was dissolved 1 ml fresh CaCl2 by gently resuspending and subsequently 
incubated for 30 up to 60 min on ice. Before freezing the bacteria suspension at -80°C in 50 
µl aliquots, glycerol was added to a final concentration of 20%. 
 
5.7.3 E. coli transformation 
 
For each transformation, 50 μl competent cells were incubated with plasmid for 30 min on ice 
followed by a heat shock step (1 min, 42°C). After addition of 300 μl LB-liquid medium, the 
bacteria were incubated for 1 h at 37°C and 225 rpm. Finally, the bacteria were plated on LB-
agar plates supplemented with the corresponding antibiotics (100 μg/ ml ampicillin or 50 μg/ 
ml kanamycin) and incubated at 37°C over night. 
 
5.7.4 Heterologous expression in E. coli and purification of the recombinant proteins 
 
pBAD/Thio-TOPO® vector and pBAD/TOPO® vector systems 
 
In this work, recombinant Hsap38 MAPK-α, EmMPK2, EmMPK3, EmMKK2 and EmFR were 
expressed in DH5α using the pBAD/Thio-TOPO® vector and pBAD/TOPO® vector, 
respectively (Invitrogen). Both vectors allow the expression of fusion proteins under the 
control of the inducible araBAD promoter (pBAD) with an N-terminal thioredoxin tag which 
can be cleaved off at the enterokinase site (pBAD/Thio only). A second tag, the V5 epitope, 
is fused to the C-terminus followed by a 6xHis tag. The former can be used to easily detect 
the fusion protein with the anti – V5 antibody and the latter to purify the fusion protein under 
native and denaturing conditions by affinity chromatography. The tags contribute 
approximately 16 kDa (6 kDa in the case of pBAD/TOPO® expression) to the overall size of 
the fusion protein. For the selection and propagation in E. coli an ampicillin resistance and 
pUC origin of replication are encoded on the plasmid. The transcriptional regulator of the 
pBAD, AraC, is also encoded on the plasmid. 
The corresponding PCR products were cloned into the cloning sites of the pBAD/Thio-
TOPO® vector and pBAD/TOPO® vector via TA cloning according to the manufacturer’s 
instructions (Invitrogen). Positive clones validated by sequencing were used for the over 
night culture. LB-medium containing 100 µg/ml ampicillin was inoculated 1:200 with the 
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corresponding starter culture. When the bacteria reached an OD600 of 0.5, the protein 
expression was induced by supplementation of 0.2% L-arabinose into the medium. After 
incubation for 4 h at 37°C and 225 rpm, the cells were pelleted by centrifugation at 6000 rcf 
and 20 min at 4°C. The supernatant was discarded and the pellet resuspended in lysis buffer 
(depending on the purification method). Finally, 5 mg/ ml lysozyme was added and the 
suspension frozen at -20°C over night.  
The recombinant proteins were purified under native and denatured conditions. For the latter 
purification method, the lysisbuffer contained 500 mM NaCl, 20 mM Na-phosphat-buffer and 
6 M guanidine-HCl. Cell debris was removed by centrifugation at 6000 rcf at 4°C for 20 min. 
The supernatant was transferred to 4 ml slurry Ni beads (ProBond Resin, Invitrogen), which 
had been equilibrated with lysis buffer. After slow rotation at 4°C over night, the beads were 
washed three times with 300 ml denaturing wash buffer (500 mM NaCl, 20 mM Na-phosphat-
buffer, 8 M Urea, pH5.8). The protein was eluted initially with 6 ml elution buffer (500 mM 
NaCl, 20 mM Na-phosphat-buffer, 8 M Urea, pH3.8) and subsequently, with 6 ml imidazol 
elution buffer (300 mM NaCl, 50mM Na-phosphat-buffer, 250 mM imidazol, pH8.0).  
For the native purification the procedure was done analogously with the following buffers 
containing increasing concentrations of imidazol: lysis buffer (300mM NaCl, 50 mM Na-
phosphat-buffer pH8.0, 10 mM imidazol), washing buffer (300mM NaCl, 50 mM Na-
phosphat-buffer pH8.0, 20 mM imidazol), elution buffer I (300mM NaCl, 50 mM Na-phosphat-
buffer pH8.0, 250 mM imidazol), elution buffer II (300mM NaCl, 50 mM Na-phosphat-buffer 
pH8.0, 500 mM imidazol). The isolated fractions were analysed by Coomassie staining as 
well as Western blot analysis. The protein containing fractions were pooled and dialysed 
overnight against 2 l 1x PBS at 4°C. 
 
Recombinant protein Vector Purification Primers used for ORF amplification 
EmMPK2 pBAD native and denatured p38-5EC / p38-3EC  
EmMPK3 pBAD native Emmpk3 dw expr/ Emmpk3 up expr 
Hsap38 MAPK-α pBAD native  hsMAPK14 dw/ hsMAPK14 up 
EmMKK2 pBAD and 
pBad/Thio 
native Sor-67-dw/ Sor-ohne-up 
EmFRex pBAD and 
pBad/Thio 
 FRex-dw/ FRex-up 
 
EmNIP pBAD/Thio native TRI-dw/ TRI- up 
 
pGEX-3X Vector System  
 
The pGEX-3X system (Amersham) was used to express recombinant proteins of EmMKK1, 
EmFRex and EmSkip. The protein expression is under control of the IPTG (isopropyl-β-D-
thiogalactopyranoside) inducible tac promoter and leads to proteins with a N-terminally fused 
glutathione-s-transferase (GST) of S. japonicum. The GST- tag increases the size of proteins 
by 26 kDa and allows the purification on immobilized glutathione.  
For the recombinant expression, the LB-medium (100 µg/ ml ampicillin) was inoculated 1:50 
with E. coli BL21 over night culture and the suspension was shaken at 225 rpm and 37°C 
until OD600 of 0.5. Protein expression was induced by the addition of 1 mM IPTG. After 2 h of 
further incubation, the culture was pelleted by 6000 rcf and 4°C for 20 min. The supernatant 
was decanted and the pellet was resuspended in a total volume of 10 ml cold 1x TBS. To 
brake the bacterial cell walls 5 mg lysozyme were added and the pellets were frozen by  
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-20°C for 4 h to over night. This step was followed by sonification of the bacterial suspension 
for at least 5 times for 30 s (continuous output of 4-5, duty-cycle of 40-50%) until the 
suspension was slightly viscous. After addition of RNase, DNase (each 5 mg/ml) and the 
protease inhibitors 1 μM pepstatin A, 10 μg/ml aprotinin A, 1 μg/ml leupeptin, 1 mM PMSF, 
Triton-X-100 was added to a final concentration of 1%. The suspension was incubated for 1 
h at 4°C on an overhead agitation wheel and the cell debris was subsequently pelleted by 
centrifugation at 13000 rpm at 4°C for 30 min. The supernatant was transferred to a fresh 15 
ml reaction tube and glutathione sepharose beads that had been previously equilibrated with 
1x PBS 1% Triton X-100 were added. After 4 h at 4°C on an overhead agitation wheel, the 
beads were washed three times with 1x TBS supplemented with 1% Triton – X-100 to 
remove unbound protein. Bound protein was collected in six fractions by adding three times 
elution buffer I (25 mM glutathione in 1x TBS) and three times elution buffer II (50 mM 
glutathione in 1x TBS). Protein containing fractions were pooled, dialyzed overnight against 
1x PBS at 4°C and supplemented with the above listed phosphatase and protease inhibitors. 
 
Pinpoint-Xa-3 system 
 
The pinpoint expression vector Xa-3 was used to express and purify the recombinant 
EmFRex (extracellular domain of EmFR) according to the manufacturer’s manual. 
 
 
5.8 Working with yeast 
 
5.8.1 Yeast strains and media 
 
Yeast strains   
   
AH109 BD Biosciences Clontech MATa, trp1-901, leu2-3, 112, ura3-52, his3-
200, gal4Δ, gal80Δ, LYS2::GAL1UAS- 
GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, 
URA3::MEL1UAS-, MEL1TATA-lacZ 
Y187 BD Biosciences Clontech MATα, ura3-52, his3-200, ade2-101, trp1-901, 
leu2-3, 112, gal4Δ, met -,gal80Δ, 
URA3::GAL1UAS-GAL1TATA-lacZ, MEL1 
   
Media   
   
YPDA 20 g/l Difco Peptone 
10 g/l yeast extract 
20 g/l Bacto agar (for plates) 
distilled H20 ad 950 ml 
pH 6.5 adjusted by adding 25% HCl; 
after autoclaving 50 ml of 40% glucose and 3 
ml of 1% adenine-hemisulfate solution were 
added. Both solution were filter sterilized. 
 
   
SD  6,7 g Difco™ Yeast Nitrogen 
Base w/o Amino Acids 
20 g Difco™ Bacto Agar 
X g of the corresponding drop out 
supplement (DOS) (Clontech) 
lacking the selective amino acid 
distilled H20 ad 930 ml or 950 ml 
 
pH 6.5 adjusted by adding 25% HCl; 
after autoclaving 50 ml of 40% glucose 
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SD - Trp + 0.64 g/l Leu/- Trp DOS 
+ 20 ml 50x Leu (5 mg/ 1ml) 
 
 
SD - Leu + 0.64 g/l Leu/- Trp DOS 
+ 20 ml 50x Trp (1mg/ 1ml) 
 
 
SD - Leu/- Trp + 0.64 g/l Leu/- Trp DOS 
  
SD - Leu/- 
Trp/ -His 
+ 0.6 g/l Ade/- His/- Leu/-Trp DOS 
+ 20 mg/l histidine HCl mono-
hydrate (Sigma) 
 
 
SD - Leu/- 
Trp/ -His/-Ade 
+ 0.6 g/l Ade/ - His/ - Leu/ - Trp 
DOS  
 
 
 
5.8.2 Yeast two hybrid analysis 
 
For analysis of protein-protein interactions, the Gal4-based MATCHMAKER system 
(Clontech) was used. For the expression of proteins of interest fused to the C-terminal end of 
either the DNA-binding domain or the activation domain of the Gal4 transcription factor, the 
corresponding reading frames were cloned into pGBKT7 and pGADT7, respectively, and co-
transfected into S. cerevisiae strain AH109. The construction of EmRAF, Em1433, EmMKK1 
and EmMPK1 translational fusions was described by Spiliotis [86]. The EmMPK2 constructs 
were produced as published by Gelmedin et al. [179]. The ORF for EmMKK2 constructs was 
amplified from cDNA with the primers SOR-67-Nde1-dw and SOR-ohne-EcoRI and was 
cloned via the restriction sites NdeI and EcoRI into the yeast vectors. Using the 
oligonucleotids EmMPK3-ADBD-BamH1-dw and MPK3-Pst1-5-3-up, the complete ORF of 
EmMPK3 was amplified and cloned via BamHI and PstI into the expression vectors (used in 
this work). For the cloning of EmMPK3’s N-terminus and C-terminus, the primer pairs 
EmMPK3-ADBD-BamH1-dw and MPK3-Pst1-N-up and EmMPK3-ADBD-BamH1-CT-dw and 
MPK3-Pst1-5-3-up were employed, respectively. 
For the transfection, YPDA was inoculated with AH109 and incubated overnight at 30°C and 
200 rpm. For each transformation, 1 ml overnight culture was pelleted and the supernatant 
discarded. The pellet was washed with 1xPBS and subsequently resuspended in 100 µl of 
freshly prepared transfection buffer (40% PEG 3350, 200 mM lithium acetate, 100 mM DTT) 
and mixed with 200 ng DNA of each plasmid. The yeast-suspension was plated on selection 
plates after incubation at 45°C for 30 minutes. Yeast clones were selected for double 
transfection on leucin-tryptophan-deficient SD medium for 4 d at 30°C. Protein expression of 
each clone was confirmed by Western blot analysis. For protein-protein interaction under 
high stringency conditions, yeasts were selected on leucin-tryptophan-histidin-adenin-
deficient (quad) SD plates. Individual yeast colonies were picked and plated repeatedly on 
quad SD plates for 48 h at 30°C to avoid false positive clones.  
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5.9 Working with mammalian cell lines 
 
5.9.1 Cell lines and media 
 
Cell lines  ATCC no. Media 
    
Rat Reuber hepatoma cells  RH-  CRL-1600 Dulbecco’s minimal essential medium 
(DMEM; GIBCO BRL) 
Human embryonic kidney cells  HEK293 CRL-1573 DMEM; GIBCO BRL 
Human brain-derived endothelial cells  HBMEC   described in [180] 
 
5.9.2 Quantitative live-dead staining of mammalian cell lines 
 
The cell lines RH-, HEK293 and HBMEC were seeded into 24 well plates with 1x 104 cells 
per well and incubated in DMEM supplemented with 10% FCS 1% penicillin/ streptomycin 
under 5% CO2 atmosphere in presence of DSMO or inhibitor, respectively. After 4 d crystal 
violet staining was performed according to the established protocol [114]. To this end, the 
medium was aspirated by a vacuum pump and the cells were washed with 1x PBS. Cells 
were fixed with 1% glutaraldehyde for 15 min on a seesaw. After three washing steps, the 
cells were dried at RT and stained with 0.1% crystal violet solution. The staining process was 
stopped after 30 min and the non-absorbed crystal violet was removed. The cells were 
washed under microscopical observation. Cells were destained by addition of acetic acid for 
5 min. The absorbance measurement at 570 nm of 100 µl supernatant was measured on a 
96 well plate. 
 
5.9.3 Transfection of HEK293 cells 
 
HEK293 cells were transfected with constructs of the vector pSecHygro A encoding EmFR 
and EmER (see section 3.10). The day prior to the transfection, the medium was removed 
and the cells were detached by adding 2 ml trypsin/ETDA solution for 5 min at 37°C. The 
suspension was then mixed with 8 ml DMEM 10% FCS 1% P/S. The number of viable cells 
was determined by trypane blue staining and counting in a Neubauer chamber. 1 x 106 cells 
were seeded per well of a 6-well plate containing 3 ml DMEM 10% FCS 1% P/S and 
incubated overnight at 37°C and 5% CO2. The next day, the medium was replaced by 4 ml 
fresh medium and the transfection solution was added drop wise. The transfection solution 
consisted of 7.5 μg of plasmid DNA mixed with 62 μl 2 M CaCl2 and brought to a final volume 
of 500 μl with double distilled water. After mixing, 500 μl 2x HBS buffer (50 mM HEPES, 1.5 
mM Na2HPO4, 280 mM NaCl, 10 mM KCl, 12 mM α-D-glucose pH7.1) were added. Then, the 
suspension was inverted for 2-4 times and incubated for 30 min at RT prior to the addition to 
the seeded cells. After 7 h, the medium was carefully replaced with fesh medium and the 
incubation was continued for another 48 h. For the analysis of protein expression by Western 
blotting, the medium was removed and the cells were lysed in 200 μl 1xTBS lysis buffer ( 20 
mM Tris, 150 mM NaCl, 1 mM Na3VO4, 1 mM EDTA, 10 mM NaF, 1 mM PMSF, 1 μg/ml 
aprotinin A, 1 μg/ml pepstatin hemisulfate, 1 μM leupeptin, 1% Triton-X 100) under over head 
agitation for 1 h at 4°C. Cell debris was collected by centrifugation at 15,000 rpm for 15 min. 
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20 µl of the supernatant were mixed with 2x stop mix. The remaining supernatant was frozen 
at -20°C for further analysis. 
 
5.10 Working with E. multilocularis 
 
5.10.1 E. multilocularis isolates 
 
Isolate Source Use 
   
H95 primary infection of M. unguiculatus by oncosphere 
uptake 
metacestode cultivation in 
vitro  
Java, 7030, J31 Java monkey as intermediate host, secondary 
infection of M. unguiculatus 
protoscoleces isolation 
 
 
5.10.2 In vivo cultivation of metacestode larvae 
 
The long-term maintainance of E. multilocularis metacestodes requires repeated passages in 
laboratory animals. To this end, Mongolian jirds (Meriones unguiculatus) were infected with 
homogenized larval material by intraperitoneal injection to develop a secondary alveolar 
echinococcosis. Approximately two month p.i., the larval material was isolated under sterile 
conditions upon sacrificing the animal with CO2. The sterility was preserved by working in a 
sterile bench, repeated substitution of the used sterile instruments and by avoiding the injury 
of the digestive tract of the animals. Additionally, it was avoided to contaminate the parasite 
material with fur hair. The isolated parasite tissue was cut into small pieces (1-2 mm slices) 
and subsequently strained through a metallic tea sieve. The ground material was then 
washed at least three times with sterile 1x PBS to remove host cells. After this step, the 
parasite material was treated in different ways depending of the subsequent experiments. 
For the isolation of protoscoleces, see section 5.10.3. For other applications, the suspension 
was subsequently incubated in the presence of 10 μl/ml Ciprobay 400 (ciprofloxacin) and/or 
100 U/ml penicillin G/ streptomycin for 16 h at 4°C to eliminate any contaminating bacteria. 
After removal of the antibiotics by repeated washing steps with 1x PBS, 0.3-0.5 ml of the 
decontaminated suspension were used for injection into a new jird (0.9 µl canula). The 
decontaminated material was also used to start the cultivation of metacestode larvae in vitro. 
 
5.10.3 Isolation and activation of protoscoleces 
 
For the isolation of protoscoleces, the freshly isolated and ground parasitic material (5.10.2) 
was diluted with 1x PBS to obtain a 1:4 suspension und vigorously shaken for approximately 
10 min to release the protoscoleces from the metacestode material. Afterwards, the 
suspension was firstly sieved through a polyester gauze (pore size 150 µm). Then, the flow 
through was decanted onto a second polyester gauze (pore size 30 µm). On the top of the 
gauze, the retained material contained the protoscoleces, which were collected by 
resuspension in 1x PBS and transfer into a Petri dish (diameter 10 cm).  By horizontal 
rotation of the Petri dish on the working bench, the protoscoleces gathered in the middle and 
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were subsequently transferred with a 1000 µl pipette to a fresh reaction tube for further 
applications. 
The protoscoleces were activated by mimicking the gastrointestinal passage by adding 
0.05% pepsin in DMEM without FCS at pH2. After 30 min at 37°C and careful rotation at 125 
rpm, the protoscoleces were allowed to precipitate by gravity and were subsequently washed 
three times with 1x PBS. Afterwards, the protoscoleces were resuspended in 0.2% sodium 
taurocholate in DMEM without FCS at pH7.4 and were incubated for another 3 h at 37°C and 
125 rpm. After several washing steps, the protoscoleces were prepared according to the use 
that followed. Both activating solutions (25 ml each for 500-1000 µl protoscoleces solution) 
were freshly prepared and filter sterilized.  
 
5.10.4 In vitro Cultivation of metacestode larvae 
 
The homogenized parasite material isolated from the animal (see section 5.10.2) was 
subsequently employed for the in vitro cultivation system in the absence or presence of host 
cells as follows [86].  
 
Co-cultivation  
 
1 ml parasite suspension was incubated in 50 ml normal culture medium (see table below) in 
a 75 cm2 flask  and the presence of 1x107 freshly trypsinized feeder cells (RH- ; see section 
5.9) at 37°C and 5% CO2 atmosphere. After approximately 10 d, the parasite material was 
precipitated by gravity and the medium was decanted and replaced. In the following long-
term incubation, the medium was replaced weekly by precipitating or percolating through a 
plastic tea sieve. At each medium replacement, feeder cells were added, but the flask was 
used repeatedly. At a diameter of 3-5 mm, the metacestode vesicles were used for the 
experiments. 
 
Axenic cultivation 
 
Co-cultivated metacestode vesicles (diameter approximately 3 mm) were adapted to axenic 
cultivation conditions by transfer into pre-conditioned medium (A4) supplemented with 
reducing agents (see table below) [86]. The most critical point for the adaptation is the 
elimination of contaminating feeder cells. To this end, the vesicles were intensively washed 
with pre-warmed 1x PBS prior to passage to a fresh culture flask (75 cm2). At every 
subsequent passage, the same flask was re-used. For 10 ml vesicles, a total volume of 40 ml 
medium was used. Every 48-72 h of incubation at 37°C under a nitrogen atmosphere, the 
medium was replaced. After approximately 4 weeks, the vesicles have adapted to the axenic 
conditions and can be used for experiments.  
 
Media     
normal culture medium DMEM 10% FCS 1% P/S 
starvation medium DMEM 0.2% FCS  1% P/S 
pre-conditioned medium (A4) filter sterilized supernatant of RH- culture 
(1x106 RH- in 20 ml DMEM 10% FCS 1% P/S  
for 1 week in a 75 cm2 flask) 
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axenic culture medium 
(nitrogen atmosphere) 
A4 1µl/ml ß-MEtOH, 1µl/ml BAT, 1µl/ ml L-Cys  1% P/S 
 
5.10.5 Treatment of the metacestode vesicles 
 
Co-cultivated and axenically cultivated metacestode vesicles with a minimal diameter of 3 
mm were used in all experiments. For the analysis of effects of the drugs examined in this 
work, vesicles were manually picked, extensively washes with 1x PBS, and cultivated in 
groups of five per well in a 24 well plate. The pre-set culture medium consisted of 1 ml 
DMEM, 10% FCS and 1% P/S. Vesicles were incubated in presence or absence of the 
inhibitor in different concentrations and the solvent DMSO. All experiments were repeated 
four times for each dilution. The viability as indicated by the integrity of the cyst wall was 
repeatedly examined using an inverted light microscope, in particular upon transfer to the 
multiwell plates.  
The same experimental setups were used for the cultivation under oxidative stress 
conditions. The induction was carried out for 30 minutes, 2 h and 8 h by supplementing with 
the following compounds: 50 µM and 200 µM H2O2, 1 µM and 10 µM paraquat, 1% and 10% 
DMSO. For the analysis of the effect of growth factors, metacestode vesicle were incubated 
under starving condition (DMEM 0.2% FCS 1% P/S) for 4 days prior to the stimulation.  
 
5.10.6 Quantitative measurement of E. multilocularis alkaline phosphatase activity 
 
The activity of E. multilocularis Alkaline Phosphatase EmAP was measured after treatment of 
the in vitro cultivated metacestode vesicles using the previously published protocol [113]. In 
brief, 30 µl of culture supernatant were mixed with 170 µl AP buffer containing 0.5 M 
ethanolamine, 0.5 mM MgCl2, pH 9.8, and 1 mg/ml p-nitrophenyl phosphate as substrate. 
The incubation took place at 37°C for 30 min in 96 well plate. The absorbance at 405 nm was 
measured with the ELISA reader Multiscan Ex Primary EIA V.2.1-0 (Thermo). 
 
5.10.7 Isolation and cultivation of E. multilocularis primary cells 
 
E. multilocularis primary cells were obtained from metacestode vesicles, which had been 
axenically cultivated for two months. The procedure has been published by Spiliotis et al. 
[86]. After washing three times with 1x PBS, the vesicles were disrupted by sucking into a 10 
ml pipette and carefully resuspending. The vesicles were centrifuged for 10 min at 2600 rcf, 
the supernatant was poured off, and the pellet was resuspended in 8 volumes of pre-warmed 
trypsin/ EDTA solution. The suspension was subsequently incubated at 37°C under 
seesawing from time to time until the suspension became turbid. The germinal layer cells 
were separated from the remaining debris by a two minutes shaking step followed by 
passage trough a 30 µm gaze. The flowthrough containing the germinal layer cells was 
centrifuged for 10 min and 2200 rcf. The supernatant was decanted and the pellet was 
carefully resuspended in the leftover supernatant. The resulting cell suspension was taken 
up in 1x PBS to a total volume of 1 ml. Cells were seeded on 24-well plates at a 
concentration of 60 µl suspension in 1 ml culture medium per well. Pre-conditioned DMEM 
(A4) supplemented with 100 U/ ml penicillin G, 100 mg/ ml streptomycin (both Biochrom), 10 
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mM bathocuproinedisulfonic acid (BAT; Sigma), β-mercaptoethanol (β-MEtOH) and L-cystein 
(L-Cys) or the hydatide fluid of axenically cultivated vesicles served used as medium. The 
plates were incubated at 37°C under a nitrogen atmosphere.  
 
5.10.8 Treatment of E. multilocularis primary cells 
 
For the drug treatment experiments, the primary cells were isolated and seeded as described 
in section 5.10.7. Alternatively, the primary cells were seeded into DMEM 10% FCS 1% P/S.  
For the stimulation with growth factors, the primary cells were starved in DMEM 0.2% FCS 
1% P/S for 2, 8 and 24 h upon isolation. The respective stimulus was added for 3 and 24 h. 
The long-term observation in the presence of growth factors took place in medium containing 
1% FCS.  
 
5.10.9 Verification of pure of Echinococcus material 
 
To verify the absence of DNA originating from feeder cells, the synthesized echinococcal 
cDNA was subjected to PCR analysis for the presence of host tubulin cDNA using the 
primers Tub12up (5' CCCCAAGTGTATGATACTGG) und Tub12ST (5' 
CTGGGCAGTGCGGCAACCA) [35]. 
Protein samples were examined for contamination with feeder cells using human specific 
anti-phospho-CREB (Ser133) or anti-phospho-histon H3 (Ser10) antibodies for the Western 
blot experiments. Both antibodies do not cross-react with Echinococcus proteins as 
examined (data not shown).  
 
5.11 Computer analyses and statistics  
 
Amino acid sequence comparisons were performed using the basic local alignment research 
tool (BLAST) software on the nr-aa database collection (http://blast.genome.jp). Pileups were 
constructed employing the software tool BioEdit using the BLOSUM62 matrix. Kinase domain 
predictions were done as described by Schultz et al. [106] using the simple modular 
architecture research tool (SMART; http://smart.embl-heidelberg.de). Important residues and 
motifs were predicted by ELM [120]. For statistical analyses, the GraphPad Prism software 
(GraphPad Software) version 4 was used. Error bars represent the standard deviation. 
Differences were considered significant for p values below 0.05 indicated by (*), very 
significant for p between 0.001 to 0.01 (**), extremely significant for p < 0.001 (***) and non-
significant for p > 0.5 (ns). Survival curves after drug treatment were compared using the log-
rank test. The influences of drugs on metacestode vesicles and mammalian cell lines were 
analyzed using ANOVA and Tukey’s multiple comparison test. For IC50 determination, linear 
regression was performed according to Pearson’s correlation. R2 values indicate the 
‘goodness of fit’. The confidence interval was calculated as 95% in all analyses.  
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6. Supplements  
 
6.1 Survey of the yeast two hybrid studies 
 
 
Tab. 6.1: Protein-protein interactions studied by yeast two hybrid experiments. 
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6.1 Alignment of Elp 
 
Fig. 6.1: Amino acid alignment of Elp and human ERM proteins. Shown are the sequences of Elp 
(Q05768) and human ezrin (P15311), radixin (P35241), moesin (P26038). The threshold for identical 
amino acid residues, which are highlighted in white on black background, is set to 60%. Similar 
residues are shaded in blue. ‘P’s above the lines mark residues which are modified during the 
activation process (see sections 3.6.1 and 4) 
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6.2 Alignment of EmMPK3 
 
Fig. 6.2: Amino acid sequence comparison of EmMPK3 with homologue MAPKs from different 
phylogenetic origens. Displayed are the sequences of EmMPK3, human Erk8 (Q8TD08), Rattus 
norvegicus Erk7 (Q9Z2A6), Caenorhabditis elegans YPC2 (Q11179) and yeast SLT2 (Q00772). 
Identical amino acid residues are highlighted in white on black background by a threshold at 60%. 
Similar residues are shaded in blue. ‘M’ indicates the residue Lys43 of human Erk8 which replacement 
to Arg resulted in a kinase inactive mutant (see sections 3.9 and 4). 
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7. List of abbreviations 
 
°C  Grad Celsius 
A  Ampère 
AA  amino acid 
aFGF  acidic fibroblast growth  
  factor 
AP  alkaline phosphatase 
APS  ammonium persulfate 
ATP  adenosine triphosphate 
bFGF  basic fibroblast growth  
  factor 
BMP  bone morphogenetic protein 
bp  base pair 
cDNA  complementary DNA 
Ce  Caenorhabtidis elegans 
CIP  calf intestine alkaline  
  phosphatase 
Da  dalton 
dATP  deoxy ATP 
Dm  Drosophila melanogaster 
DMEM  Dulbecco’s minimal  
  essentiell medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxyribonuleotide  
  triphosphate 
EGF  epidermal growth factor 
Elp  Ezrin-Radixin-Moesin like 
  protein 
Em  Echinococcus multilocularis 
Erk  extracellular signal  
  regulated kinase 
EtOH  ethanol 
FCS  fetal calf serum 
Fig.  Figure 
GST  glutathione s-transferase 
h  hour 
H2O2  hydrogen peroxide 
HBMEC human brain microvascular
  endothelial cell 
HEK  human embryonic kidney 
  cells 
Hs  Homo sapiens 
JNK  c-Jun N-terminal kinase 
LM  light microscopy 
M  Mol 
MAPK  mitogen activated protein 
  kinase 
MBP  myelin basic protein 
MetOH  methanol 
min  minutes 
MKK  mitogen activated protein 
  kinase kinase 
MV  metacestode vesicles 
Mw  molecular weight 
NES  nucleus exclusion sequence 
ORF  open reading frame 
P  protoscolices 
p.i.  post infection 
PAA  polyacrylamide 
Pact  activated protoscoleces 
PAGE  polyacrylamide gel  
  electrophoresis 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
RACE  rapid amplification of cDNA 
  end 
Raf  rapidly growing fibrosarcoma 
rATP  ribosomal ATP 
RH  Reuber hepatoma 
RNA  ribonucleic acid 
rpm  rotations per minute 
RT PCR reverse transcriptase PCR 
RT  room temperature 
SAPK  stress activated phospho 
  kinase 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
sec  seconds 
SM  stop mix 
SMART switching mechanism at 5’ 
  end of RNA transcript 
Tab.  Table 
TBS  Tris buffered saline 
TBST  TBS Tween  
Tc  Taenia crassiceps 
TEMED N, N, N’, N’-tetra-  
  methylethylenediamine 
TGF-α  transforming growth factor 
  alpha 
TGF-β  transforming growth factor 
  beta 
UV  ultra violet 
V  Volt 
WB  Western blot 
Xl  Xenopus laevis 
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Thesis: Targeting flatworm signaling cascades for the development of 
novel anthelminthic drugs 
PI: Klaus Brehm 
 
Funding by the international graduate college Würzburg-Nice 1141: 
Signal transduction: where cancer and infections converge 
   
Oct 1999 – March 2005  Diploma studies  
 
Undergraduate studies in Biology  
Philipps University, Marburg, Germany 
 
Diploma studies in Microbiology, Biochemistry and Biotechnology  
Julius-Maximilians-University, Würzburg, Germany 
 
Thesis: Molecular characterization of nuclear hormone receptors from the 
fox tapeworm Echinococcus multilocularis 
PI: Klaus Brehm 
   
Sep 1998 - Aug 1999  Voluntary year of social service, Universical Clinic of Freiburg, Germany 
   
Aug 1985 - June 1998  School education  
 
Gymnasium Marienschule, Saarbrücken, Germany 
Abitur (A-level)  
 
Grundschule St. Barbara, Saarbrücken, Germany 
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